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ABSTRACT 
Multiple copy prescription laws have been implemented or 
proposed in several states to better track the distribution of 
drugs in Schedule II to the ultimate consumer. The states 
with such statutes report a 30 to 50 percent decrease in the 
number of Schedule II prescriptions written as well as a 
reduction in diversion of these drugs and forgeries. Risk 
factors were assessed for the effect of the Rhode Island 
Duplicate Prescription program on prescribers. A question-
naire was mailed to all prescribers (N=3016) registered with 
the Rhode Island Department of Health Division of Drug Control 
to prescribe Schedule I I drugs. The response rate was 
approximately 22%. The response group was evaluated for 
demographics, prescribing history, perception of the impact of 
the law on prescribing, and knowledge of the law. 
Associations were determined between prescriber character-
istics and two outcomes (effect of ·the Rhode Island duplicate 
prescription form on decision-making and therapeutic pre-
ference to choose an alternative drug to a clearly indicated 
Schedule II drug) . Both the pre- and post-law groups were 
evaluated for the outcomes. Odds ratios were calculated for 
variables significant at the 0.15 level. 
Risk factors which explain some of the variation of the 
outcomes are age, sex, primary professional degree, specialty 
practice, practice type, number of years licensed, issuance of 
Schedule II prescriptions, and knowledge of Division of Drug 
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Control review of duplicate prescriptions for Schedule II. 
Multivariate regression models were devised to evaluate 
prescribers for the risk of perceiving an effect of the form 
on decision-making and of choosing an alternative drug to a 
Schedule II. These models assist in identifying those pre-
scribers at higher risk for a certain outcome. 
It appears that education of the prescribers about the 
Rhode Island Duplicate Prescription Law, its purpose, its 
intent and its workings is needed. 
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Substance abuse and drug diversion have been and continue 
to be considerable national problems in terms of health care, 
economics and societal stability. In an effort to address, in 
part, these two issues insofar as they relate to legal pre-
scription drugs, nine states have implemented and one state 
has proposed multiple copy prescription programs. The premise 
of these programs is to track the distribution of drugs in 
Schedule II to the ultimate consumer thereby identifying the 
prescriber, the drug and the patient. The success of these 
programs in decreasing the number of prescriptions written for 
Schedule II drugs has prompted an interest in a national 
multiple copy prescription program. These programs have 
prompted several special interest groups to question whether 
multiple copy prescription programs inhibit the prescriber's 
willingness and ability to prescribe drugs in Schedule II 
thereby impacting negatively upon good medical practice, 
economics and the health of patients. 
This study shall investigate. the impact of the Rhode 
Island Duplicate Prescription Law on prescribing practices 
for Schedule II as well as identifying risk factors which may 
explain a practitioner's willingness to prescribe those 
substances. 
INTRODUCTION 
A. Historical Perspectives of Drug Control 
The United States has recognized the significance of drug 
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abuse, illegal drug distribution and the impact of these on 
society at large. In terms of historical perspective, the 
first one hundred years of Federal law dealt primarily with 
quality control (Strauss and Sherman 1985). The Harrison 
Narcotic Act of 1914 mandated a tax on narcotics as a means of 
discouraging utilization. In 1927, the Food, Drug and In-
secticide Administration was formed as a law enforcement 
agency which became the Food and Drug Administration (FDA) in 
1931. The Federal Food, Drug and Cosmetic Act of 1938 (FDCA) 
was enacted as a result of the sulfanilamide disaster which 
required manufacturers to prove safety of products prior to 
distribution. In 1951, the Durham-Humphrey Amendments 
required that drugs which could not safely be used without 
medical supervision must be dispensed pursuant to a pre-
scription written by a licensed practitioner. In 1965, the 
Drug Abuse Control Amendments were implemented to deal with 
problems resulting from three therapeutic categories - central 
nervous system stimulants, central .nervous system depressants 
and hallucinogens. Iri 1968, the Bureau of Narcotics and Dan-
gerous Drugs (BNDD) in the Department of Justice was formed 
from the FDA Bureau of Drug Abuse Control to monitor illegal 
drug trafficking . Following the passage of the Drug Abuse 
Prevention and Control Act of 1970, the Drug Enforcement Ad-
ministration (DEA) was created by merging components of 
several agencies with the BNDD. It mandated the evaluation of 
all drugs with the potential for abuse and designated these 
drugs into five distinct schedules (I-V) . Those drugs in 
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schedule I have no currently accepted medical use in the 
united States and have the highest potential for abuse. Those 
drugs in Schedule II are defined as having a currently 
accepted medical use in the United States and a high abuse 
potential, with severe psychological or physical dependence 
liability. The higher the schedule number, the lower the 
abuse potential. Despite these regulatory efforts, drug abuse 
and diversion continue to exist in the United States. 
According to a 1985 National Household Survey on Drug 
Abuse by the National Institute on Drug Abuse (NIDA 1985), 
that of the estimated 15.7% of the United States population 
over age 12 who have reported using psychotherapeutic drugs, 
approximately 31% of these respondents have admitted to using 
these drugs for non-medical purposes. According to the 1985 
Drug Abuse Warning Network (DAWN) statistics, legal controlled 
substances were involved in 53.5% of all drug-related 
emergency room visits and 49.6% of drug-related deaths 
(NIDA 1986). In the 1986 list of the top DAWN emergency room 
statistics, nearly 20% of those drugs listed were Schedule II 
substances (NIDA 1986). The Drug Enforcement Administration 
statistics reveal that 80 to 90 percent of drug diversion for 
non-medical use is at the practitioner and pharmacy levels 
(U.S. Department of Justice 1987). The concern over Schedule 
II drugs is that categorically these drugs have a high 
prevalence for non-medical use, and they result in large 
health consequences when used non-medically (AMA Department of 
Substance Abuse 1988) . 
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s. Multiple Copy Prescription Programs in the United States 
To provide greater control in the area of distribution of 
schedule II drugs to the ultimate user, the multiple copy 
prescription was devised. According to DEA, the multiple copy 
prescription creates a closed-distribution system which shows 
the final level of distribution to the non-hospitalized 
patient (U.S. Department of Justice 1987). The multiple copy 
prescription system allows for the collection of information 
for law enforcement and regulatory purposes in identifying 
potential diversion by prescribing and dispensing prac-
titioners, "doctor shoppers" (those indi victuals who attempt to 
obtain prescriptions from multiple prescribers), drug abusers 
and forgers. The system provides a deterrent to 
indiscriminant prescribing and dispensing by making the 
practitioner more aware that he is being monitored. 
Multiple copy prescription laws have existed since 1913 
when New York State passed a law in .an effort to control opium 
usage and distribution. This law was revoked in 1915. To 
date only nine states have implemented and one state has 
proposed multiple copy prescription laws. These states are 
California (whose program merits as the oldest, continuous 
program in existence since 1940), Illinois, Idaho, Hawaii, 
New York (whose system recently included Schedule III 
benzodiazepines), Texas, Indiana, Michigan and Rhode Island. 
Massachusetts recently passed legislation to create a multiple 
copy prescription program. Collectively, these states 
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represent over 40% of the total number of prescribers in the 
United States registered with DEA to prescribe controlled 
substances (U.S. Department of Justice 1987). Each state, 
with the exceptions of Michigan and Indiana due to the infancy 
of their programs, has reported a 30 to 50 percent reduction 
in Schedule II prescribing within the first two years of the 
implementation of the program (N.Y.S. Department of Health 
1980, U.S. Department of Justice 1987). All states 
participating in such programs have reported a decrease in the 
incidence of armed robbery, breaking and entering and other 
categories of diversion (N.Y.S. Department of Health 1980, 
U.S. Department of Justice 1987). The DEA's Automation of 
Reports and Consolidated Orders System data reveal a shift in 
the purchasing of Schedule III and IV drugs in these states 
(U.S. Department of Justice 1987). House Representative 
Fortney H. (Pete) Stark of California has introduced legis-
lation in the 1990 and 1991 Congresses to consider a national 
multiple copy prescription program . as a means to protecting 
the nation's health care (HR 5529, HR 5530, and HR 5531). 
C. The Rhode Island Duplicate Prescription Law 
In February 1979, Rhode Island became the sixth state to 
institute a multiple copy prescription program by statute. As 
defined in Title 21, Chapter 28, Section 3.18(d) of the 
Rhode Island Uniform Controlled Substances Act, 
Prescriptions for controlled substances in 
schedule II shall be filed separately and shall not 
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be refilled. The form of record for prescription 
slips for controlled substances in schedule II shall 
consist of two (2) parts, an original and a duplicate 
which are required to be presented to the pharmacy 
by the ultimate user or his representative. 
Pharmacies dispensing controlled substances 
in schedule II are required to deliver to the 
division of drug control all duplicate copies of 
such prescriptions on or before the fifth day of 
the month following the date of dispensing. The 
prescription slip shall be a form provided by the 
director of health. 
Division of Drug Control (DDC) personnel review each duplicate 
form received. Based upon this data collection, the ident-
ification of prescribers, dispensers and patients who might 
utilize the prescription route to obtain or distribute legal 
drugs for illegal purposes is readily accessible, as well as 
information relative to legitimate prescribing patterns and 
use. 
Rhode Island reports a decrease in the number of Schedule 
II prescriptions as well as a decrease in the number of units 
of drug dispensed since the implementation of the program. 
Between 1978 and 1990, there has been an overall 50% re-
duction in the number ·of Schedule II prescriptions dispensed 
(R.I. Department of Health 1990). After an initial distri-
bution of 200 duplicate forms to each prescriber, only 2% of 
all practitioners reordered forms more than once between 1979 
and 1984 (R.I. Department of Health 1989). Between 1979 and 
1986, ten practitioners have surrendered or had their licenses 
revoked due to investigation of their Schedule II prescribing 
practices (R.I. Department of Health 1989). 
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D. Perceptions of the Impact of Multiple Copy Prescription 
Programs on Prescribing 
The multiple copy prescription programs have sparked 
widespread controversy. Although such programs have shown 
to reduce the quantity of drug dispensed thereby reducing the 
potential for abuse and diversion, the multiple copy pre-
scription programs have not been uniformly accepted by the 
medical community. Both the American Medical Association and 
the American Pharmaceutical Association have made stands 
against the implementation of a national multiple copy pre-
scription law. These organizations argue that such programs 
are an invasion of the prescriber's confidentiality to 
prescribe and patient confidentiality. The argument of 
patient confidentiality was heard in the New York State case 
Whalen v. Roe (Whalen 1977). The District Court ruled that 
the use of the triplicate form in New York was an 
unconstitutional invasion of privacy. This ruling was 
overturned by the U.S. Supreme Court in 1977 stating that the 
identification of a pa~ient on a prescription was a reasonable 
means of the State's police powers. 
The DEA contends that no significant complaints from 
patients or physicians have been received in any of the 
program states concerning the laws' interference with 
prescribing these substances or ability to obtain quality 
health care (U.S. Department of Justice 1987). A study 
conducted in Texas following the implementation of its 
triplicate prescription law showed a 60.4% decrease in the 
number of Schedule II prescriptions written in the first year 
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of the program and concluded that the law discouraged the 
prescribing of Schedule II drugs (Sigler et al. 1984). In an 
overview article about states with multiple copy prescription 
programs, the authors acknowledge the reduction of the 
prescribing of Schedule II drugs and offer several anecdotal 
reasons such as prescriber education or the utilization of 
Schedule III, IV or V drugs for the sake of convenience 
(Strauss and Bracelin 1984). Some manufacturers of Schedule 
II medications argue that multiple copy prescription programs 
are costly for the number of diversion cases convicted, 
patient confidentiality is compromised, the forms have street 
value thereby endangering the prescriber and his staff, and 
prescribers may alter their practices to avoid scrutiny by the 
law enforcement officials (Konnor, 1983). 
A review of the literature reveals several theories for 
predicting physicians' prescribing (Soumerai and Avorn 1987, 
Boreham 1989), the interaction among criteria when prescribing 
(Zelnio 1982) and means to improve physicians' decision making 
(Soumerai and Avorn 1990, Peterson and Goldberg 1989). These 
theories do not provide an understanding of how a law such as 
the multiple copy prescription law interacts or affects pre-
scribing practices. 
The identification of the effects of the Rhode Island 
Duplicate Prescription Law on prescribing practices for 
Schedule II drugs is potentially inferable to other states 
already implementing such programs or to states proposing 
similar statutes. The purpose of this research project 
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is to describe the perceptions of licensed practitioners 
concerning the Rhode Island Duplicate Prescription Law on 
prescribing practices, to document the practitioner's 
willingness and ability to prescribe Schedule II drugs which 
are indicated as the primary drug(s) of choice and to describe 
the prescribers' perceptions of the Program and how it has 
affected their behavior by certain risk factors. 
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DATA COLLECTION 
A cover letter and questionnaire were mailed to all po-
tential prescribers (n=3016) of Schedule II drugs registered 
with the Rhode Island Division of Drug Control. The purpose 
of these vehicles was to define the impact of the Rhode Island 
Duplicate Prescription law on prescribing practices for 
Schedule II drugs. The target population was comprised of 
medical physicians, osteopathic physicians, dentists, 
podiatrists and veterinarians. This population represented 
both in-state and out-of-state practitioners. A set of 
mailing labels of those practitioners registered with Rhode 
Island Division of Drug Control (DDC) to prescribe Schedule II 
drugs was obtained from DDC in June, 1990. It contained the 
names and addresses of 2724 medical and osteopathic 
physicians, 211 dentists, 33 podiatrists and 48 veterinarians 
(3016 in toto). A cover letter (Appendix A) describing the 
intent of the questionnaire as a data collection vehicle and 
the intent of the authors to utilize the data was included 
with the two-paged questionnaire. A self-addressed stamped 
return envelope was included in each packet. 
The questionnaire (Appendix A) was developed to define 
several study categories. All questions were followed by 
several answer options. The questionnaire was divided into 
four parts, each prefaced by an explanation of the purpose of 
the section, instructions on how to identify one's responses, 
and qualifying statements which assured the anonymity of the 
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respondent due to the sensitive nature of the subject matter 
and the aggregate manner in which the data would be processed. 
Each question was column-coded for ease of data entry. 
The purpose of part I, Sections A and B was to demo-
graphically describe the respondent. Section A gathered in-
formation concerning the practitioner's primary professional 
degree, specialty practice, board certification and practice 
setting. Inquiries to the number of years as a licensed prac-
titioner in any jurisdiction and in Rhode Island, to location 
of practice, to sex and to age were made in Section B . 
The strategy of Part II was two-fold . First, information 
concerning the practitioner's issuance of prescriptions for 
Schedule II drugs was gathered. This also included the types 
of Schedule II drugs written for as well as an approximation 
of the number of prescriptions for these substances issued per 
month. Second, the respondent was asked if he/she was a 
licensed practitioner in Rhode Island prior to 1979, the year 
in which the Duplicate Prescription law was passed. If the 
answer was positive, the respondent was then queried whether 
a change was perceived in prescribing patterns for Schedule II 
drugs. If yes, a battery of questions identifying several 
reasons explaining the change was included. The purpose of 
the dichotomization of respondents into the categories of 
practicing prior to and after 1979 was to describe a variation 
in the two groups as well as to analyze change in prescribing 
patterns. 
Part III attempted to determine the effect of the Rhode 
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Island Duplicate Prescription law on the practitioner's pre-
scribing of Schedule II drugs and to ascertain the prac-
titioner's knowledge of the law and its intent. Answer 
options to all questions in Part III were based on a LIKERT 
scale ranging from 1 (strongly agree) to 5 (strongly 
disagree) . The first eight questions in Part III asked if and 
how the duplicate prescription law affected the prescriber's 
choice of drugs in creating a therapeutic regimen as well as 
how the prescriber perceived the impact of the law on the 
patient. The next eight questions challenged the prescriber's 
knowledge of the law and how the prescriber perceived the 
intent and benefits of the law. 
The fin al section (Part IV) of the questionnaire was 
designed to establish the direct repercussions the law has had 
on the prescriber. This included a question on how the 
prescriber perceived the impact of the law on quality of care 
and a question relating to Division of Drug Control review of 
the duplicate prescription forms and knowledge of a colleague 
who has undergone licensure limitations due to his Schedule II 
prescribing practices and the subsequent effect on the 
respondent's prescribing practices. This final section also 
created a forum by which the respondent was invited to convey 
his extemporaneous thoughts about the Rhode Island Duplicate 
Prescription Law. 
The mailing of the questionnaire began in November, 1990. 
A cut-off date of January 1, 1991 was made for the inclusion 
of responses for the data file. No attempt for a second 
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mailing of the questionnaire was made. All responses were 
reviewed and hand-coded for specialty practice. 
DATA ANALYSIS 
The data collected from the questionnaire were analyzed 
using the Statistical Analysis System (SAS) Version 6.06 on 
the IBM mainframe computer at the University of Rhode Island. 
The focus of the analysis was the relationship between the 
Rhode Island Duplicate Prescription Law and the therapeutic 
decision-making process and certain demographic character-
istics. 
The PROC FREQ procedure was used in the initial analysis 
to describe the frequency of each variable. This led to an 
identification of potential dependent variables to be used in 
later analyses. These dependent variables were recoded to a 
bivariate structure. Chi-square statistics were performed on 
dependent variables to measure association. The levels of 
significance were chosen as follows: highly significant 
relationships had p-values of less than 0.01, significant 
relationships had p-values of 0.01 to 0.10, and marginally 
significant relationships had p-values of greater than 0.10 to 
0.15. The dependent variables chosen for the analysis of this 
project were the effect of the Rhode Island Duplicate 
Prescription form on the prescriber's decision-making in the 
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creation of a therapeutic regimen (Part III, Question 3 of the 
questionnaire) and the preference of a prescriber to choose an 
alternative drug to a Schedule II in a situation where the 
schedule II drug was clearly indicated (Part III, Question 1 
of the questionnaire). The research questions examined were: 
1.) what is the effect of the Rhode Island Duplicate 
Prescription Form on prescriber's decision-
making, and 
2.) is there a preference for the prescriber to choose 
an alternative drug to a clearly indicated 
Schedule II drug. 
The independent variables of interest were identified as the 
following: primary professional degree, specialty practice, 
practice setting, current practice location, number of years 
as a licensed professional in any jurisdiction, practice in 
Rhode Island before 1979, issuance of prescription (s) for 
Schedule I I drugs, approximate number of Schedule I I pre-
scriptions issued per month, knowledge of review of 
prescribing by Division of Drug Control, age and sex. Odds 
ratios (OR) for the · bivariate relationship between the 
dependent and independent variables were calculated to 
estimate risk ratio using the following formula (Kleinbaum 
1982): 
OR~ (#exposed cases)*(# unexposed non-cases) (I exposed non-cases)*(# unexposed cases) 
A 95% confidence interval (91% CI) was calculated on the odds 
ratio using the following formula: 
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1 + (1.96/X) 
95% CI = OR 
where OR is the odds ratio and X is the square root of Chi-
square. 
Possible interaction terms were explored for the 
model. These terms were created in the DATA step of the 
SAS program. The interaction terms were included in the 
analysis of the model. 
in the Results. 
interaction terms in 
These interaction terms are listed 
The purpose of 
the creation 
the exploration of 
of the Rhode Island 
Duplicate Prescription Form Effects Model and the Ther-
apeutic Preference Model is that the interaction effect 
between two or more independent variables may be lesser or 
greater that the sum of the effect of those independent 
variables. 
The initial models were tested for multicollinearity 
using the PROC REG procedure with COLLIN option. Those 
variables having high collinearity were dropped from the 
model, and the model was retested for multicollinearity with 
the remaining variables. Final models were tested using 
PROC LOGIST with the STEPWISE option. Statistics derived from 
this final step were used to determine the multivariate 
adjusted risk odds ratios of the independent variables. 
The adjusted risk odds ratios, ROR (adj.), for all 
independent variables in the final model as well as the model 
was calculated using the following formula (Kleinbaum 1982): 
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ROR = a 
The ninety-five percent confidence intervals for the estimates 
of relative risk were calculated using the following 
formula: 
B + z (Var) 
CI = a 
Dichotomization of Variables 
Dependent Variables: 
Rhode Island Duplicate Prescription 
Form Affects Therapeutic Decision-
making Process 
Prefer to Prescribe an Alternative 
Drug in a Situation Where a Schedule 
II Drug is Indicated 
Independent Variable 
Primary Professional Degree 
Specialty Practice 
Practice Type 
Presently Practicing in Rhode Island 
Number of Years Licensed in 
Any Jurisdiction 
Practiced in Rhode Island Prior 
to 1979 
Has Ever Issued Schedule II 
Prescription 
Number of Schedule II Prescriptions 
Issued per Month 
16 
O=Disagree 
l=Agree 
O=Disagree 
l=Agree 
O=Non-MD 
l=MD 
O=No 
l=Yes 
O=Solo 
l=Non-Solo 
O=No 
l=Yes 
O=Up to 10 
l=Over 10 
O=No 
l=Yes 
O=No 
l=Yes 
O=Zero 
1=~ One 
Knowledge of Division of Drug 
Control Review 
Age 
Sex 
17 
O=No 
l=Yes 
O=Up to 40 
l=Over 40 
O=Male 
l=Female 
RESULTS 
A total of 3016 questionnaires were mailed to prescribers 
registered with Division of Drug Control. The number of un-
deliverable questionnaires was 43. Of those considered 
mailable, 20 were returned either unanswered or incomplete, 3 
were returned after the proposed cut-off date, and 661 were 
considered complete (22.2%). 
A. Characteristics of Prescribers 
1. Demographics of Prescribers 
A total of 661 prescribers responded to the survey. 
Medical physicians represented 80.5% of the total number of 
respondents, and of those in practice in Rhode Island before 
1979, 85.4% were medical physicians compared to 76.1% of those 
in practice in Rhode Island after 1979. Males dominated the 
study group, representing 82.5% of the study group. Nearly 
25% of the respondents in the post-1979 group were female, 
while only 6.4% of the pre-1979 group were females. This 
reflects a general trend that women are representing a 
greater percentage of those in health care professions. 
Although 39.2% of the study group were under 40 years of age, 
more than 70% of the respondents in the post-1979 group were 
under 40 years of age, and 2.7% of the respondents in the pre-
1979 group were under 40. Only 16. 5% of the study group 
stated that it did not have a specialty practice. A list of 
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the distribution of specialties is found in Appendix C. 
(Table 1) 
Table 1. Demographic Characteristics of Prescribers 
Characteristic 
Sex 
Male 
Female 
Age Category 
Under 30 
30 to 39 
40 to 49 
50 to 59 
60 to 69 
Over 70 
% Total 
(n=661) 
82.5 
16.3 
2.9 
36.3 
27.5 
16.2 
11. 0 
5.7 
Professional 
MD 
Degree 
DO 
DMD/DDS 
DPM 
DVM 
Specialty Practice 
80.5 
6.1 
9.7 
2.0 
1.5 
Yes 78.5 
No 16.5 
Board Certification 
Yes 68 . 1 
No 16 . 5 
19 
% in Practice 
Before 1979 
(n=295) 
91. 5 
6.4 
0.0 
2.7 
33.9 
28.1 
22.7 
12.2 
85.4 
4.4 
7.8 
1. 0 
1. 0 
85.4 
14.9 
66.4 
19.0 
% in Practice 
After 1979 
(n=355) 
74.9 
24.8 
5 . 4 
65.1 
22.8 
5.4 
0. 9 
0.3 
76.1 
7 . 3 
11. 5 
2.8 
2.0 
76.1 
17.7 
69.0 
14.4 
2. Demographics of Prescribers' Practices 
Forty-one percent of the respondents described their 
practice type as solo, and 2.1% stated that they are employed 
in the government or industry sectors. Moreover, 21.1% of the 
prescribers in the post-1979 group indicated that the hospital 
setting was their practice type while 10.2% of the respondents 
in the pre-1979 group stated that they were presently prac-
ticing in a hospital. Nearly 90% of the respondents were 
currently practicing in Rhode Island. More than 94% of those 
in the post-1979 group stated that they had been licensed in 
any jurisdiction for no more than 20 years (versus 40.4% for 
the pre-1979 group}, while 59.3% of the pre-1979 group had 
been licensed for more than 20 years (versus 3.9% for the 
post-1979 group}. An overwhelming majority of respondents 
(91.1%} indicated that they have practiced in Rhode Island for 
more than 10 years. (Table 2}. 
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Table 2. Characteristics of Prescribers' Practices 
Characteristic 
Practice Type 
Solo 
Small Group 
(2-4) 
Large Group 
(~5) 
Hospital 
Government/ 
Industry 
Other 
Number of Years 
Licensed 
Under 5 
6 to 10 
11 to 20 
21 to 30 
31 to 40 
Over 40 
% Total 
(n=661) 
41. 0 
19.5 
12.4 
16.5 
2.1 
5.4 
15.6 
25.0 
28.9 
15.4 
8.5 
6.2 
Presently Practicing 
in Rhode Island 
Yes 89.4 
No 9.5 
Number of Years 
in Rhode Island 
0 
1 to 10 
11 to 20 
21 to 30 
Over 30 
Practiced in RI 
Before 1979 
2.9 
52. 3· 
23.4 
11. 3 
9.2 
Yes 44.6 
No 53.7 
21 
% In Practice 
Before 1979 
(n=295) 
59.0 
14.6 
10.2 
10.2 
1. 7 
2.7 
0.7 
0.7 
39.0 
29.8 
17.3 
12.2 
89.8 
9.2 
1. 4 
7.1 
46.1 
24.7 
20.3 
% In Practice 
After 1979 
(n=355) 
26.2 
23.7 
14.4 
21.1 
2.5 
7.9 
28.2 
45.9 
20.6 
3.1 
0.7 
1.1 
91. 0 
8.5 
3.7 
90.7 
4.5 
0.3 
0.0 
3. Prescribinq of Schedule II Druqs 
Regarding the total sample, 88.5% have prescribed drugs 
in Schedule II for their ambulatory, non-hospitalized 
patients. Seventy percent of the sample also revealed that 
they prescribed between one and twenty-five Schedule II pre-
scriptions per month, and analgesic narcotics in that schedule 
were prescribed by 76.6% of the group. (Table 3) . 
Table 3. Prescribinq of Schedule II Druqs 
Characteristic 
Prescribes Schedule 
II Drugs 
% Total 1 
(n=661) 
Yes 88.5 
No 9.4 
Number of Schedule 
I I Rx Per Month 
0 
1 to 25 
Over 25 
Type of Schedule 
II Drug Prescribed 
Narcotic 
Sedative/ 
Hypnotic 
CNS Stimulant 
Other 
21. 6 
70.5 
4.4 
76.6 
22.1 
17.9 
5.9 
% In Practice 
Before 1979 
(n=295) 
89.5 
9.5 
20.0 
72.2 
5.4 
77.6 
27.8 
14.9 
5.1 
% In Practice 
After 1979 
(n=355) 
89.9 
9.3 
23.7 
70.7 
3.4 
77.5 
19.0 
20.3 
6.8 
1% of total may be larger or smaller than range between pre-
and post-1979 groups due to attrition from lack of response. 
22 
4. Change in Prescribing Practices for Schedule II Drugs for 
Those in Practice in Rhode Island Before 1979 
Of those in practice in Rhode Island prior to the passage 
of the Duplicate Prescription Law, 59 respondents (20%) 
perceive a change in their prescribing practices for Schedule 
II drugs. The availability of therapeutic alternatives to 
Schedule II drugs and a better risk-benefit ratio for the 
patient by utilizing an alternative to the Schedule II drug 
were indicated as reasons for the change in prescribing by 
44.1% of this group. However, the most commonly mentioned 
reason for the decrease in prescribing of Schedule II drugs 
was that the Schedule II prescription form was not handy to 
use. Nearly half of the respondents (40.7%) state that the 
form was not difficult to use. Lack of prescribing confi-
dentiality, lack of patient confidentiality and pharmacy 
problems were not reasons for the decrease in prescribing of 
Schedule II drugs by approximately one-third of the respon-
dents of this sub-group (35.6%, 32.2% and 33.9% respectively). 
(Table 4). A plot of the reverse scores to indicate 
convenience of the form, i.e. the higher the score, the more 
inconvenient the form appears to be for the prescriber, shows 
a skew to the right. (Figure 1). 
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Table 4. Reasons Identified for the Decrease in Prescribing 
Schedule II Drugs by Those in Practice in Rhode 
Island Before 1979 Whose Prescribing Patterns Have 
Changed (n=59). 
% No Effect 
Reasons % Agree % Disagree No Answer 
Availability of Therapeutic 
Alternatives 44.1 18.6 37.3 
Better Risk-Benefit Ratio 44.1 15.3 40.6 
Patient Mix 15.3 13.6 71.1 
Fewer Utilization Problems 
with Alternatives 28.8 15.3 55.9 
Difficulty with Form 22.0 40.7 37.3 
Lack of Handiness of Form 47.5 18.6 33.9 
Lack of Prescribing 
Confidentiality 11. 9 35.6 52.5 
Lack of Patient 
Confidentiality 20.3 32.2 52.5 
Pharmacy Problems 16.9 33.9 50.8 
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5. The Rhode Island Duplicate Prescription Law and 
Prescribing Practices 
Of the entire study group, 34.2% stated that the Rhode 
Island Duplicate Prescription Law affected their decision 
process in the creation of a therapeutic regimen. Nineteen 
percent of those in the pre-1979 group had knowledge of a 
colleague whose prescribing practices for Schedule II drugs 
resulted in license limitation, suspension or revocation or in 
mandatory drug rehabilitation, while only 9.9% of the 
respondents in the post-1979 group were aware of a colleague 
in such a situation (X2=12.38, p=0.0). Of those who did 
respond affirmatively, 23.4% of that group felt that they had 
limited their own prescribing practices for Schedule II drugs 
as a result. (Table SA) . The associations between the 
responses and practicing before or after 1979 is reported in 
Table SB. 
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Table SA. The Rhode Island Duplicate Prescription Law and 
Prescribing Practices1 
Effect of 
Law 
Duplicate Rx 
Affects Decision 
Agree 
Disagree 
No Effect 
Knowledge of 
Colleague 
Under Review 
Yes 
No 
Limitation of 
Schedule II 
Prescriptions 
Yes 
No 
% Total 
..illl. 
34.2 (226) 
36.8 (243) 
23.2 (153) 
14.1 (93) 
81.4 (538) 
23.4 (22) 
65.6 (61) 
% In Practice 
Before 1979 
..illl. 
35.3 (104) 
33.9 (100) 
24.4 (72) 
19.0 (56) 
75.9 (224) 
25.0 (14) 
66.1 (37) 
% In Practice 
After 1979 
l!1L 
34.1 (121) 
40.0 (142) 
22.5 (80) 
9.9 (35) 
88.2 (313) 
20.0 (7) 
65.7 (23) 
1column totals may not add up to 100% due to lack of response. 
Table SB. The Rhode Island Duplicate Prescription Law and 
Prescribing Practices and the Association Between 
Pre- and Post-1979 Groups. 
Effect of Law x2 P-value 
Duplicate Prescription Affects 
Decision 1.14 0.29 
Knowledge of Colleague 
Under DOC Review 12.38 0.00 
Limitation of Schedule II 
Prescriptions 0.17 0.68 
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6. Prescribers' Perceptions of the Rhode Island Duplicate 
Prescription Law 
Prescribers were asked how they perceived the benefits of 
the Rhode Island Duplicate Prescription Law. A majority 
(64.1%) agreed that the law helped to reduce the abuse of 
schedule II drugs. The difficulty for forgery of pre-
scriptions for these drugs was identified as a beneficial end 
by 77.7% of the study group. For purpose of comparison, only 
those who agreed (i.e. those who strongly agreed plus those 
who agreed) and those who disagreed (i.e. those who strongly 
disagreed plus disagreed) were studied. The Chi-square for the 
relationship between the response for forgery and whether the 
respondent had practiced in Rhode Island before the passage of 
the law was 3.29 (p=0.07) indicating a significant 
relationship. Slightly more than 50% of the target group was 
aware that Division of Drug Control reviewed each duplicate 
prescription form, and a statistically significant relation-
ship existed between knowledge of the review and whether the 
respondent had practiced in Rhode Island before the passage of 
the law (X2=6.76, p=0.01). Of those respondents in the 
pre-1979 group, 55.3% agreed that the state should mandate 
review of prescribing for Schedule II drugs, while 62.8% of 
the post-1979 group agreed. This perception and practicing 
after the passage of the law had a highly associated rela-
tionship (X2=6.04, p=0.01). Most respondents (76.4%) stated 
that their patients did not report problems concerning phar-
macies when attempting to fill Schedule II prescriptions, 
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and there was no difference between the pre- and post-1979 
groups for this response. Overall, 45.1% of the study group 
felt that the Rhode Island Duplicate Prescription Law had no 
effect on the quality of care they delivered to their 
patients, while 22.5% of the total group stated that the 
Law had a beneficial effect on quality of care. The relation-
ship between responses for this question and whether a 
respondent practiced before 1979 or not was significant 
(X2=6.33, p=0.04). Table 6A summarizes the perceptions of the 
law, and Table 6B summarizes the Chi-square and p-values for 
the relationships between the perceptions of the law and the 
pre- and post-1979 groups. 
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Table 6A. Prescribers' Perceptions of the Rhode Island Duplicate 
Prescription Lav1. 
Perception 
Reduces Abuse of C-II Drugs 
Agree 
Disagree 
No Effect 
Thwarts Doctor Shoppers 
Agree 
Disagree 
No Effect 
Decreases C-II Availability 
Agree 
Disagree 
No Effect 
Makes Forgery Difficult 
Agree 
Disagree 
No Effect 
Makes Aware of Side Effects 
Agree 
Disagree 
No Effect 
Decreases Overutilization 
Agree 
Disagree 
No Effect 
Identifies Abusers in 
Medical Community 
Agree 
Disagree 
No Effect 
Protects Prescriber from 
the Patient 
Agree 
Disagree 
No Effect 
Aware of DDC Review 
Yes 
No 
t 'l'ota12 
(n=661) 
64.1 
14.1 
13.3 
58.1 
16.3 
17.1 
46.0 
24.1 
21.3 
77.2 
6.8 
8.5 
57.3 
18.6 
17.1 
66 . 4 
11.0 
15 . 6 
51. 6 
16.8 
22.1 
64.0 
9.8 
19.5 
50.1 
45.7 
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t in Practice 
Before 1979 
(n=295) 
66.1 
13.6 
11.5 
63 . 1 
16.3 
12.5 
49.5 
23.1 
18.6 
77.3 
8.8 
6.4 
61.0 
16.6 
14.9 
71.5 
11.2 
10.5 
56.9 
14.9 
19.0 
69.5 
9.2 
16.3 
55.6 
40.3 
t Xn Practice 
After 1979 
(n=355) 
64.7 
14.6 
15.2 
55.2 
16.9 
21.1 
43.7 
25.6 
24.2 
78.9 
5.1 
10.4 
55.8 
20.6 
19.2 
63.7 
11. 0 
20.3 
48.2 
18.6 
25.4 
60.8 
10.4 
22.8 
46.5 
51.3 
Table 6.A. (Cont. ) 
perception 
State Should Mandate 
Review of Prescribing 
Agree 
Disagree 
No Effect 
Patients Report Problems 
with Pharmacy 
Yes 
No 
Affects Quality of Care 
Yes, Beneficial 
Yes, Negative 
No 
t In Practice 
t 'l'otal Before 1979 
(n=661) (n=295) 
58.5 55.3 
23.1 12.4 
11.2 9.2 
19.3 19.0 
76.4 76.3 
22.5 23.7 
6.2 8.5 
45.1 42.0 
1Columns do not add up to 100% due to lack of responses. 
' 
In Practice 
After 1979 
(n=355) 
62.8 
19.7 
13.0 
18.3 
78.0 
22.3 
4.2 
48.5 
2Percent of total group may appear larger or smaller than the range 
between the two separate groups due to attrition in reponses in 
dichotomizing the study group. 
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Table 6B. The Association Between the Prescribers' Perceptions of the 
Rhode Island Duplicate Prescription Law and Practice in Rhode 
Island Before or After the Passage of the Law. 1 
Perception 
Reduces Abuse of C-II Drugs 
Thwarts Doctor Shoppers 
Decrease C-II Availability 
Makes Forgery Difficult 
Makes Aware of Side Effects 
Decreases Overutilization 
Identifies Abusers in the 
Medical Community 
Protects Prescriber from 
the Patient 
Aware of DDC Review 
State Should Mandate 
Review of Prescribing 
Patients Report Problems 
With Pharmacy 
Affects Quality of Care 
x2 P-value 
0.18 0.68 
0.61 0.44 
1.38 0.24 
3.29 0 . 07 
2.07 0.15 
0.15 0.70 
3.04 0.08 
0 . 94 0 . 33 
6. 76 0.01 
6.04 0.01 
0.08 0.77 
6.33 0.04 
1Chi-squares and p-values are for the comparison of the extremes in 
responses (i.e., agree and disagree) and the pre- and post- 1979 
groups. 
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7. Perceptions of Prescribers' Willingness to Prescribe 
Agents in Schedule II Which are the Primary Drug(s) 
of Choice 
Prescribers were asked several questions designed to 
measure their willingness and ability to prescribe Schedule II 
drugs. Nearly one-third (32.8%) of the respondents stated 
that they preferred to prescribe drugs other than Schedule II 
medications (i.e. Schedule I I I, IV or V or non-scheduled 
legend drugs) in situations where a Schedule II drug is 
clearly indicated. The availability of alternative med-
ications to Schedule II drugs was a reason for not prescribing 
Schedule II drugs for 71% of the total group. The concern 
over malpractice litigation resulting from the use of an 
alternative drug to a Schedule II when the Schedule II was 
clearly indicated is apparent in 18.2% of the target group. 
Although 51% and 54% of the study group agreed that the use 
of a scheduled alternative or a non-scheduled alternative 
respectively may have adverse consequences for the patient, 
56.6% of the respondents believe that there is not less 
risk for the patient in using an alternative drug to the 
Schedule II (X2=7.02, p=0.01). Nearly 62% of the study group 
disagreed that there was better patient compliance in using 
an alternative drug to a Schedule II, and a significant 
relationship between that response and spatial time 
with respect to the passage of the Law (X2=3.34, p =0.07). 
Table 7A summarizes the responses to the questions concerning 
perception of the willingness to prescribe Schedule II drugs, 
and Table 7B summarizes the Chi-squares and p-values. 
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Table 7A. Prescribers' Perceptions of the Willingness to Prescribe 
Aqents in Schedule II 11hich are the Primary Drugs of 
Choice. 1 
Perception 
Prefer to Prescribe 
Alternative to C-II 
Agree 
Disagree 
No Effect 
Therapeutic Alternative 
Reason to Not Prescribe 
Schedule II Drug 
Agree 
Disagree 
No Effect 
use of Alternative May 
cause Malpractice 
Agree 
Disagree 
No Effect 
use of Schedule III,IV or 
V Alternative May Cause 
Pt. Adverse Consequence 
Agree 
Disagree 
No Effect 
Use of Non-Scheduled 
Alternative May Cause 
Pt. Adverse Consequence 
Agree 
Disagree 
No Effect 
Less Risk for Patient 
in Using Alternative 
Agree 
Disagree 
No Effect 
Better Patient Compliance 
with Non-Schedule II 
Agree 
Disagree 
No Effect 
t Tota12 
(n=665) 
32.8 
53.4 
8.2 
71.0 
14.1 
9.1 
18.2 
54.9 
20.1 
51. 0 
27.8 
14.2 
54.0 
21.5 
14.5 
19.4 
56.6 
16.0 
5.9 
61. 9 
24.4 
t In Practice 
Before 1979 
(n=295) 
31. 9 
51.5 
10.8 
69.8 
14.9 
8 . 5 
19.3 
49.8 
23.4 
47.5 
29.8 
14.9 
53.2 
23.7 
13.5 
23.4 
50.8 
17.3 
7.8 
60.3 
23.7 
Columns do not add up to 100% due to lack of responses. 
2% of total may appear larger or smaller due to attrition. 
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t In Practice 
After 1979 
(n=355) 
34.4 
55.5 
6.2 
73.2 
13.5 
9.9 
17.2 
60.6 
18.0 
54.6 
27.0 
16.9 
55.5 
20.3 
15.7 
16.6 
62.3 
15.5 
4.5 
64.5 
25.4 
Tab1e 7B. The Association Between the Prescribers' Perceptions of 
the Wi11ingness to Prescribe Agents in Schedu1e II Which 
Are the Primary Drugs of Choice and Practice in Rhode 
Is1and Before or After the Passage of the Dup1icate 
Prescription Law. 1 
Perception 
Prefer to Prescribe 
Alternative to Schedule II 
Therapeutic Alternative 
Reason to Not Prescribe 
Schedule II 
use of Alternative May 
cause Malpractice 
use of Schedule III, IV or 
v Alternative May Cause 
Patient Adverse Consequence 
use of Non-scheduled 
Alternative May Cause 
Patient Adverse Consequence 
Less Risk for Patient in 
Using Alternative 
Better Patient Compliance 
with Non-schedule II 
P-va1ue 
0.00 0.99 
0.41 0.52 
2.16 0.14 
1.68 0.19 
1.00 0.32 
7.02 0.01 
3.34 0.07 
1Chi-squares and p-values are for the comparison of the extremes in 
responses (i.e. agree and disagree) and the pre- and post-1979 
groups. 
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B. Bivariate Analysis of Independent and Dependent Variables 
The analysis between the independent and dependent 
variables was limited to eleven pertinent independent 
variables and the two dependent variables of interest 
(whether the Schedule II duplicate prescription form affected 
decision making when creating a therapeutic regimen and if 
there existed a preference for the prescriber to select 
alternatives to a Schedule II drug in a situation where the 
Schedule II drug was clearly indicated) . Most variables, 
both independent and dependent, were altered in such a way 
to create a bivariation within the variable to illustrate 
exposure versus unexposure. This allowed for calculation of 
Chi-square, p values, odds ratio and 95% confidence intervals. 
The following independent variables were altered in such a 
manner: 
1. Age 
2. Sex 
3. Degree 
4. Specialty 
5. Practice Type 
6. Presently Practicing 
in Rhode Island 
7. Number of Years Licensed 
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Over 40 years of age 
40 or younger 
Female 
Male 
Medical physicians 
Non-MD professionals 
Has specialty practice 
Does not have specialty 
Non-solo practice 
Solo practice 
Yes 
No 
Over 10 years 
Up to 10 years 
8. Practiced in RI Prior to 
1979 
9. Has Ever Issued Schedule II 
Prescription 
10. Number of Schedule II 
Prescriptions Per Month 
11. Knowledge of Division of 
Drug Control Review 
Yes 
No 
Yes 
No 
One or more 
Zero 
Yes 
No 
The dependent variables of interest were collapsed as follows: 
1. RI Duplicate Prescription 
Form Affects Decision-making 
2. Prefers to Prescribe Alter-
natives to Schedule II 
Agree 
Disagree 
Agree 
Disagree 
Odds ratios and 95% confidence intervals were calculated. 
1. The Bivariate Relationship Between the Independent 
Variables and If the Rhode Island Duplicate Pre-
scription Form Affects Decision-making for the Study Group 
The summary of the relationship between whether the Rhode 
Island duplicate prescription form affects the decision-making 
process in the creation of a therapeutic regimen and the in-
dependent variables for the entire study group is found in 
Table 8. Six variables exhibited Chi-squares greater than 
2.00 (degree, specialty, number of years licensed, presently 
practicing in Rhode Island, sex and number of prescriptions 
issued per month) . Practitioners with an MD degree were 2.03 
times as likely to agree that the form affects one's decision 
(95% CI 1.25, 3.29). The risk that having a specialty 
practice was associated with agreeing that the form affects 
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one's decision was 2.16 (95% CI 1.26, 3.70). Two variables, 
sex and number of prescriptions issued per month, had odds 
ratios of less than 1 (OR=0.47 and 0.68 respectively). 
Table 8. Summary of the bivariate association of the in-
dependent variables and the effect of the form. 
variable x2 p-value OR 95% CI 
Degree 
(MD vs. Non-MD) 8.23 0.004 2.03 1. 25, 3.29 
Specialty 
(Yes vs. No) 7.86 0.005 2.16 1. 26, 3.70 
Practice Type 
(Solo vs. Not) 0.11 0.745 
# Yrs Licensed 
(>10 vs :s_lO) 2.93 0.087 1. 38 1.05, 1. 45 
Practice in RI 
(Yes vs. No) 2.07 0.150 1. 74 1. 22, 3.70 
Sex 
(F vs. M) 8.00 0.005 0.47 0. 2 8' 0.79 
Age 
(>40 vs. <40) 1. 63 0.202 
Issuance of Rx 
(Yes vs. No) 0.36 0.547 
# Rx/Month 
(>1 vs 0) 2.61 0.106 0.68 0. 53' 0.90 
Before 1979 
(Yes vs. No) 1.14 0.286 
Review 
(Yes vs. No) 1. 81 0.178 
2. Bivariate Association Between Independent Variables and 
If the Rhode Island Duplicate Prescription Form Affects 
Decision-making for the Pre-1979 Group 
The analysis for the group of respondents who stated 
that they were in practice in Rhode Island prior to 1979 
and the association of independent variables and if the 
Schedule II prescription form affects decision-making is 
presented in Table 9. The bivariate analysis reveals that 
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there are three variables which have cells too small to count, 
i.e., there were five or less respondents in a particular 
cell. These variables were the number of years licensed, 
presently practicing in Rhode Island and age. Of the 
remaining variables, the review variable had a Chi-square of 
3.03 and was significant (p=0 . 082). The odds ratio associated 
with this variable was 0.61. 
Table 9. Summary of the bivariate association of the inde-
pendent variables and the effect of the form for 
the pre-1979 group. 
Variable x2 p-value OR 95% CI 
Degree 
(MD Vs. Non-MD) 1.25 0.264 
Specialty 
(Yes vs. No) 0.42 0.520 
Practice Type 
(Solo vs. Not) 0.07 0.787 
# Yrs Licensed 
(>10 vs. ,S.10) CELLS TOO SMALL TO COUNT 
Practice in RI 
(Yes vs. No) CELLS TOO SMALL TO COUNT 
Sex 
(F vs. M) 0.00 0.949 
Age 
(>40 vs. ,S.40) CELLS TOO SMALL TO COUNT 
Issuance of Rx 
(Yes VS. No) 0 . 7 1 0.398 
# Rx/Month 
(~1 vs. 0) 0.14 0.713 
Review 
(Yes vs. No) 3.03 0.082 0.61 0.35, 0 . 94 
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3. Bivariate Association Between Independent Variables and 
If the Rhode Island Duplicate Prescription Form Affects 
Decision-making for the Post-1979 Group. 
The analysis for bivariate association for the post-
1979 group revealed five statistically significant variables. 
They were degree, specialty, number of years licensed, sex 
and number of schedule II prescriptions written per month . 
The range of the Chi-squares for the independent variables 
was 0.00 (practice type) to 9.07 (specialty). The odds 
ratios for the significant variables ranged from 0.42 
(sex) to 2.99 (specialty). The results are summarized in 
Table 10. 
Table 10. Summary of the bivariate association between the 
independent variables and the effect of the form 
on decision-making for the post-1979 group. 
Variable x2 p-value OR 95% CI 
Degree 
(MD vs. Non-MD) 6.88 0.009 2.27 1. 23 I 4 . 19 
Specialty 
(Yes vs. No) 9.07 0.003 2.99 1. 4 7 I 6.10 
Practice Type 
(Solo vs. Not) 0. 00 . 0.955 
# Yrs Licensed 
(>10 vs. ,S,10) 2.98 0.084 1. 62 1.07, 2.08 
Practice in RI 
(Yes vs. No) 0.17 0.681 
Sex 
(F vs. M) 8.17 0.004 0.42 0. 23, 0.77 
Age 
(>40 vs. ,S,40) 1. 03 0.310 
Issuance of Rx 
(Yes vs. No) 0.00 0 . 956 
# Rx/Month 
(~1 vs. 0) 6.03 0.014 0.47 0 • 2 6 I 0.86 
Review 
(Yes vs. No) 0.30 0.587 
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4. Bivariate Association Between the Independent Variables 
and Therapeutic Preference for an Alternative Drug to a 
Schedule II Drug for the Study Group. 
All Chi-squares for the independent variables were below 
3.0 with the exception of three variables. The issuance of 
schedule II prescriptions had the highest chi-square (5.41) 
and a p-value of 0.02. The odds ratio associated with this 
variable was 0.48 (95% CI=0.26, 0.89). The variable with 
the least association was a whether a prescriber practiced 
in Rhode Island prior to 1979 (X2=0.00, p=0.994). Table 11 
summarizes these statistics. 
Table 11. Summary of the bivariate association between in-
dependent variables and therapeutic preference in 
the study group 
Variable x2 p-value OR 95 % CI 
Degree 
(MD vs. Non-MD) 3.42 0 . 064 0.68 0.45, 0.98 
Specialty 
(Yes vs. No) 0.52 0.469 
Practice Type 
(Solo vs. Not) 2.53 0.112 0.75 0.52, 0.94 
# Yrs Licensed 
(>10 vs. <10) 0.20 0 . 653 
Practice in RI 
(Yes vs. No) 0.19 0.667 
Sex 
(F VS. M) 0 . 48 0.495 
Age 
(>40 vs. ~40) 0.57 0.449 
Issuance of Rx 
(Yes vs . No) 5.41 0.020 0.48 0. 2 6' 0.89 
# Rx/Month 
(~1 vs. 0) 5.03 0 . 025 0.62 0.41, 0.94 
Befor e 1979 
(Yes vs. No) 0.00 0.994 
Review 
(Yes vs. No) 0.01 0.930 
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s. Bivariate Association Between the Independent Variables 
and Therapeutic Preference for an Alternative Drug to a 
schedule II Drug for the Pre-1979 Group. 
The summary of the association between the independent 
variables and therapeutic preference for the pre-1979 group 
is found in Table 12. One variable had cells too small to 
count for Chi-square statistics (number of years licensed) . 
The variable, issuance of a Schedule II prescription, was the 
only statistically significant variable (X2=3.41, p=0.065). 
The remaining variables had Chi-squares ranging from 0.06 
(age) to 1.74 (number of prescriptions issued per month). 
Table 12 . Summary of the bivariate association between the 
independent variables and therapeutic preference 
in the pre-1979 group 
Variable 
Degree 
(MD vs. Non-MD) 
Specialty 
(Yes vs . No) 
Practice Type 
(Solo vs. Not) 
# Yrs Licensed 
(>10 vs. <10) 
Practice in RI 
(Yes vs. No) 
Sex 
(F vs. M) 
Age 
(>40 vs. <40) 
Issuance of Rx 
(Yes vs. No) 
# Rx/Month 
(~l vs. 0) 
Review 
(Yes VS. No) 
p-value 
0.12 0.725 
0.07 0.796 
1.44 0.231 
CELLS TOO SMALL TO COUNT 
0.63 
0.46 
0.06 
3.41 
0 . 427 
0.498 
0.804 
0.065 
0 . 09 0.761 
1.74 0.187 
42 
0.399 
95% CI 
0.15, 0.95 
6. Bivariate Association Between the Independent Variables 
and Therapeutic Preference for an Alternative Drug to a 
Schedule II Drug for the Post-1979 Group. 
The number of prescriptions for Schedule II drugs issued 
per month was highly associated with therapeutic preference 
for an alternative drug to a Schedule II drug (X2=6.54, 
p=0.011) for the post-1979 group. The odds ratio for that 
variable was 0.50 and the 95% confidence interval was 0.29 to 
0.98. Two additional variables were shown to be associated to 
the dependent variable. Those variables were degree and the 
issuance of a schedule II prescription. Table 13 summarizes 
the bivariate statistics. 
Table 13. Summary of the bivariate association between the 
independent variables and therapeutic preference 
for the post-1979 group 
Variable x2 p-value OR 95% CI 
Degree 
(MD vs. Non-MD) 4.03 0.045 0.59 0.35, 0.99 
Specialty 
(Yes vs. No) 0.65 0.421 
Practice Type 
(Solo vs. Not) 1. 33 . 0.249 
# Yrs Licensed 
(>10 vs. ~10) 0.05 0.825 
Practice in RI 
(Yes vs. No) 0.02 0.881 
Sex 
(F vs. M) 0.08 0.773 
Age 
(>40 vs. ~40) 1. 31 0.252 
Issuance of Rx 
(Yes vs. No) 2.70 0.101 0.50 0.22, 0.87 
# Rx/Month 
(~1 vs. 0) 6.54 0.011 0.50 0 • 2 9 t 0.98 
Review 
(Yes vs. No) 1. 68 0.195 
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c. Multivariate Analysis of Independent and Dependent 
variables 
The original binary regression models contained the 
eleven independent variables which have been discussed in 
previous sections. These variables were regressed on the 
two dependent variables. Collinearity was assessed for 
each model, and preliminary regression models were run. 
Table 14 summarizes the binary regression statistics 
for the original model for the effect of the form on 
decision-making, and Table 15 also summarizes these sta-
tistics for the original model for the dependent variable, 
therapeutic preference. The former model Chi-square was 
27.88 with 11 degrees of freedom and a p-value of 0.003 
while the latter model exhibited a Chi-square of 15.39 
with 11 degrees of freedom and a p-value of 0.167. 
Table 14. Summary of the results of the binary regression 
procedure on the initial form effects model. 
Variable beta xz p-value 
.£ 
Intercept -1.6115 5.4534 0.0195 
Degree 0.4422 2.0007 0.1572 0.094 
Practice Type -0.0269 0.0148 0.9032 -0.007 
Specialty 0.5280 2.4451 0.1179 0.105 
# Yrs Licensed 0.2941 0.6702 0.4130 0.080 
Practice in RI 0.9818 3.7054 0.0542 0.121 
Age 
-0.1837 0.2937 0.5878 -0.050 
Sex 
-0.7402 5.3504 0.0207 -0.146 
Before 1979 -0.1548 0.2315 0.6304 -0.042 
Issuance of Rx 0.7019 2.0391 0.1533 0.097 
# Rx/Month -0.8333 7.0039 0.0081 -0.180 
Review -0.1824 0.7787 0.3775 -0.050 
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Table 15. Summary of the results of the binary regression 
procedure on the initial therapeutic preference 
model. 
variable 
Intercept 
Degree 
Practice Type 
Specialty 
# Yrs Licensed 
Practice in RI 
Age 
Sex 
Before 1979 
Issuance of Rx 
# Rx/Month 
Review 
0.3715 
-0.3259 
-0.3713 
0.0527 
-0.2547 
0.2097 
0.4762 
0.1091 
-0.2632 
-0.4086 
-0.4267 
0.1026 
0.4072 
1. 5017 
3.2502 
0.2876 
0.5934 
0.2736 
2.2383 
0.1596 
0.7495 
0.9303 
2.6424 
0.2876 
p-value 
0.5234 
0.2204 
0.0714 
0.8521 
0.4411 
0.6009 
0.1346 
0.6895 
0.3866 
0.3348 
0.1040 
0.5918 
-0.093 
-0.100 
0.011 
-0.069 
0.028 
0.130 
0.022 
-0.071 
-0.055 
-0.093 
0.020 
The regression models were tested for collinearity and 
for interactions between two or more variables. Models were 
also designed for both dependent variables to determine the 
association between the independent variables for the pre-
and post-1979 groups. 
1. Collinearity 
The PROC REG procedure with C04LIN option was invoked to 
assess collinearity problems. A summary of the collinearity 
diagnostics is found in Appendix D. A collinearity value of 
greater than 0.5 was used as an indicator of possible 
problems. All collinearities greater than 0.5 involved 
interaction terms. 
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2. Interactions 
The models were assessed for the interactions between 
two or more of the independent variables. The interaction 
terms which were evaluated were: 
SEXAGE 
DE GAGE 
SEXDEG 
PRAC79 
DEG79 
sex x age 
degree x age 
sex x degree 
practice type x practice in RI before 1979 
degree x practice in RI before 1979 
The interaction terms were evaluated in the models using the 
PROC LOGIST with STEPWISE option. No interaction terms were 
found to be significant in any of the models. 
3. Evaluation of Interim Models 
The interim models were evaluated for model Chi-squares 
and model p-values. Each independent variable for each model 
was evaluated for Chi-square value, p-value and standard 
error. Those models with low chi-squares and low p-values 
plus model variables with low chi-squares, low p-values and 
high standard error were eliminated. The PROC LOGIST 
procedure with STEPWISE option was used to determine the 
best fit models. 
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4. The Final Models 
The following models were chosen which best describe 
the relationship of the independent variables and the 
dependent variables. The SAS output for the regression 
models may be found in Appendix E. 
A. Table 16 summarizes the results of the binary 
logistic regression model on the final form effects model 
for the entire study group. The test statistics for the 
model were: 
Model Chi-Square 23.353 
Degrees of Freedom 9 
p-value 0.0051 
This model was significant. 
Table 16. The summary of results of binary logistic 
regression on the final form effects model 
for the entire study group. 
Variable beta x2. p-value r 
Intercept -0. 2399 0.3668 0.5448 
# Rx/Month -0.5169 3.8384 0.0501 -0.112 
Before 1979 -0.1262 0.1562 0.6927 -0.034 
Sex -0.8337 7.0291 0.0080 -0.165 
Age -0.2003 0.3527 0.5526 -0.054 
Specialty 0.5206 2.4135 0.1203 0.103 
Review -0.2560 1. 5828 0.2084 -0.070 
Degree 0.4459 2.0855 0.1487 0.095 
Practice Type -0.00840 0.0015 0.9692 -0.002 
# Yrs Licensed 0.3127 0.7688 0.3806 0.080 
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The multivariate adjusted odds risk ratio, ROR (adj.) was 
calculated for each variable in the model. A 95% confidence 
interval was ascertained from the odds ratio. 
Those variables with the greatest ROR (adj.) were specialty 
(1.68), degree (1.56) and number of years licensed (1.37). 
summaries of the ROR (adj.) and confidence intervals are 
found in table 17. 
Table 17. Summary: Logistic Regression - Prescriber Charac-
teristics as Predictors of Self-Reports of Whether 
the RI Duplicate Prescription Form Affects 
Prescribing for Schedule II Drugs for the Entire 
Study Group. 
Variable 
Intercept 
# Rx/Month 
(~1 vs. 0) 
Before 1979 
(Yes vs. No) 
Sex 
(Female vs. Male) 
Age 
(>40 vs. ~40) 
Specialty 
(Yes vs. No) 
Review 
(Yes vs. No) 
Degree 
(MD VS. Non-MD) 
Practice Type 
(Solo vs. Non-Solo) 
# Yrs Licensed 
(>10 vs. ~10) 
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ROR (adj.) 
0.79 
0.60 
0.88 
0.43 
0.82 
1. 68 
0.77 
1.56 
0.99 
1. 37 
95% CI 
0.36, 1.71 
0.36, 1.00 
0.47, 1.65 
0.24, 0.81 
0.42, 1.59 
0.87, 3.25 
0.52, 1.15 
0.85, 2.86 
0.65, 1.52 
0.68, 2.75 
B. Table 18 summarizes the statistics for the final 
therapeutic preference model for the entire study group. 
The test statistics for the model were: 
Model Chi-Square 
Degrees of Freedom 
P-Value 
This model was significant. 
15.084 
9 
0.0887 
Table 18. The summary of results of binary logistic 
regression on the final therapeutic 
preference model for the entire study group. 
Variable Beta x2 p-value £ 
Intercept 0.3103 0.8090 0 . 3684 
Before 1979 -0.2570 0.7198 0.3962 -0.070 
Sex 0.1461 0.2965 0 . 5861 0.029 
Age 0.4860 2.3440 0 . 1258 0.133 
Specialty 0.0586 0.0433 0.8352 0.012 
# Rx/Month -0.5353 5.2626 0.0218 -0 . 116 
Degree -0.3343 1.5981 0.2062 -0.075 
Practice Type -0.4172 4.1794 0.0409 -0.133 
# Yrs Licensed -0.2656 0.6467 0.4213 -0.070 
Review 0.0946 0.2495 0.6175 0.026 
Th e adjusted odds ratios calculated for each variable 
reveal those with the greatest association are the intercept 
(1.36), sex (1.16), age (1.63) and specialty (1.06). Those 
95% confidence intervals which did not include 1 in the 
interval were number of prescriptions written per month and 
practice type . (Table 19) 
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Table 19. Summary: Logistic Regression - Prescriber Charac-
teristics as Predictors of Self-Reports of Thera-
peutic Preference to Prescribe an Alternative Drug 
to an Indicated Schedule II Drug for the Entire 
Study Group. 
variable 
Intercept 
Before 1979 
(Yes vs. No) 
sex 
(Female vs. Male) 
Age 
(>40 vs. ~40) 
Specialty 
(Yes vs. No) 
# Rx/Month 
(.~l vs. 0) 
Degree 
(MD vs. Non-MD) 
Practice Type 
(Solo vs. Non-Solo) 
# Yrs Licensed 
(>10 vs ~10) 
ROR (adj.) 
1. 36 
0.77 
1.16 
1. 63 
1. 06 
0.59 
0.72 
0.66 
0.77 
95% CI 
0.69, 2.68 
0.43, 1.40 
0.68, 1.96 
0.87, 3.03 
0.61, 1.84 
0.37, 0.93 
0.43, 1.20 
0.44, 0.98 
0.40, 1.47 
C. Table 20 summarizes the results of the binary 
logistic regression model on the final form effects model for 
the pre-1979 group. The test statistics for the model were: 
Model Chi-Square 5.446 
Degrees of Freedom 4 
P-value 0.2445 
This model was not significant. 
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Table 20. The summary of results of binary logistic 
regression on the final form effects model 
for those in practice in Rhode Island before 1979. 
variable Beta x2 p-value .!: 
Intercept -0.6887 0.9033 0.3419 
f Rx/Month -0.3699 0.6309 0.4271 -0.076 
Review -0.4487 2.2838 0.1307 -0.121 
Practice Type 0.0543 0.0339 0.8539 0.014 
Issuance of Rx 1.3089 2.6142 0.1059 0.167 
Table 21 summarizes the multivariate adjusted odds ratios 
and the 95% confidence intervals for each variable. Practice 
type and issuance of prescriptions for schedule II drugs had 
the highest ROR (adj.) (1.06 and 3.70 respectively); however, 
the confidence intervals both include 1 in the interval. 
Table 21. Summary: Logistic Regression - Prescriber Charac-
teristics as Predictors of Self-Reports of Whether 
the RI Duplicate Prescription Form Affects 
Prescribing for Schedule II Drugs for Those in 
Practice in Rhode Island Before 1979. 
Variable ROR (adj.) 95% CI 
Intercept 0.50 0.12, 2.08 
# Rx/Month 
(2:,1 vs . 0) 0.69 0. 2 8' 1. 72 
Review 
(Yes VS. No) 0.64 0. 36' 1.14 
Practice Type 
(Solo vs. Non-Solo) 1. 06 0. 59' 1. 88 
Issuance of Rx 
(Yes VS. No) 3.70 0.76, 18.09 
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D. Table 22 summarizes the results of the binary 
logistic regression model on the final therapeutic pre-
ference model for the pre-1979 group. The model test 
statistics are as follows: 
Model Chi-Square 
Degrees of Freedom 
P-value 
This model was significant. 
9.621 
5 
0.0867 
Table 22. The summary of results of binary logistic 
regression on the final therapeutic preference 
model for those in practice in Rhode Island 
before 1979. 
Variable beta x2 p-value 
Intercept 0.9578 1. 7120 0.1907 
£ 
Specialty -0.0685 0.0255 0.8731 0.013 
Degree 0.000708 0.0000 0.9986 -0.000 
Practice Type -0.6066 3.9508 0.0468 -0.164 
Review -0.5184 3.1732 0.0749 -0.141 
Issuance of Rx -0.9430 2.7307 0.0984 -0.128 
The variables with the greatest ROR (adj.) were the 
intercept (2.61) and degree (1.00); however, the 95 % 
confidence intervals included 1 in the interval. (Table 23). 
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Table 23. Summary: Logistic Regression - Prescriber Charac-
teristics as Predictors of' Self-Reports of Thera-
peutic Preference to Prescribe an Alternative Drug 
to an Indicated Schedule II Drug for Those in 
Practice in Rhode Island Before 1979. 
variable ROR (adj.> 95% CI 
Intercept 2.61 0.62, 10.94 
Specialty 
(Yes vs. No) 0.93 0.40, 2.16 
Degree 
(MD vs. Non-MD) 1. 00 0.45, 2.24 
Practice Type 
(Solo vs. Non-Solo) 0.55 0.30, 0.99 
Review 
(Yes vs. No) 0.60 0.34, 2.97 
Issuance of Rx 
(Yes vs. No) 0.40 0. 13' 1.19 
E. The results of the binary logistic regression 
procedure on the final form effects model for those 
prescribers who were in practice in Rhode Island after 1979 
are presented in table 24. The test statistics for the model 
were: 
Model Chi-Square 18.501 
Degrees of Freedom 7 
P-value 0.0099 
This model was highly significant. 
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Table 24. The summary of results of binary logistic 
regression on the final form effects model 
for those prescribers who were in practice in 
Rhode Island after 1979. 
variable beta x2 p-value 
.£ 
Intercept 0.0207 0.0024 0.9608 
sex -0.8632 6.7491 0.0094 -0.203 
Age -0.0114 0.0010 0.9742 -0.002 
t Rx/Month -0.8234 5.7377 0.0166 -0.184 
Review -0.1321 0.2424 0.6225 -0.036 
Degree 0.6814 3.9487 0.0469 0.155 
Practice Type 0.1468 0.2347 0.6281 0.037 
# Yrs Licensed 0.3469 0.9100 0.3401 0.083 
The calculation of the odds risk ratios and the 
95% confidence intervals show that the intercept, degree, 
practice type and number of years licensed have the greatest 
magnitude (1.02, 1.98, 1.16, and 1.42 respectively). The 
number of prescriptions for schedule II drugs written per 
month, sex and the degree have confidence intervals which do 
not contain 1 in the interval. (Table 25). 
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Table 25. Summary: Logistic Regression - Prescriber Charac-
teristics as Predictors of Self-Reports of Whether 
the RI Duplicate Prescription Form Affects 
Prescribing for Schedule II Drugs for Those in 
Practice in Rhode Island After 1979. 
variable ROR (adj.) 95% CI 
Intercept 1. 02 0.45, 2.33 
Sex 
(Female vs. Male) 0.42 0.22, 0.81 
Age 
(>40 vs. <40) 0.99 0. 4 9' 1. 98 
# Rx/Month 
(~1 vs. 0) 0.44 0.22, 0.86 
Review 
(Yes vs. No) 0.88 0.52, 1. 48 
Degree 
(MD vs. Non-MD) 1. 98 1.01, 3.87 
Practice Type 
(Solo vs. Non-Solo) 1.16 0.64, 2.10 
# Yrs Licensed 
(>10 vs. ~10) 1. 42 0. 6 9' 2.89 
F. Table 26 summarizes the results of the binary 
logistic regression model on the final therapeutic preference 
model for those in practice in Rhode Island after 1979. The 
test statistics for the model were: · 
Model Chi-Square 
Degrees of Freedom 
P-value 
This model was significant. 
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16.097 
8 
0.0410 
Table 26. The summary of results of binary logistic 
regression on the final therapeutic pre-
ference model for those in practice in Rhode Island 
after 1979. 
variable beta x2 p-value .£ 
Intercept 0.2394 0.3235 0.5695 
sex 0.0408 0.0179 0.8936 0.009 
Age 0.5253 2.4018 0.1212 0.128 
specialty 0.1037 0.0753 0.7838 0.023 
Degree -0.5013 1. 9842 0.1589 -0.118 
Practice Type -0.2068 0.5375 0.4635 -0.051 
# Rx/Month -0.7879 6.9361 0.0084 -0.181 
# Yrs Licensed -0.1636 0.2271 0.6337 -0.039 
Review 0.4793 3.6337 0.0566 0.130 
Several variables exhibited multivariate adjusted odds 
risk ratios greater than 1. The only variable which did not 
contain 1 in its 95% confidence interval was number of pre-
scriptions written per month (95% CI=0.25, 0.82). Table 27 
summarizes these results. 
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Table 27. Summary: Logistic Regression - Prescriber Charac-
teristics as Predictors of Self-Reports of Thera-
peutic Preference to Prescribe an Alternative Drug 
to an Indicated Schedule II Drug for Those in 
Practice in Rhode Island After 1979. 
variable ROR (adj.) 95% CI 
Intercept 1.27 0. 56, 2.90 
sex 
(Female vs. Male) 1. 04 0.57, 1. 89 
Age 
(>40 vs. <40) 1. 69 0.87, 3.29 
specialty 
(Yes vs. No) 1.11 0.53, 2.33 
Degree 
(MD vs. Non-MD) 0.61 0.30, 1. 22 
Practice Type 
(Solo vs. Non-Solo) 0.81 0.47, 1. 41 
# Rx/Month 
(2:.1 vs . 0) 0.46 0.25, 0.82 
# Yrs Licensed 
(>10 vs. ,S.10) 0.85 0.43, 1. 66 
Review 
(Yes vs. No) 1. 62 0. 9 9, 2.64 
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DISCUSSION 
A. Independent and Dependent Variables 
1 . Demographic Characteristics of Prescribers and Practices 
The responding prescribers represented a blend of various 
professions, varying specialty practices, a span of age groups 
and both males and females. The study group included 
prescribers who had practiced in Rhode Island prior to (44. 6%) 
and following (53.7%) the passage of the Rhode Island Dupli-
cate Prescription Law. Most respondents ( 8 9. 4%) presently 
practiced in Rhode Island. The respondents were primarily 
male (82.5%); however, while only 6.4% of those responding to 
the survey who practiced in Rhode Island prior to the imple-
mentation of the law were female (6.4%), nearly one-quarter of 
the respondents in the post-1979 group (24 . 8%) were female. 
More than two-thirds of the respondents (66.7%) were under 50 
years of age. As expected in the comparison between the pre-
and post-1979 groups, there was a higher percentage of those 
under 50 (93.3%) in the post-1979 group than in the pre-1979 
group (36.6%). 
The distribution of respondents in the pre- and post-1979 
groups appeared to be different with regard to professional 
degree. Al though medical physicians (MD) dominated both 
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groups, 85.4% of the respondents in the pre-1979 group were 
MD'S, while only 76.1% of the respondents in the post-1979 
group were identified by that professional degree. Dentists 
(DDS/DMD) represented the next largest group ( 9. 7% of the 
total), and veterinarians (DVM) represented the smallest group 
(1.5%). It is interesting to note that the distribution of 
the professions in the original mailing was as fallows: 
medical and osteopathic physicians (90.6%), dentists (7.0%), 
podiatrists (1.1%) and veterinarians (1. 6%), and this was 
similar to the overall distribution of professions responding 
to the survey. Most respondents claimed to have one or more 
specialty practices (78.5%), and most respondents were board 
certified (68.1%). 
There was a marked difference in the distribution of 
practice type between the pre- and post-1979 groups. Clearly, 
most respondents in practice prior to the passage of the 
law were presently practicing alone (59%) while only 26.2% 
of those in the post-1979 group stated to have a solo prac-
tice. Nearly 2.5 time~ more respondents in the post-1979 
group than the pre-1979 group work primarily in the hospital 
environment. As should be noted, many respondents who claimed 
to work in "other" sites extemporaneously stated to work in a 
health maintenance organization (HMO) . 
More than 98 percent of the respondents in the pre-1979 
group had been licensed in any jurisdiction for more than 
ten years, and more than 91 percent of this group also worked 
in Rhode Island for more than 11 years; whereas, 74.1% of the 
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respondents in the post-1979 group had been licensed for 10 or 
less years, but 94.4% of this group had practiced in Rhode 
Island for up to 10 years. 
2. Prescribing of Schedule II Drugs 
Most respondents (88. 5%) had prescribed Schedule II drugs 
at some time since initial licensure for an ambulatory, non-
hospitalized patient, and this was consistent for the pre- and 
post-1979 groups (89.5% and 89.9% respectively). Nearly 
three-quarters (74.5%) of the respondents indicated to have 
prescribed one or more Schedule II prescriptions per month. 
Considering that nearly 90% of the respondents presently 
practice in Rhode Island, a majority of the study group has 
had the opportunity to be exposed to the Rhode Island Dupli-
cate Prescription Law, and again this was consistent for both 
the pre- and post-1979 groups (77.6% and 74.1% respectively). 
A slightly larger percentage of the . respondents in the post-
1979 group (23.7%) indicated prescribing no Schedule II drugs 
per month as compared to the pre-1979 group (20.0%). It is 
important to note that some of the respondents who indicated 
prescribing zero Schedule II prescriptions per month extem-
poraneously stated that overall they prescribe less than 1 
prescription per month. Although this study did not inves-
tigate why a prescriber did not issue a Schedule II pre-
scription in Rhode Island, there may be several reasons to 
explain this behavior. For example, one would expect that a 
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pathologist would not issue a prescription for Schedule II 
drugs; therefore, a specialty type may be a cause for a 
prescriber to not prescribe Schedule II drugs. The pos-
sibility exists that non-prescribers make a conscious decision 
to not prescribe Schedule II drugs, but this was not measured 
in the study. There may be clinical reasons which cause a 
prescriber to not select a Schedule II drug or concerns about 
identification if the prescriber utilizes the Schedule II 
prescription form. Practice status may preclude the pre-
scribing of Schedule II drugs, but, again, this was not 
measured in this study. 
The percentage of respondents who prescribe certain 
classes of Schedule II drugs reflected the Division of Drug 
Control's data describing the percentage of classes of 
Schedule II drugs prescribed (DDC 1990) . Most respondents 
(76.6%) prescribed narcotic analgesics in Schedule II. There 
appears to be a difference between the pre- and post-1979 
groups with regard to the prescribing of CNS stimulants (14.9% 
and 20.3% respectively) and to the prescribing of sedative/ 
hypnotics (27.8% and 19.0% respectively). There are possible 
reasons which may explain these differences. Although there 
appears to be a difference between the pre- and post-1979 
groups with regard to having a specialty practice (85.4% and 
76.1% respectively), perhaps a difference in the distribution 
of specialty types between these two groups would explain the 
difference in prescribing patterns. Education about the law 
and its implications may be an explanation for the differences 
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between the pre- and post 1979 groups due to the nature of 
change and discussion throughout the state which occurred in 
order to prepare those prescribers for the implementation of 
the law in February 1979; however, education nor continuing 
education about the law was not measured in this study. 
3. Perceived Change in Prescribing for the Pre-1979 Group 
Although 48.8% of the group in practice before the pas-
sage of the law perceived that their prescribing practices for 
Schedule II drugs had not changed, 20% stated their pre-
scribing patterns had changed. Because there had been an 
overall decrease in the number of Schedule II prescriptions 
written in Rhode Island since the passage of the law, it was 
important to ascertain the reasons for the decrease by those 
in practice before the law who felt that their prescribing 
practices had changed. 
The availability of therapeutic alternatives was iden-
tified as a reason for the decrease in prescribing of 
Schedule II drugs by 44.1% of those who perceived their 
prescribing patterns had changed. Over 40% of this group 
(44.1%) also indicated that there was a better risk-benefit 
ratio for the patient in selecting an alternative drug to a 
Schedule II. 
Nearly 50% of the respondents in this group stated that 
the Rhode Island Duplicate Prescription Form was not handy to 
use (47.5%), i.e., not readily available, inconvenient. Con-
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versly, 40.7% stated that the form was not difficult to use, 
i.e., ease in filling out form, self-explanatory. Approx-
imately one-third of the respondents perceiving a change in 
their prescribing patterns in the pre-1979 group stated that 
lack of prescribing confidentiality (35.6%), lack of patient 
confidentiality (32.2%) and pharmacy problems associated with 
filling and dispensing Schedule II drugs (33. 9%) were not 
reasons for the decrease in prescribing of Schedule II drugs. 
No one reason seemed to overwhelmingly describe why 
there may be a decrease in prescribing of Schedule II drugs 
for this group. However, a number of prescribers felt that 
therapeutic alternatives and better risk-benefit ratios 
impacted upon reasons not to write Schedule II prescriptions. 
A lack of convenience of the form may impact upon a prescriber 
to not use the form. The reverse score plot of a convenience 
measure shows that the skew to the right could indicate a lack 
of convenience, although this was not clearly measured. Con-
venience of the form may be related to choosing not to pre-
scribe Schedule II drugs. There may be other reasons which 
would explain the decrease of prescribing of Schedule II drugs 
as indicated by those who perceive a change in their pre-
scribing since the passage of the law; however, these were not 
measured. 
4. Prescribing Practices for Schedule II Drugs 
Although more than one-third of the overall respondents 
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(36.8%) state that the Rhode Island Duplicate Prescription 
form does not affect the decision-making process in the 
creation of a therapeutic regimen and 23.2% state that the 
form has no effect on the decision-making, another one-third 
of the respondents stated that the form does affect the 
decision-making process. There appears to be an unwillingness 
or concern to prescribe Schedule II drugs or a perception of 
an obstacle to prescribe Schedule II drugs for the 34.2% who 
state that the form does affect decision-making. The effect of 
the form on decision-making could be on several levels such as 
the unwillingness to prescribe a Schedule II drug or the 
unwillingness to prescribe certain quantities of drug, an 
awareness of the potential side effects and adverse conse-
quences for the patient in utilizing a Schedule II drug or for 
the need to more closely monitor the patient who is treated 
with Schedule II drugs. 
There was no statistical difference between the pre- and 
post-1979 groups with regard to the self-report of the 
effect of the form on prescribing (X2=1.14, p=0.29). 
In attempting to ascertain if the Rhode Island Duplicate 
Prescription Law had an effect on prescribing of Schedule II 
drugs, the respondents were asked if knowledge of a colleague 
whose prescribing practices for Schedule II drugs caused the 
colleague licensure limitation, suspension or revocation or 
mandatory drug rehabilitation. If the response was yes, the 
respondent was asked if that knowledge had caused the re-
spondent to curtail his/her prescribing. There was a highly 
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significant association between knowledge of a colleague under 
ooc review and practicing before 197 9 (X2=12. 38, p=O. 00) . 
While only 14.1% of the total group was aware of a colleague 
under DOC review, nearly one-quarter of these respondents 
(23.4%) stated that their prescribing practices had become 
limited as a result. This indicates that one of the out-
comes of the law may be to have some inhibitory effects on 
prescribing. 
5. Prescribers' Perceptions of the Law 
Since the law was designed to accomplish several ends 
such as reducing abuse of Schedule II drugs, preventing 
forgeries and elevating awareness of the potential risks 
involved for the patient who uses a Schedule II drug, an 
attempt was made to ascertain how prescribers perceived 
the above stated variables. 
Most respondents agreed that the Rhode Island Dupli-
cate Prescription Law decreases the abuse of Schedule II 
drugs (64.1%), that it thwarts patients who attempt to obtain 
Schedule II drugs from a multitude of legitimate prescribers 
(58.1%), and that it provides protection for the prescriber 
from the patient (64.0%). The responses in these categories 
were similar for the pre- and post-1979 groups. It is 
interesting to note that a large percentage of prescribers 
(46.0%) believe that the Rhode Island Duplicate Prescription 
Law decreases the availability of Schedule II drugs, although 
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the definition of "availability" was not stated. 
There were differences in several responses between the 
pre- and post-1979 groups. Although 77.2% of the study group 
felt that the Rhode Island Duplicate Prescription Law helped 
make forgeries for Schedule II prescriptions more difficult, 
a significant relationship existed between the response to the 
question and whether the prescriber practiced in Rhode Island 
after the passage of law (X2=3.29, p=0.07). A higher per-
centage of the respondents (8.8%) in the pre-1979 group as 
compared to the post-1979 group (5.1%) believed the law did 
not make forgery difficult. This is an interesting response 
since ' the control produced by the forms was discussed with 
those in practice before the law was implemented, and the pre-
1979 group have been able to realize the trends in prescribing 
of Schedule II drugs, in forgery and diversion and other 
factors since the passage of the law. 
There is a marginally significant relationship between 
practicing after the passage of the law and the response to 
the question concernin·g the law raising consciousness about 
the potential side effects and toxicities of Schedule II 
drugs (X2=2.07, p=0.15). A higher percentage of the respon-
dents in the pre-1979 group (61. 0%) believed the law made 
prescribers more aware of the side effects of these drugs, and 
16.6% of this group did not believe the law caused prescribers 
to be more conscious of side effects, while only 55.8% of the 
post-197 9 group agreed that the law made prescribers more 
aware, and 20.6% of this group did not. This reinforces the 
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education component regarding use of Schedule II drugs as well 
as reflecting a possible difference in education about the law 
and about therapeutics between the pre- and post-1979 groups. 
Slightly more than one-half (50.1%) of the respondents 
were aware of Division of Drug Control review of received 
duplicate prescriptions, while 45.7% of the respondents were 
not aware of the review. A highly significant relationship 
existed between knowledge of DDC review and practicing before 
the passage of the law (X2=6.76, p=0.01), and a larger per-
centage of the pre-1979 group were aware of the review (55.6%) 
while only 46.5% of the post-1979 group were cognizant of the 
review. This might be related to when an individual became 
licensed in Rhode Island. Those who were in practice in Rhode 
Island before the passage of the law were exposed to sym-
posiums, continuing education, and educational literature in 
an effort to familiarize these prescribers to the law and its 
implications. Those who have come to practice in Rhode Island 
after the passage of the law have been exposed to little 
educational material concerning the Rhode Island Duplicate 
Prescription Law. 
Although 50.1% of the prescribers were aware of Di-
vision of Drug Control review of the duplicate forms received, 
it is interesting to note that most respondents (58.5%) felt 
the State of Rhode Island should mandate the review of pre-
scribing practices for Schedule II drugs, and a highly 
significant relationship existed between the responses and 
practicing in Rhode Island before the passage of the law 
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(X2=6.04, p=0.01). While only 55.6% of the respondents in the 
pre-1979 group stated that the state should mandate review of 
prescribing, 62. 8% of the post-1979 group felt the state 
should mandate review. While 19.7% of the post-1979 group 
felt that the state should not mandate review, only 12.4% of 
the respondents in the pre-1979 group disagreed. 
About one-half of the study group (51.6%) stated that the 
law helped identify abusers in the medical community, while 
16.8% stated that the law did not, and 22.1% felt that there 
was no effect of the law on identifying these abusers. A 
difference existed between the pre- and post-1979 groups with 
regard to this question (X2=3.04, p=0.08). More than half of 
the pre-1979 group (56.9%) versus 48.2% of the post-1979 group 
agreed that the law helped identify abusers . This relates to 
the knowledge of a colleague under DDC review, and it appears 
more likely that those who practiced in Rhode Island before 
the passage of the law were more aware of DDC review and its 
consequence for the prescriber than those in the post-1979 
group. This may be related to an actual working knowledge of 
the law which may be related to a lack of initial and 
continuing education about the law, its workings and its 
consequences. 
The impact of the law on quality of care appeared to be 
an issue which needs further investigation. A highly sig-
nificant relationship existed between the response to the 
effect the law has on quality of care and the pre- and post-
1979 groups (X2=6.33, p=0.04). While only 4.2% of the re-
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spondents of the post-1979 group stated that the law had 
a negative impact upon the dispensing of quality of care, 
more than twice the percentage of respondents in the pre-
1979 groups (8.5%) stated that the law had a negative effect 
on quality of care. The pre-1979 group had experienced a 
change in prescribing routine as a direct result of the law, 
for example, the prescriber had to change from utilizing a 
private prescription blank to a prescribed Schedule II pre-
scription form issued by the state. The law required a 
change in practice by mandating a specific form for 
Schedule II drugs. This is different from the post-1979 group 
which did not go through a mechanical change and process for 
writing Schedule II drugs but immediately used the prescribed 
form. 
6. Perceptions of the Willingness to Prescribe 
Schedule II Drugs 
In a situation where a Schedule II drug is clearly 
indicated, 53.4% of the respondents stated that they would 
not choose an alternative drug to the Schedule II; however, 
32.8% of the study group stated that they would choose an 
alternative drug. There was no statistical difference between 
the pre- and post-1979 groups (X2=0.00, p=0.99). Although the 
use of an alternative medication to a Schedule II drug may not 
harm the patient, others may question if the use of non-
Schedule II alternatives to a clearly indicated Schedule II 
drug may impact beyond the health care arena. Although a 
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patient may be helped to the same or larger extent by using 
an alternative (which was not measured in this study), the 
result in not prescribing an indicated drug in an indicated 
circumstance may be an increase in spending of health care 
dollars by the patient to alleviate or irradicate the 
health care problem (e.g. the need for additional 
prescriptions, hospitalization), loss of wages and workdays 
by the patient who may not be getting better due to sub-
optimal therapy, 
structure. 
and a disruption of the patient's social 
Most prescribers felt that the use of an alternative to 
a Schedule II drug does not cause malpractice for the 
prescriber (54.9%). There existed a marginally significant 
association between the response and the pre- and post-1979 
groups (X2=2.16, p=0.14). A higher percentage of the 
prescribers in the post-1979 group (60.6%) believed that the 
utilization of an alternative drug to a Schedule II would not 
bring malpractice litigation against the prescriber while 
49.8% of the pre-1979 group stated that malpractice was not 
a result of prescribing an alternative. This may indicate 
that malpractice is not an issue for the prescriber in 
choosing to prescribe an alternative to a clearly indicated 
Schedule II drug; however, 18.2% of the respondents believed 
that choosing an alternative would have an impact on mal-
practice litigation, yet one-third would prescribe an 
alternative. 
A majority of the respondents recognized that the use of 
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a scheduled alternative (51%) or a non-scheduled alternative 
(54%) to a Schedule II drug may cause the patient adverse 
consequences. This study did not compare the prescribers' 
perceptions of the magnitude of adverse consequences resulting 
from Schedule II drugs and from non-Schedule II drugs. Given 
that most respondents believe use of an alternative may cause 
adverse consequences for the patient and that one-third of the 
respondents choose to prescribe alternatives to Schedule II, 
it appears that the possibility of adverse consequences for 
the patient by using an alternative is not a factor in 
selecting the alternative. 
A majority of respondents (56.6%) stated that there is 
not less risk for the patient in utilizing an alternative to 
a Schedule II drug; therefore, it is possible that the alter-
native may pose more risk for the patient than the Schedule II 
drug in the eyes of the prescriber, yet one-third of the 
prescribers stated that an alternative drug to a Schedule II 
would be selected, and 18% of the . prescribers state that 
choosing an alternative .may result in malpractice litigation 
for the prescribe. Therefore, it appears that risk for the 
patient may not be a consideration for the prescriber. There 
existed a highly significant relationship between response to 
the patient risk question and the pre- and post-1979 groups 
(X2=7. 02, p=O. 01). A majority of the prescribers in the post-
1979 group (62.3%) stated that they perceive there is more 
risk for the patient in using an alternative; whereas, a 
smaller percentage of the respondents in the pre-1979 group 
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(S0.8%) stated that there is more risk. 
similarly, 61.9% of the respondents (60.3% of the pre-
1979 group and 64.5% of the post-1979 group) stated that 
they disagree that there is better patient compliance with 
a non-Schedule II drug versus a Schedule II drug; therefore, 
there may be worse compliance with the alternative, yet one-
third of the prescribers would choose an alternative. 
compliance appears not to be an issue, and a significant 
relationship existed between responses to compliance issues 
and the pre- and post-1979 groups (X2=3.34 p=0.07) . 
It appears that issues of therapeutics, malpractice, 
risk for the patient and compliance do not wholly explain 
the unwillingness to prescribe Schedule II drugs; however, 
it appears, from the results of the descriptive statistics, 
that the Rhode Island Duplicate Prescription Law may play a 
role in not prescribing a Schedule II drug as illustrated by 
the effect of the form on decision-making, knowledge of DDC 
review of prescribing and knowledge of a colleague under DDC 
review for prescribing. 
B. Bivariate Association Between Independent Variables 
and the Dependent Variables 
The relationship between the effect of the Rhode Island 
Duplicate Prescri ption form in decis i on-making for the 
creation of a therapeutic regimen and selected independent 
variables for the study group revealed several significant 
associations. 
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Those respondents who are medical physicians (MD) are 
2. 03 times more likely to indicate that the form affects their 
decision-making process than those prescribers who are not 
medical physicians. This may relate to the high percentage of 
respondents who were medical physicians as well as to the 
nature of medical treatment of the human body in toto. 
Those respondents who stated to have specialty prac-
tice (s) are 2.16 more likely for being affected by the form 
than those who do not have specialty practices. Certain 
specialty practices are associated with the treatment of 
medical conditions which indicate the use of Schedule II 
drugs; therefore, the higher risk may be related to the 
nature of the specialty. 
The more years (greater than 10) a respondent has been 
licensed, the more likely (OR=l.38) the respondent has the 
perception that the form affects decision-making as compared 
to those who have been licensed for less no more than 10 
years. This increased likelihood · may be associated with 
perceived impact of the form on long-established prescribing 
patterns. 
Those respondents presently practicing in Rhode Island 
are 1.74 times more likely to indicate the form affects the 
decision-making process than those who do not practice in 
Rhode Island. This is expected since those who practice in 
Rhode Island must practice under the guise of the law. 
Females are 0.47 times less likely to indicate that the 
the form affects decision-making versus males; i.e. female 
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prescribers appear to have a lesser risk than males. 
Those issuing one or more Schedule II prescriptions per month 
are 0.68 times less likely to indicate the form affects 
decision-making than those who issue zero Schedule II 
prescriptions per month. It may be postulated that prescribers 
who choose not to prescribe Schedule II drugs may do so as a 
result of the influence of the law, due to specialty types or 
due to therapeutic preference. 
To better understand which variables influenced the 
prescribers who practiced in Rhode Island before the passage 
of the law and those who came into practice in Rhode Island 
after 1979 and the perceived affect of the form, it was 
necessary to dichotomize the data set into two subsets 
(pre- and post-1979 prescribers). 
The only variable which had a significant association 
with the effect of the form for those in practice before 
1979 was knowledge of Division of Drug Control review of 
the duplicate prescriptions (X2=3.03, · p=0.082). However, 
those prescribers in th~ pre-1979 group who were aware 
of the review were 0.61 times less likely to perceive the 
form affects decision-making than those who were not aware of 
DDC review. 
Several variables appeared to be associated with the 
effect of the form for those prescribers in the post-1979 
group. Unlike the pre-1979 group, review was not a sig-
nificant variable (X2=0.30, p=0.587). Those prescribers 
who had specialty practices were nearly 3 times more likely 
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to report that the form affects decision-making in a ther-
apeutic regimen than those who do not have specialty prac-
tices for the post-1979 group. The variable with the next 
highest odds ratio was degree, and medical physicians in the 
post-1979 group are more likely (OR=2. 27) to exhibit the 
studied outcome. A significant variable which carries the 
lowest odds ratio was sex, that females in the post-1979 group 
were 0.42 times less likely than the males to exhibit the 
exposure outcome. 
The second dependent variable of interest, therapeutic 
preference to select an alternative to a Schedule II drug in 
a situation where the Schedule II is clearly indicated, would 
seem to be congruent to the form effects dependent vari able, 
i.e., those who choose not to prescribe a Schedule II drug may 
or may not be influenced by the duplicate prescription form, 
and those whose decision-making is affected by the duplicate 
prescription form may or may not choose an alternative drug to 
a clearly indicated Schedule II drug. Since these two 
variables seem intertwi~ed, it would be interesting to see 
if the same variables influence the same outcomes. 
With regard to the study group, four variables were 
associated with therapeutic preference to choose an 
alternative. Those independent variables were degree, 
practice type, issuance of Schedule II prescriptions, and 
the number of Schedule II prescriptions written per month. 
The exposed levels of each of these variables appeared to 
have some protective effect on therapeutic preference, i.e., 
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the odds ratios were less than 1.0. 
For the pre-1979 group, only the issuance of prescription 
variable was significant (X2=3.41, p=0.065) for the assoc-
iation with therapeutic preference. The odds ratio was 0.399, 
thus the likelihood for those issuing a Schedule II drug to 
choose a therapeutic alternative was only about 40% that of 
those who never issued a Schedule I I prescription. This 
again indicates that those who choose not to prescribe 
Schedule II prescriptions may be affected by the law. 
The variables which were associated with therapeutic 
preference for those in practice after the passage of the law 
were similar to the profile of the entire group. A medical 
physician (MD), issuance of a Schedule II prescription, and 
prescribing more than one Schedule II prescription per month 
were associated with the dependent variable of interest, and 
each had odds ratios less than 1.0 (0.59, 0.50 and 0.50 re-
spectively) . The influence on therapeutic preference is in 
part related to an effect by the law~ 
C. The Final Multivariate Models 
Multivariate regression models were tested to best 
describe the relationship between the dependent variables of 
interest (effect of the form on decision-making and ther-
apeutic preference to choose an alternative to a Schedule 
76 
II drug) for the study group and for the pre- and post-1979 
subgroups. 
1. The Form Effects Models 
The final form effects model for the study group is as 
follows: 
FORM EFFECTS = -0.2399(intercept) - 0.5169(#Rx/month) -
0.1262(RI1979) - 0.8337(Sex) - 0.2003(Age) + 
0.5206(Specialty) - 0.2560(Review) + 
0.4459(Degree) - 0.0084(Practice Type) + 
0.3127(1 Yrs Licensed) 
This model was significant (X2=23.353, p=0.0051) for 
explaining the variation in the responses to whether the Rhode 
Island Duplicate Prescription form affected the prescriber's 
decision in the creation of a therapeutic regimen. 
The multivariate adjusted odds risk ratio, ROR (adj.), 
was calculated for each independent variable. Three variables 
have ROR (adj.) greater than 1.0 (an ROR which equals 1.0 
indicated that the risk of the exposed versus the 
unexposed is equal thus there is no effect in the exposure) . 
Those variables which are associated with a risk greater 
than 1.0 are specialty (1.68), degree (1.56) and the number of 
years licensed (1.37). In a multivariate model, all other 
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variables are controlled, and in this model it indicated that 
those who have a specialty practice, those who are medical 
physicians and those who have been licensed for more than 10 
years are at slightly higher risk for the affect of the form. 
It is important to note that the 95% confidence intervals for 
these variables do contain 1.0 in the intervals; therefore, 
it is possible that these vari ables may not have an effect on 
the final outcome. 
The multiple logistic regression form effects model for 
those in practice before 1979 was not significant (X2= 5.446, 
p=0.2445), and no inferences may be made about this model. 
The final model was: 
FORM EFFECTS = -0.6887(Intercept) - 0.3699(#Rx/month) -
0.4487(Review) + 0.0543(Practice type) + 
1 . 3089(issuance of Rx) 
The multivariate logistic regression form effects model 
for the post-1979 group was significant (X2=18.501, p=0 . 0099). 
The final model was: 
FORM EFFECTS = O. 0207 (intercept) - 0. 8632 (sex) -
0.0114(Age) - 0.8234(#Rx/month) -
0 . 132l(Review) + 0.6814(Degree) + 
0.1468(Practice Type) + 0.3469(# Yrs Licensed) 
The degree variable was highly associated with the e f fect 
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of the form and had the largest ROR ( 1. 98) , thus medical 
physicians are at nearly twice the risk to report the form 
affects decision-making as compared to non-MD prescribers. 
The ROR for number of years licensed is 1.42; thus, those 
prescribers in the post-1979 group who had been licensed for 
more than 10 years are nearly one and one-half times more 
likely to report that the form affects decision-making. 
2. The Therapeutic Preference Models 
The final therapeutic preference model for the entire 
study group was marginally significant (X2=15.084, p=0.0887) 
and is as follows: 
THERAPEUTIC PREFERENCE = 0. 3103 (Intercept) -
0.2570(RI1979) + 0.146l(Sex) + 
0.4860(Age) · + 0.0586(Specialty) -
0. 5353 (# Rx/month) - 0. 3343 (Degree) -
0.4172(Practice type) -0.2656(# Years 
Licensed) + 0.0946(Review) 
The model revealed that those respondents over 40 years 
of age have 1. 63 times higher risk than those prescribers 
under 40 years of age to choose a therapeutic alternative to 
a clearly indicated Schedule II drug. Female prescribers 
had 1.16 times higher risk than male prescribers to choose a 
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therapeutic alternative. 
The therapeutic preference model for the pre-1979 group 
was significant (X2=9.621, p=0.0867) and is as follows: 
THERAPEUTIC PREFERENCE = 0. 9578 (Intercept) -
0.0685(Specialty) + 0.000708(Degree) -
0.6066(Practice type) - 0.5184(review) 
- 0.9430(Issuance of Rx) 
It is interesting to note that the degree variable 
displays a risk odds ratio of 1.0 which indicates that the 
risk for medical physicians is the same as non-MD. 
The final therapeutic preference model for the post-1979 
group is a significant model (X2=16 . 097, p=0.04) and is as 
follows: 
THERAPEUTIC PREFERENCE = 0. 2394 (Intercept) + 0. 0408 (Sex) 
+ 0.5253(Age) + 0.1037(Specialty) -
0.5013(Degree) - 0.2068(Practice Type) 
- 0.7879(1 Rx/Month) - 0.1636(# Years 
Licensed) + 0.4793(Review) 
Many variables for the post-1979 group had adjusted odds 
ratios greater than 1.0. The age variable had the greatest 
ROR (1. 69). This indicates that those prescribers over 40 
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years of age in the post-1979 group have 1.69 times the risk 
to prescribe a therapeutic alternative compared to younger 
prescribers. Knowledge of Division of Drug Control review had 
a large ROR associated with prescribing a therapeutic 
alternative (1.62). This implies that knowing DDC reviews 
schedule II prescriptions places the prescriber at nearly 
twice the risk for selecting a therapeutic alternative than a 
prescriber who is not aware of the review. It appears that 
choosing an alternative may be a response to the law. This 
provides reinforcement for the need for on-going education 
concerning the law and its implications. 
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CONCLUSIONS 
The study of the impact of the Rhode Island Duplicate 
Prescription Law on prescribing practices for Schedule II 
drugs examined factors relating to prescribers and their 
perceptions of the knowledge of the law as well as their 
willingness to prescribe Schedule II drugs as a function 
of the influence of the law. 
The respondents represented a mix of physicians, 
dentists, podiatrists and veterinarians, those young and old, 
in various types of practice settings. The respondents 
represented both in-state and out-of-state prescribers as 
well as those who had practiced in Rhode Island before the 
implementation of the law and those who did not. 
The study revealed that several factors impact upon the 
choice to prescribe a Schedule II drug or not. A variety of 
law variables and therapeutic variables combine to influence 
prescribing choices such as knowledge of Division of Drug 
Control review of duplicate prescription forms, knowledge of 
a colleague who has undergone licensure limitation as a result 
of his prescribing patterns and awareness of side effects 
associated with Schedule II drugs. It has been shown that 
certain variables do not appear to impact upon drug therapy 
selection such as threat of malpractice for those who choose 
alternatives to a clearly indicated Schedule II drug and 
selection of alternative despite the admission that the 
alternative may pose a greater risk for the patient. 
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There are differences between those who practiced in 
Rhode Island before the implementation of the law and those 
who practiced in Rhode Island following the passage of the 
law. The differences between the groups are related, in 
part, to the knowledge of the workings of the law and its 
implications, to the effect of the duplicate prescription form 
on decision-making for a therapeutic regimen and therapeutic 
preference to chose an alternative drug to an indicated 
Schedule II drug. 
Also, several demographic variables determine which 
prescribers are at greater risk for perceiving an effect 
of the duplicate prescription form on therapeutic decision-
making as well as therapeutic preference to choose an alter-
native to a Schedule II drug. These variables include but 
are not limited to age, sex, practice type, degree, specialty 
practice, issuing prescriptions for Schedule II, number of 
years licensed in any jurisdiction, number of Schedule II 
prescriptions issued per month and knowledge of Division of 
Drug Control review. 
It is clear that there is a need for educating the 
prescriber about the Rhode Island Duplicate Prescription Law 
and about its implications. Prescribers need to receive 
information about how the law works when an initial 
registration is sought for licensure from Division of Drug 
Control. Follow-up or continuing education is necessary to 
keep prescribers abreast of changes in the law. 
The study revealed that there are several areas which 
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need additional study. Issues surrounding therapeutics and 
the power of the law need to be evaluated and defined to 
gain an understanding of the their impact on the choice of an 
alternative drug to a Schedule II drug. Likewise, the effect 
on patients, prescribers, and the health care system resulting 
from the choice of an alternative drug to a Schedule II drug 
needs further investigation. 
Although many states have implemented or are seeking to 
implement multiple copy prescription programs and there have 
been proposals made for a national multiple copy prescription 
program, caution is heeded that the results of this study are 
applicable to Rhode Island only. 
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The University of Rhode lsl•nd. Kingston, RI 02881-0809 · 
Department of Pharmacy Practice, College of Pharmacy (401) 792-2734 or 2789 
FAX# (401) 792-2181 
Dear Health Care Provider: 
In February of 1979, the Rhode Island Duplicate Prescription 
Lav vas passed in an effort to track the distribution of Schedule 
II controlled substances to the ambulatory, non-hospitalized 
patient via a tvo-part prescription blank iss~ed to the prescriber 
by the Department of Health. Rhode Island is one of ten states 
vhich have similar statutes-. 
The purpose of the enclosed survey is to gather information 
concerning this lav . There are no identifiers in the questionnaire 
thereby assuring your anonymity, and the data gathered vill be 
analyzed Jn aggregate form. The analyses vlll be ' the basis of my 
Master of Science thesis in Pharmacy Administration. 
Your responses and opinions are greatly appreciated. 
you for your time in completing this survey. 
Thank 
cc: Albert H. Taubman, Ph.D., 
Hajor Professor 
The University ol Rhode Island is an affirmative action and equal opportunity employer. 
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Sincerely, 
~-d~.Q~~ 
Bridgit A. Anness, R.Ph. 
Haster of Science Candidate 
part I. A. The folloving inforaation is needed to describe your professional practice. 
Please ansver each question bi checking one number vhich best describes 
your practice. There are no identifiers on this survey thus assuring your 
anonymity. Data v!ll be analyzed in aggregate form only. 
1. 
2. 
3. 
What is your primary professional degree? 
l DDS/DHD _3 DPH 
=2 DO _4 DVH 
_5 HD 
Do you have a specialty practice? 
_l Yes _2 Ho 
If yes, please state your specialty 
Are you board certified in your specialty? 
_l Yes 2 Ho 
Please describe 
_l Solo 
your type of practice 
2 Saall group (2-4) 
==3 Large group (~5} 
_4 Hospital _6 Industry 
_5 Governaent/Industry _7 Other 
( l) 
( 2-4) 
( 5) 
Part I. B. The folloving information ls needed to demographically describe you and 
your practice. Please check one number vhich best fits. 
1. 
2. 
3. 
4. 
s. 
Please state the 
jurisdiction. 
_l Under 5 
_2 6-10 
Are you.presently 
_l res 
number of years you have been a licensed practitioner in any (6) 
_3 11-20 
_4 21-30 
practicing ln Rhode Island? 
2 No 
_5 31-40 
_6 over 40 
If no,liave you ever practiced in Rhode Island? 
_1 res _2 No 
(7-8) 
Hov many years have you practiced in Rhode Island? (9) 
_l 0 _3 11-20 _s 31-40 
_2 1-10 
-
4 21-30 
-
6 over 40 
Sex (10) 
_l Hale 
-
2 Feaale 
Age category 
_l Under 30 _3 40-49 
-
5 60-69 
_2 30-39 4 50-59 
-
6 over 70 
-
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Part II. This section ls designed to gathir lnforaatlon concerning your use of the 
Rhode Island Duplicate Prescription for Schedule II drugs. Again, ve 
remind you that there are no identifiers thereby assuring your anonymity. 
1. Have you ever issued a presciiption (versus a hospital order) for a Schedule Ill) 
II (C-II) medication? 
2. 
_l Yes _2 No 
Please approximate the number of C-II 
for your ambulatory, non-hospitalized 
1 0 3 26-50 
=2 1-25 =4 51-75 
prescriptions you prescribe per month 
patients. 
5 76-100 
=6 over 100 
( 12) 
J. Please identify the category or categories of C-II medications you prescribe (13-16) 
5. 
6. 
_1 Harcot!c analges!cs 
_2 Sedat1ve/hypnot1cs 
_3 CNS st!mulants 
4 Other 
Were you a licensed practitioner ln Rhode Island prior to 1979? 
_l Yes _2 No 
If No, go to Part III. If Yes, do you feel your prescribing 
practices have changed since 1979? 
_l. Yes _2 Ho 
If No, go to Part III. If Yes, please ansver questions 5 ' 6. 
Please ~rate the folloving statements according to the folloving scale: 
!-strongly agree 2-Agree 3-Ho effect 4-DJsagree 5-Strongly disagree 
I feel I may be prescribing fever Schedule II medications because: 
_a. availability of better therapeutic alternatives 
_b. better risk-benefit ratio for the patient by using Schedule III, IV or V 
or non-controlled legend drug 
c. patient aix 
(17-18) 
(19-23) 
d. fever underutilization/overutilizatlon problems vlth Schedule III, IV or V 
or non-controlled legend drug 
_e. stateaent does not apply 
Please rate the follovlng state•ents according to the follovlng scale: 
!-Strongly agree 2-1gree · 3-No effect 4-DJsagree 5-Strongly disagree 
I feel I may be prescribing fever Schedule II 1edlcations because: 
_a. the RI C-II prescription for• ls difficult to use 
_b. the RI C-II prescription for• ls often not handy to use 
_c. the RI C-II prescription fora does not provide the confidentiality to 
prescribe as one chooses 
(2HO) 
_d. the RI C-II prescription fora does not provide patients vlth confidentiality 
_e. probleaa vith pharmacy/pharaacist vhen utilizing C-II prescription 
_f. state•ent does not apply 
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Part III. This section concerns your oplnlons about prescrlblng C-II medications and 
and the Rhode Island Duplicate Presclptlon Lav. For each of the folloving 
statements, please indicate the extent to vhlch -you agree according to the 
folloving scale: · 
1- Strongly agree 2-Agree 3-No effect 4-Dlsagree 5-Stcongly disagree 
1. 
2. 
3. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
H. 
15. 
16. 
In a situation vhere a Schedule II medication ls clearly indicated, I (31) 
prefer to prescribe a therapeutic alternative vhlch ls a Schedule !II, 
IV or V or non-controlled legend drug. 
The availability of therapeutic alternatives to Schedule II medications (32) 
in certain situations is a factor in not prescribing the C-II medication . 
In the creation of a therapeutic regimen, us ln g a RI C-I I presc r i ption (3 3) 
form affects my decision process. 
Vt111z1ng a therapeutic alternative rather than a schedule II med- (34) 
icatlon, vhlch may be the drug of choice, may be cause for malpractice 
litigation for the prescriber. 
Utilizing a Schedule III, IV or V drug vs. a Schedule II medication (35) 
(vhen clearly indicated) aay have adverse consequences for the patient. 
Ut111zlng a non-controlled legend drug vs. a schedule II ned!cat!on (36) 
(vhen clearly indicated) aay have adverse consequences for the patient. 
There ls less medical risk to the patient by using a Schedule III , IV (37) 
or V or non-controlled legend drug vhen a Schedule II is appropriate. 
There ls better patient compliance vith a Schedule III , IV or v or non- (38) 
controlled legend drug over a Schedule II medication . 
The RI Duplicate Prescription Lav (RIDPL) helps reduce the abuse of 
legal controlled drugs ln Schedule II. 
The RIDPL helps thvart •doctor shoppers• (individuals vho attempt to 
to obtain prescriptions fro• aultiple prescribers). , 
The RIDPL causes a decrease in the availability of Schedule· II drugs. 
The RIDPL aakes forgery of prescriptions for Schedule II drugs 
more difficult. · 
( 39) 
(40) 
( 41) 
( 42) 
The RIDPL has aade practitioners vho prescribe Schedule II 11edlcatio'ns (43) 
aore avare of the abuse potential/side effects/toxicities of these drugs. 
The RIDPL is beneficial for decreasing potential overutillzatlon of 
Schedule II medications. 
The RIDPL helps ln identifying drug dealers or abusers in the medical 
community. 
(44) 
( 45) 
It ls necessary foy Rhode Island to regulate and revlev the prescribing (46) 
practices of licensed practitioners for Schedule II substances . 
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Part IV. In this final section, ve vould like t~ get your opinion concerning the 
Rhode Island Duplicate Prescription Lav and !ts effect on you, your 
2. 
3. 
4. 
5. 
practice, your patients and the state of health care in Rhode Island. 
Does the Rhode Island Duplicate Prescription i:..av ' affectsthe quality of care 
health care professionals provide to their patients? 
_l Yes, It has beneficial effects _3 No 
_2 Yes, lt has negative effects _4 Not sure/don't knov 
Are you avare that the Rhode Island Division of Drug Control rev!evs each 
Schedule II duplicate prescription fora received? 
_l Yes _2 Ho 
Have any of your patients reported to you dlff lculties in trying ~o f 111 
Schedule II prescriptions? 
_l Yes _2 No 
The Rhode Island Duplicate Prescription 
protecting the prescriber from patients 
Lav ls beneficial as a means of 
vho may try to obtain leg! t!ma ta dt_u~p1 
for illicit means. 
_l strongly agree 
_2 Agree 
_3 No effect 
_4 Disagree 
_s Strongly disagree 
Have you ever been avare of a situation vhere a colleague vhose Schedule II 
prescribing practices resulted in licensure limitation, suspension or 
revocation or in aandatory drug rehabilitation? 
_l Yes _2 No _3 Do not vbh to ansver 
If Yes, do you feel the situation ha& caused you to limit the 
number of C-II prescriptions you vrlte? 
_l Yes _2 No 
( 47) 
( 4 8) 
( 49) 
(50) 
(51-52) 
Thank you for taking the tlae to coaplete this questionnaire. If you vould like to comment 
on the Rhode Island Duplicate Prescription Lav, please feel free to vrite your opinion 1n 
the space belov. 
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SAS Programs 
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r; PTIONS LS=80 NODATE NONUMBER; 
PROC FORMAT PRINT; 
VALUE DEGFMT l='DDS/DMD' 
2='DO' 
3='DPM' 
4='DVM' 
5='MD' 
9='N / A'; 
VALUE QUESFMT l='YES' 
2='NO' 
9= 'N I A I; 
VALUE QUESFMTX l='YES' 
0= 'NO'; 
VALUE AGEX O='UP TO 40' 
1 = ' 40 AND OVER ' ; 
VALUE SEXX O='MALE' 
l= 'FEMALE I; 
VALUE DEGX O='NON-MD DEGREES' 
l= 'MD'; 
VALUE LICX 0='10 YEARS & UNDER' 
l= ' OVER 10 YEARS'; 
VALUE PRACX O=' SOLO' 
l= ' NON-SOLO PRACTICE'; 
VALUE NUMX l='l OR MORE RX PER MONTH' 
O='NO RX PER MONTH'; 
VALUE SPECFMT Ol='ALLERGY' 
02='ANESTHESIOLOGY' 
03='CARDIOLOGY' 
04='DERMATOLOGY' 
05='EMERGENCY MEDICINE' 
06='ENDOCRINOLOGY' 
07='ENDODONTICS' 
08='FAMILY MEDICINE' 
09='GASTROENTEROLOGY' 
lO='GENERAL PRACTICE' 
ll='GERIATRICS' 
12='HEMATOLOGY' 
13='IMMUNOLOGY' 
14='INFECTIOUS DISEASE' 
15='INTERNAL MEDICINE' 
16='NEPHROLOGY' 
17='NEUROLOGY' 
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18='NUCLEAR MEDICINE' 
19='0BSTETRICS1GYNECOLOGY' 
20='0RTHODONTICS' 
21='0PHTHALMOLOGY' 
22='0NCOLOGY / RADIATION ONC' 
23='0RTHOPEDICS' 
24='0TORHINOLARYNGOLOGY' 
25='PATHOLOGY ' 
26='PEDIATRICS ' 
27='PERIODONTICS' 
28='PROSTHODONTICS' 
29='PHYSICAL MEDICINE' 
30='PROCTOLOGY' 
3l='PSYCHIATRY' 
32='PULMONARY' 
33='RADIOLOGY' 
34='RHEUMATOLOGY' 
35='SPORTS MEDICINE' 
36='SURGERY-GENERAL' 
37='SURGERY-DENTAL' 
38='SURGERY-PLASTIC' 
39='SURGERY-OTHER' 
40='UROLOGY' 
41='0THER' 
42='NOT SPECIFIED' 
43=~SURGERY-PODIATRIC' 
99= 'NI A'; 
VALUE PRCFMT l='SOLO' 
2='SMALL GROUP (2 - 4)' 
3='LARGE GROUP ( >5) ' 
4 =' HOSPITAL ' 
5= ' GOVT / INDUSTRY ' 
6='INDUSTRY' 
7='0THER' 
9='N / A'; 
VALUE YRPRCFMT l='UNDER 5' 
2='6-10' 
3='11-20' 
4='21-30' 
5='31-40' 
6='0VER 40' 
9= ' N I A / '; 
VALUE YRSFMT 1='0' 
2='1-10' 
3='11-20' 
4='21-30' 
5='31-40' 
6='0VER 40' 
9= 'NI A' ; 
VALUE SEXFMT l='M' 
2='F' 
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9= 'N / A I ; 
VALUE AGEFMT l='UNDER 30' 
2='30-39' 
3='40-49' 
4='50-59' 
5='60-69' 
6='0VER 70' 
9= ' NI A I ; 
VALUE RXNUMFMT l='O' 
2='1-25' 
3='26-50' 
4='51-75' 
5='76-100' 
6='0VER 100' 
9='N / A'; 
VALUE NARCFMT l='NARCOTIC ANALGESIC' 
9='N/A'; 
VALUE SEDFMT l='SEDATIVE / HYPNOTIC' 
9= 'N/A I; 
VALUE CNSFMT l='CNS STIMULANT' 
9= I NI A I; 
VALUE OTHRFMT l='OTHER' 
9= 'N/ A I; 
VALUE LIKERT l='STRONGLY AGREE' 
2='AGREE' 
3='NOEFFECT' 
4='DISAGREE' 
5='STRONGLY DISAGREE' 
9= 'N/ A I; 
VALUE LIKERTB l='AGREE' 
0= I DISAGREE I; 
VALUE CAREFMT l='YES, BENEFICIAL' 
2='YES, NEGATIVE' 
3='NO' 
4='NOT SURE ! DON"T KNOW' 
9='N / A'; 
VALUE COLLGFMT l='YES' 
2='NO' 
DATA THESIS; 
3='DO NOT WISH TO ANSWER' 
9= 'N I A I; 
INFILE 'RIDPL DATA A'; 
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INPUT (DEGREE SPECLTY) (1.) (SPECTYPl) (2.) (BORDCERT PRACTYPE LICYEARS RIPRACTl 
RIPRACT2 YRSRIPRA SEX AGECAT RXISSUE RXNUM CATNARC CATSED 
CATCNS CATOTHER RI1979 CHNGPRAC THERACT RISKBENE PTMIX 
UTILPROB NOTAPPLl DIFICULT HANDY PRESCONF PTCONF PHARMPRB 
NOTAPPL2 THERPREF THERALT FORMAFF MALPRAC ADVCONSl ADVCONS2 
LESSRISK COMPLNCE DECABUSE DOCSHOP DECAVAIL FORGRX AWARESE 
DECOVRUT IDABUSR REGULATE QLTYCARE REVIEW FILLRX PROTECT 
COLLEAG LIMITRX) (1.) (SPECTYP2 SPECTYP3) (2. ); 
IF DEGREE=9 THEN DEGREE=.; 
IF SPECLTY=9 THEN SPECLTY=.; 
IF SPECTYP1=99 THEN SPECTYPl=.; 
IF BORDCERT=9 THEN BORDCERT=.; 
IF 5 LE PRACTYPE LE 6 THEN PRACTYPE=5; 
IF PRACTYPE=9 THEN PRACTYPE=.; 
IF LICYEARS =9 THEN LICYEARS=.; 
IF RIPRACT1=9 THEN RIPRACTl=.; 
IF RIPRACT2=9 THEN RIPRACT2=.; 
IF YRSRIPRA=9 THEN YRSRIPRA= . ; 
IF SEX=9 THEN SEX=.; 
IF AGECAT=9 THEN AGECAT=.; 
IF RXISSUE=9 THEN RXISSUE=.; 
IF RXNUM=9 THEN RXNUM=.; 
IF CATNARC=9 THEN CATNARC=.; 
IF CATSED=9 THEN CATSED=.; 
IF CATCNS=9 THEN CATCNS=.; 
IF CATOTHER=9 THEN CATOTHER= . ; 
IF RI1979=9 THEN RI1979= .: 
IF CHNGPRAC=9 THEN CHNGPRAC= .; 
IF f LE THERACT LE 2 THEN THERACTl=l; 
ELSE IF 4 LE THERACT LE 5 THEN THERACTl=O; 
ELSE IF THERACT .EQ 3 OR 9 THEN THERACTl= . ; 
IF 1 LE RISKBENE LE 2 THEN RISKBENl=l; 
ELSE IF 4 LE RISKBENE LE 5 THEN RISKBENl =O; 
ELSE IF RISKBENE EQ 3 OR 9 THEN RISKBENl = .; 
IF 1 LE PTMIX LE 2 THEN PTMIXl=l; 
ELSE IF 4 LE PTMIX LE 5 THEN PTMIXl=O; 
ELSE IF PTMIX EQ 3 OR 9 THEN PTMIXl=.; 
IF 1 LE UTILPROB LE 2 THEN UTILPROl =l; 
ELSE IF 4 LE UTILPROB LE 5 THEN UTILPROl =O; 
ELSE IF UTILPROB EQ 3 OR 9 THEN UTILPROl =. ; 
IF 1 LE NOTAPPLl LE 2 THEN NOTAPPll=l ; 
ELSE IF 4 LE NOTAPPLl LE 5 THEN NOTAPPll =O; 
ELSE IF NOTAPPLl EQ 3 OR 9 THEN NOTAPPll = . : 
IF DIFICULT=9 THEN DIFICULT= . ; 
IF HANDY=9 THEN HANDY=.; 
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IF PRESCONF=9 THEN PRESCONF= . ; 
IF PTCONF=9 THEN PTCONF=.; 
IF PHARMPRB=9 THEN PHARMPRB=.; 
IF NOTAPPL2=9 THEN NOTAPPL2=.; 
IF 1 LE THERPREF LE 2 THEN THERPREl=l; 
ELSE IF 4 LE THERPREF LE 5 THEN THERPREl =O; 
ELSE IF THERPREF EQ 3 OR 9 THEN THERPREl=.; 
IF 1 LE THERALT LE 2 THEN THERALTl=l; 
ELSE IF 4 LE THERALT LE 5 THEN THERALTl=O; 
ELSE IF THERALT EQ 3 OR 9 THEN THERALTl=. ; 
IF 1 LE FORMAFF LE 2 THEN FORMAFFl=l ; 
ELSE IF 4 LE FORMAFF LE 5 THEN FORMAFFl=O; 
ELSE IF FORMAFF EQ 3 OR 9 THEN FORMAFF 1 = . ; 
IF -·l LE MALPRAC LE 2 THEN MALPRACl=l; 
ELSE IF 4 LE MALPRAC LE 5 THEN MALPRACl=O; 
ELSE IF MALPRAC EQ 3 OR 9 THEN MALPRAC 1 = . ; 
IF 1 LE ADVCONSl LE 2 THEN ADVCONll=l; 
ELSE IF 4 LE ADVCONSl LE 5 THEN ADVCONll=O; 
ELSE IF ADVCONSl EQ 3 OR 9 THEN ADVCONll= .; 
IF 1 LE ADVCONS2 LE 2 THEN ADVCON21=1; 
ELSE IF 4 LE ADVCONS2 LE 5 THEN ADVCON~l=O; 
ELSE IF ADVCONS EQ 3 OR 9 THEN ADVCON21=.; 
IF 1 LE LESSRISK LE 2 THEN LESSRISl =l; 
ELSE IF 4 LE LESSRISK LE 5 THEN LESSRISl =O; 
ELSE IF LESSRISK EQ 3 OR 9 THEN LESSRISl= .; 
IF , LE COMPLNCE LE 2 THEN COMPLNCl=l; .I. 
ELSE IF 4 LE COMPLNCE LE 5 THEN COMPLNCl=O ; 
ELSE IF COMPLNCE EQ 3 OR 9 THEN COMPLNCl=. ; 
IF 1 LE DECABUSE LE 2 THEN DECABUSl=l; 
ELSE IF 4 LE DECABUSE LE 5 THEN DECABUSl=O; 
ELSE IF DECABUSE EQ 3 OR 9 THEN DECABUSl= . ; 
IF 1 LE DOCSHOP LE 2 THEN DOCSHOPl=l; 
ELSE IF 4 LE DOCSHOP LE 5 THEN DOCSHOPl=O ; 
ELSE IF DOCSHOP EQ 3 OR 9 THEN DOCSHOPl=.; 
IF 1 LE DECAVAIL LE 2 THEN DECAVAil=l; 
ELSE IF 4 LE DECAVAIL LE 5 THEN DECAVAil=O ; 
ELSE IF DECAVAIL ~Q 3 OR 9 THEN DECAVAil=. ; 
IF 1 LE FORGRX LE 2 THEN FORGRXl=l; 
ELSE IF 4 LE FORGRX LE 5 THEN FORGRXl=O; 
ELSE IF FORGRX EQ 3 OR 9 THEN FORGRX= . ; 
IF 1 LE AWARESE LE 2 THEN AWARESEl=l ; 
ELSE IF 4 LE AWARESE LE 5 THEN AWARESEl=O ; 
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ELSE IF AWARESE EQ 3 OR 9 THEN AWARESEl=.; 
lF 1 LE DECOVRUT LE 2 THEN DECOVRUl=l; 
ELSE IF 4 LE DECOVRUT LE 5 THEN DECOVRUl=O; 
ELSE IF DECOVRUT EQ 3 OR 9 THEN DECOVRUl=.; 
IF 1 LE IDABUSR LE 2 THEN IDABUSRl=l; 
ELSE IF 4 LE IDABUSR LE 5 THEN IDABUSRl =O; 
ELSE IF IDABUSR EQ 3 OR 9 THEN IDABUSRl=.; 
IF 1 LE REGULATE LE 2 THEN REGULATl=l; 
ELSE IF 4 LE REGULATE LE 5 THEN REGULATl=O; 
ELSE IF REGULATE EQ 3 OR 9 THEN REGULATl=.; 
IF QLTYCARE=9 THEN QLTYCARE=.; 
IF QLTYCARE=4 THEN QLTYCARE=.; 
IF REVIEW=9 THEN REVIEW=.; 
IF FILLRX=9 THEN FILLRX=.; 
IF 1 LE PROTECT LE 2 THEN PROTECTl=l; 
ELSE IF 4 LE PROTECT LE 5 THEN PROTECTl=O; 
ELSE IF PROTECT EQ 3 OR 9 THEN PROTECTl=.; 
IF COLLEAG=9 THEN COLLEAG=.; 
IF COLLEAG=3 THEN COLLEAG=.; 
IF LIMITRX=9 THEN LIMITRX=.; 
IF SPECTYP2=99 THEN SPECTYP2=. ; 
IF SPECTYP3=99 THEN SPECTYP3=. ; 
IF RI1979=2 AND CHNGPRAC=l THEN CHNGPRAC=. ; 
IF CHNGPRAC=2 AND 1 LE THERACT LE 5 THEN THE RA CT= . : 
IF CHNGPRAC =2 AND 1 LE RISKBENE LE 5 THEN RISKBENE = . ; 
IF CHNGPRAC=2 AND 1 LE PTMIX LE 5 THEN PTMIX= . ; 
IF CHNGPRAC=2 AND 1 LE UTILPROB LE 5 THEN UTILPROB=. ; 
IF CHNGPRAC=2 AND 1 LE NOTAPPLl LE 5 THEN NOTAPPLl=. ; 
IF CHNGPRAC=. AND 1 LE THERACT LE 5 THEN THERACT= . ; 
IF CHNGPRAC=. AND 1 LE RISKBENE LE 5 THEN RISKBENE=. ; 
IF CHNGPRAC=. AND l LE PTMIX LE 5 THEN PTMIX=.; 
IF CHNGPRAC=. AND 1 LE UTILPROB LE 5 THEN UTILPROB=. ; 
IF CHNGPRAC= . AND 1 LE NOTAPPLl LE 5 THEN NOTAPPLl=. ; 
IF CHNGPRAC=2 AND 1 LE DIFICULT LE 5 THEN DIFICULT=. ; 
IF CHNGPRAC=2 AND 1 LE HANDY LE 5 THEN HANDY= . ; 
IF CHNGPRAC=2 AND 1 LE PRESCONF LE 5 THEN PRESCONF=. ; 
IF CHNGPRAC=2 AND 1 LE PTCONF LE 5 THEN PTCONF=.; 
IF CHNGPRAC=2 AND 1 LE PHARMPRB LE 5 THEN PHARMPRB=. ; 
IF CHNGPRAC=2 AND 1 LE NOTAPPL2 LE 5 THEN NOTAPPL2 = . ; 
IF CHNGPRAC=. AND 1 LE DIFICULT LE 5 THEN DIFICULT=.; 
IF CHNGPRAC=. AND 1 LE HANDY LE 5 THEN HANDY= . ; 
IF CHNGPRAC=. AND 1 LE PRESCONF LE 5 THEN PRESCONF= . ; 
IF CHNGPRAC=. AND 1 LE PTCONF LE 5 THEN PTCONF= . ; 
IF CHNGPRAC= . AND 1 E PHARMPRB LE 5 THEN PHARM PRE= . ; 
IF CHNGPRAC= . AND 1 E NOTAPPL2 LE 5 THEN NOTAPPL2= . : 
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IF COLLEAG=2 AND 1 LE LIMITRX LE 2 THEN LIMITRX=.; 
IF COLLEAG=. AND 1 LE LIMITRX LE 2 THEN LIMITRX=.; 
IF 1 LE DEGREE LE 4 THEN DEGl=O; 
ELSE IF DEGREE=5 THEN DEGl=l; 
IF RIPRACTl=l THEN RIPRACX=l; 
ELSE IF RIPRACT1=2 THEN RIPRACX=O; 
IF RXISSUE=l THEN RXISSUX=l; 
ELSE IF RXISSUE=2 THEN RXISSUX=O; 
IF RI1979=1 THEN RI1979X=l; 
ELSE IF RI1979=2 THEN RI1979X=O; 
IF REVIEW=l THEN REVIEWX=l; 
ELSE IF REVIEW=2 THEN REVIEWX=O; 
IF SPECLTY=l THEN SPECLTYX=l; 
ELSE IF SPECLTY=2 THEN SPECLTYX=O; 
IF BORDCERT=l THEN BORDCERX=l; 
ELSE IF BORDCERT=2 THEN BORDCERX=O; 
IF SEX=l THEN SEXl=O; 
ELSE IF SEX=2 THEN SEXl=l; 
IF 1 LE AGECAT LE 2 THEN AGEl=O: 
ELSE IF 3 LE AGECAT LE 6 THEN AGEl =l: 
IF PRACTYPE=l THEN PRACTYPX=O; 
ELSE IF 2 LE PRACTYPE LE 7 THEN PRACTYPX=l; 
IF 1 LE LICYEARS LE .2 THEN LICYEARX=O; 
ELSE IF 3 LE LICYEARS LE 6 THEN LICYEARX=l; 
IF 2 LE RXNUM LE 6 THEN RXNUMX=l; 
ELSE IF RXNUM=l THEN RXNUMX=O; 
LABEL DEGREE='PRIMARY PROFESSIONAL DEGREE' 
SPECLTY='SPECIALTY PRACTICE' 
SPECTYPl='SPECIALTY PRACTICE #l' 
BORDCERT='BOARD CERTIFIED' 
PRACTYPE='PRACTICE TYPE' 
LICYEARS='# YEARS IN PRACTICE' 
RIPRACTl='PRESENTLY PRACTICING IN RI' 
RIPRACT2='EVER PRACTICED IN RI' 
YRSRIPRA='# YEARS PRACTICE IN RI' 
SEX='SEX' 
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AGECAT='AGE CATEGORY' 
RXISSUE='ISSUANCE OF C-II RX' 
RXNUM='APPROX # C-II RXS WRITTEN . XONTH' 
CATNARC='PRESCRIBES / ED NARCOTICS' 
CATSED='PRESCRIBES / ED SEDATIVE / HYPNOTICS' 
CATCNS='PRESCRIBES / ED CNS STIMULANTS ' 
CATOTHER='PRESCRIBES ! ED OTHER C-II' 
RI1979='PRACTICED IN RI PRIOR TO 1979' 
CHNGPRAC='HAS CHANGED PRESCRIBING PATTERNS' 
THERACT='THERAPEUTIC ALTERNATIVES' 
THERACTl='THERAPEUTIC ALTERNATIVES' 
RISKBENE='RISK / BENEFIT RATIO' 
RISKBENl='RISK / BENEFIT RATIO' 
PTMIX='PATIENT MIX' 
PTMIXl='PATIENT MIX' 
UTILPROB='UNDER / OVER UTILIZATION PROBS' 
UTILPROl='UNDER / OVER UTILIZATION PROBS' 
NOTAPPLl='STATEMENT DOES NOT APPLY' 
NOTAPPll='STATEMENT DOES NOT APPLY' 
DIFICULT='C-II FORM DIFFICULT TO USE' 
HANDY='C-II FORM NOT HANDY TO USE' 
PRESCONF='CONFIDENTIALITY TO PRESCRIBE' 
PTCONF='PATIENT CONFIDENTIALITY' 
PHARMPRB= ' PROBLEMS WITH PHARMACY' 
NOTAPPL2='STATEMENT DOES NOT APPLY' 
THERPREF='PREFER TO PRESCRIBE NON-C-II' 
THERPREl='PREFER TO PRESCRIBE NON-C-II' 
THERALT='AVAILABLE ALT TO C-II FACTOR' 
THERALTl='AVAILABLE ALT TO C-II FACTOR' 
FORMAFF='C-II FORM AFFECTS PRESCRIBING' 
FORMAFFl='C-II FORM AFFECTS PRESCRIBING' 
MALPRAC = ' MALPRACTICE RESULTING FROM ALT DRUG ' 
MALPRACl= ' MALPRACTICE RESULTING FROM ALT DRUG' 
ADVCONSl='ADVERSE CONSEQUENCES W/ C-III-V' 
ADVCONll='ADVERSE CONSEQUENCES W! C-III-V' 
ADVCONS2='ADVERSE CO~SEQUENCES W! NON-SCHEDULE' 
ADVCON2l='ADVERSE CONSEQUENCES W! NON-SCHEDULE' 
LESSRISK='LESS RISK USING NON-C-II DRUG' 
LESSRISl='LESS RISK USING NON-C-II DRUG' 
COMPLNCE='BETTER COMPLIANCE W/ NON-CII DRUG' 
COMPLNCl='BETTER COMPLIANCE W! NON-CII DRUG' 
DECABUSE='REDUCTION OF DRUG ABUSE' 
DECABUSl='REDUCTION OF DRUG ABUSE' 
DOCSHOP='THWARTS DOCTOR SHOPPERS' 
DOCSHOPl='THWARTS DOCTOR SHOPPERS' 
DECAVAIL='DECREASES AVAILABILITY OF C- II' 
DECAVAil='DECREASES AVAILABILITY OF C-II' 
FORGRX='MAKES RX FORGERY DIFFICULT' 
FORGRXl= ' MAKES RX FORGERY DIFFICULT ' 
AWARESE= ' MORE AWARE OF DRUG S / E' 
AWARESEl='MORE AWARE OF DRUG S : E' 
DECOVRUT='DECREASES OVERUTILIZATION OF C-II' 
DECOVRUl='DECREASES OVERUTILIZATION OF C-II ' 
IDABUSR='ID DEALERS / ABUSERS IN MED COMMUN' 
IDABUSRl='ID DEALERS / ABUSERS IN MED COMMUN' 
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REGULATE='NECESSITY TO REGULATE PRESCRIBING' 
REGULATl='NECESSITY TO REGULATE PRESCRIBING' 
QLTYCARE= ' RIDPL AFFECTS QUALITY OF CARE' 
REVIEW='KNOWLEDGE OF RI DDC REVIEW OF C-II' 
FILLRX='REPORTED DIFFICULTIES FILLING C-II ' 
PROTECT='RIDPL PROTECTS PRESCRIBER FROM PT' 
PROTECTl='RIDPL PROTECTS PRESCRIBER FROM PT ' 
COLLEAG='KNOWS COLLEAGUE UNDER DDC REVIEW' 
LIMITRX='RESULTING LIMIT OF PRESCRIBING C-II' 
SPECTYP2='2ND SPECIALTY PRACTICE' 
SPECTYP3='3RD SPECIALTY PRACTICE' 
RIPRACX='CURRENTLY PRACTICING IN RI' 
RXISSUX='EVER ISSUED C-II RX' 
RI1979X='PRACTICED IN RI PRIOR TO 1979' 
SPECLTYX='HAS SPECIALTY PRACTICE' 
REVIEWX='AWARE OF DDC REVIEW' 
BORDCERX='BOARD-~ERTIFIED' 
SEXl='SEX CATEGORY' 
AGEl= ' AGE CATEGORY' 
DEGl =' PRIMARY PROFESSIONAL DEGREE' 
PRACTYPX= ' PRACTICE TYPE' 
LICYEARX='NUMBER YEARS LICENSED ' 
RXNUMX='NUMBER OF C-II RX ISSUEDPER MONTH': 
OBS=_N_; 
FORMAT DEGREE DEGFMT. 
SPECLTY QUESFMT. 
SPECTYPl SPECFMT. 
BORDCERT QUESFMT. 
PRACTYPE PRCFMT. 
LICYEARS YRPRCFMT. 
RIPRACTl QUESFMT. 
RIPRACT2 QUESFMT. 
YRSRIPRA YRSFMT. 
SEX SEXFMT. 
AGECAT AGEFMT. 
RXISSUE QUESFMT. 
RXNUM RXNUMFMT. 
CATNARC NARCFMT. 
CATSED SEDFMT. 
CATCNS CNSFMT. 
CATOTHER OTHRFMT. 
RI1979 QUESFMT. 
CHNGPRAC QUESFMT. 
THERACT LIKERT. 
THERACTl LIKERTB. 
RISKBENE LIKERT. 
RISKBENl LIKERTB. 
PTMIX LIKERT. 
PTMIXl LIKERTB. 
UTILPROB LIKERT. 
UTILPROl LIKERTB . 
NOTAPPLl LIKERT . 
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NOTAPPll LIKERTB . 
DIFICULT LIKERT. 
HANDY LIKERT. 
PRESCONF LIKERT. 
PTCONF LIKERT. 
PHARMPRB LIKERT. 
NOTAPPL2 LIKERT. 
THERPREF LIKERT. 
THERPREl LIKERTB. 
THERALT LIKERT . 
THERALTl LIKERTB . 
FORMAFF LIKERT. 
FORMAFFl LIKERTB. 
MALPRAC LIKERT. 
MALPRACl LIKERTB. 
ADVCONSl LIKERT. 
ADVCONll LIKERTB. 
ADVCONS2 LIKERT . 
ADVCON21 LIKERTB . 
LESSRISK LIKERT. 
LESSRISl LIKERTB . 
COMPLNCE LIKERT. 
COMPLNCl LIKERTB. 
DECABUSE LIKERT. 
DECABUSl LIKERTB. 
DOCSHOP LIKERT. 
DOCSHOPl LIKERTB. 
DECAVAIL LIKERT . 
DECAVAil LIKERTB. 
FORGRX LIKERT. 
FORGRXl LIKERTB. 
AWARESE LIKERT. 
AWARESEl LIKERTB . 
DECOVRUT LIKERT. 
DECOVRUl LIKERTB. 
IDABUSR LIKERT. 
IDABUSRl LIKERTB. 
REGULATE LIKERT. 
REGULATl LIKERTB . 
QLTYCARE CAREFMT. 
REVIEW QUESFMT. 
FILLRX QUESFMT. 
PROTECT LIKERT. 
PROTECTl LIKERTB . 
COLLEAG COLLGFMT. 
LIMITRX QUESFMT. 
SPECTYP2 SPECFMT. 
SPECTYP3 SPECFMT . 
RIPRACX QUESFMTX. 
RXISSUX QUESFMTX. 
RI1979X QUESFMTX . 
REVIEWX QUESFMTX . 
SPECLTYX QUESFMTX . 
BORDCERX QUESFMTX . 
SEXl SEXX. 
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DEGl DEGX. 
LICYEARX LICX. 
AGEl AGEX. 
PRACTYPX PRACX. 
RXNUMX NUMX. ; 
PROC FORMAT PRINT; 
VALUE LCFMT l='UP TO 10' 
2= ' 11-20' 
3='21-30' 
4='GREATER THAN 30'; 
VALUE RIFMT l='UP TO 10' 
2='11-20' 
3='21-30' 
4='GREATER THAN 30'; 
VALUE AGE2FMT l='UP TO 39' 
2='40-49' 
3='50-59' 
4= '60 AND OVER'; 
VALUE CIIFMT 1='0-25' 
2='26-50' 
3='GREATER THAN 50'; 
DATA NEW; SET THESIS; 
IF 1 LE LICYF~RS LE 2 THEN LICENSE=l; 
ELSE IF LICYEARS=3 THEN LICENSE=2; 
ELSE IF LICYEARS=4 THEN LICENSE =3; 
ELSE IF 5 LE LICYEARS LE 6 THEN LICENSE=4; 
ELSE LICENSE=. ; 
IF 1 LE YRSRIPRA LE 2 THEN RIYRS=l; 
ELSE IF YRSRIPRA=3 THEN RIYRS=2; 
ELSE IF YRSRIPRA=4 THEN RIYRS=3; 
ELSE IF 5 LE YRSRIPRA LE 6 THEN RIYRS=4; 
ELSE RIYRS=. ; 
IF 1 LE AGECAT LE 2 THEN AGECAT2=1; 
ELSE IF AGECAT=3 THEN AGECAT2=2; 
ELSE IF AGECAT=4 THEN AGECAT2=3; 
ELSE IF 5 LE AGECAT LE 6 THEN AGECAT2=4; 
ELSE AGECAT2=. ; 
IF 1 LE RXNUM LE 2 THEN CIIRX=l; 
ELSE IF RXNUM=3 THEN CIIRX=2; 
ELSE IF 4 LE RXNUM LE 6 THEN CIIRX=3; 
ELSE CIIRX=. ; 
LABEL LICENSE='# YRS IN PRACTICE' 
RIYRS='# YRS PRACTICE IN RI' 
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AGECAT2 =' AGE CATEGORY' 
CIIRX='APPROX # C-II RXS WRITTEN ' MONTH': 
FORMAT LICENSE LCFMT. 
RIYRS RIFMT. 
AGECAT2 AGE2FMT. 
CIIRX CIIFMT. ; 
DATA NEW_DAT : SET NEW: 
SEXAGE=SEXl *AGEl : 
DEGAGE=AGEl ~ DEGl: 
PRAC79=PRACTYPX~RI1979X; 
DEG79 =DEGl ~ RI1979X ; 
SEXDEG=SEXl ~ DEGl: 
PROC FREQ DATA =NEW : 
TITLE ' FREQUENCIES FOR EACH VARIABLE '; 
TITLE 2 ' FOR ~NTIRE DATA SET ' : 
.PROC FREQ DATA=NEW: 
TABLES ( DEGl SPECLTYX BORDCERX PRACTYPX LICYEARX RIPRACX 
REVIEWX SEX l AGEl RXISSUX RXNUMX RI1979X ) *FORMAFF1 1CHISQ ; 
TITLE ' CHI SQUARE S FOR INDEPENDENT VARIABLES': 
TITLE2 ' BY DEPENDENT VARIABLE FORM AFFECTS DECISION ' : 
TITLE3 "BI VARIATE ANALYSIS FOR ENTIRE DATA SET : 
PROC FREQ DATA=NEW: 
TABLES (DEG l SPECLTYX BORDCERX PRACTYPX LICYEARX RIPRACX 
REVIEWX SEXl AGEl RXISSUX RXNUMX RI1979X)*THERPRE1 1CHISQ ; 
TITLE 'CHI SQUARES FOR INDEPENDENT VARIABLES ': 
TITLE2 'BY DEPENDENT VARIABLE THERPEUTIC PREFERENCE'; 
TITLE3 ' BIVARIATE ANALYSIS FOR ENTIRE DATA SET ' : 
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DATA BEFORE79: SET NEW_DAT: 
IF RI1979X=l: 
?ROC FREQ DATA=BEFORE79 : 
TABLES ( DEGl SPECLTYX BORDCERX PRACTYPX LICY2ARX RIPRACX 
REVIEWX f SXl AGEl RXISSUX RXNUMX RI1979X)•FORMAFF1 CHISQ: 
TITLE ' CHI SQUARES FOR INDEPENDENT VARIABLES ': 
TI TLE2 'BY DEPENDENT VARIABLE FORM AFFECTS DECISION ': 
TITLE3 ' BIVARIATE ANALYSIS FOR THOSE IN PRACTICE BEFORE 1979 ' : 
PROC FREQ DATA=BEFORE79: 
TABLES ( DEGl SPECLTYX BORDCERX PRACTYPX LICYEARX RIPRACX 
REVIEWX SEXl AGEl RXISSUX RXNUMX RI1979X)•THERPREl ' CHISQ: 
TITLE ' CHI SQUARES FOR INDEPENDENT VARIABLES': 
TITLE2 ' BY DEPENDENT VARIABLE THERPEUTIC PREFERENCE': 
TITLE3 BIVARIATE ANALYSIS FOR THOSE IN PRACTICE BEFORE 1979 ' : 
DATA AFT~R79 : SET NEW _DAT: 
IF RI1979X-O: 
PROC FREQ DATA•AFTER79: 
TABLES ( DEGl SPECLTYX BORDCERX PRACTYPX LICYEARX RIPRACX 
REVIEWX SEXl AGEl RXISSUX RXNUMX Ril979X)"FORMAFFl ! CHISQ: 
TITLE ' CHI SQUARES FOR INDEPENDENT VARIABLES ' : 
TITLE2 ' BY DEPENDENT VARIABLE FORM AFFECTS DECISION ' : 
TITLE3 ' BIVARIATE ANALYSIS FOR THOSE IN PRACTICE AFTER 1979 
FROG FREQ DATA-AFTER79 : 
TABLES (DEGl SPECLTYX BORDCERX PRACTYPZ LICYEARX RIPRACX 
REVIEWX SEXl AGEl RXISSUX RXNUMX RI1979X) "THERPRE1 CHISQ: 
TITLE 'CHI SQUARES F.OR INDEPENDENT VARIABLES ' : 
TITLE2 'BY DEPENDENT VARIABLE THERPEUTIC PREFERENCE ': 
TITLE3 ' BIVARIATE ANAYLSIS FOR THOSE IN PRACTICE AFTER 1979 ': 
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DATA BEFORE7 9 : SET NEW _DAT . 
IF RI1979X =l: 
PROC FREQ DATA=BEFORE79: 
TABLES (DEGl S PECLTYX BORDCERX PRACTY PX LI CYEARX RIFRA CX 
REVIEWX fE Xl AGEl RXISSUX RXNUMX RI1979X)' FORMAF F 1 CHISQ: 
TITLE ' CHI SQUARES FOR INDEPENDENT VARIABLES' : 
T ITLE 2 ' BY DEPENDENT VARIABLE FORM AFFECTS DECISION· 
TITLE3 ' BIVARIATE ANALYSIS FOR THOS E IN PRACTI CE BEFORE 1979 '. 
PROC FREQ DATA=BEFORE79: 
TABLES ( DEGl SPECLTYX BORDCERX PRACTYPX LICYEAR~ RIPRACX 
REVIEWX SEXl AGEl RXISSUX RXNUMX RI1979X)·THERPRE1 CHI SQ. 
TITLE 'CHI SQUARES FOR INDEPENDE NT VARIABLES ' : 
TITLE2 ' BY DEPENDENT VARIABLE THERFEUTIC PREF ERE NCE 
TITLE3 BIVARIATE ANALYSIS FOR THOSE IN PRACTICE BEFOR E 1979 ': 
DATA AFT~R79 SET NEW _DAT: 
I F RI1979X =O: 
PROC FREQ DATA=AFTER79: 
TABLES (DEGl S?ECLTYX BORDCERX PRACTY?X LICYEARX RIPRACX 
REVIE WX SEXl AGEl RXISSUX RXNUM X RI1979X ) ·FORMAFF1 CHISQ : 
TITLE ' CHI SQUARES FOR I NDE PENDENT VARI ABLES ' 
TITLE2 ' BY DEPENDENT VARIABLE FORM AFFECTS DECISI ON 
TITLE3 'BI VARIATE ANALYSIS FOR THOS E IN PRACTICE AFTER 1979 
FROC REQ DATA=AFTER79 ; 
ABLES (DEGl SPECLTYX BORDCERX PRACTYf~ LICYEARX R:PRACX 
EVIEWX SEXl AGEl RXISSUX RXNUMX RI1979X )·THER?RE1 CH! SQ : 
TITLE ' CHI SQUARES FOR INDEPENDENT VARIA5LES 
TI TLE2 BY DEPENDENT VARIABLE THER?EUTIC ?REFERENCE 
TITLE3 BIVARIATE ANAYLSIS FOR THOSE IN PRACTIC E AFTER 1979 
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PROC REG DATA =NEW _DAT. 
MODEL FOR MAFFl =RIPRACX RXISSUX RI 1979X SEXl AGEl SPECLTYX REVIEWX 
RXNUMX DEGl PRACTYPX LICYEARX SEXAGE DEGAGE PRAC79 
DEG79 SEXDEG COLLIN: 
PROC REG DATA=NEW_DAT. 
MODEL THER?REl=RIPRACX RXISSUX RI1979X SEX i AGEl SPECLTYX REVIEWX 
RXNUMX DEGl PRACTYPX L! CYEARX SEXAGE DEGAGE PRAC79 
DEG79 SEXDEG•COLLIN. 
PROC LOGIST DATA =NEW_DAT : 
MODEL FORMAFFl =RXNUMX RI1979X SEXl AGEl SPECLTYX REVIEWX 
DEGl PRACTYPX LICYEARX: 
TITLE ' FINAL THESIS MODEL'. 
TI TLE2 TEE DE?ENDENT VARIABLE IS FORM AFFECTS DECISION': 
TI TLE3 FOR THE ENTIRE DATA SET . 
PROC LOGlST Di-.TA =NEW_DAT : 
MODEL THER?R E! · RI1979X SEX l AG El S?ECLTYX RXN UMX 
DEGl PRACTYPX LICYEARX REVIEWX. 
TITLE FINAL TH ESIS MODEL.: 
TITLE2 THE DEPENDENT VARIABLE IS TH ERAPEUTIC ?REFERENCE ': 
TITLE3 FOR THE ENTIRE DATA SET 
DATA BEFORE79 . SET NEW _DAT · 
ff RI1979X =l. 
DATA AFTER79. SET NEW DAT. 
I F RI1979X=O 
PROC LOGIST DATA=BEFORE79 : 
MODEL FORMAFFl =RXNUMX REVIEWX ?RACTYPX RXISSUX: 
TI TLE ' FINAL THESIS MODEL ' : 
TITLE2 THE DEPENDENT VAR IABLE IS ?ORM AFFECTS DECIS ION ' . 
TITLE3 FOR THOSE IN PRACT ICE BEFORE 1979 ': 
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PROC LOGIST DATA =BEFORE79 . 
MODEL THERPREl=SPECLTYX DEGl PRACTYPX REVIEWX RXISSUX: 
TITLE FINAL THESIS MODEL ' . 
TITLE2 THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE' : 
TITLE3 ' FOR THOSE IN PRACTICE BEFORE 1979 ' : 
PROC LOGI ST DATA=AFTER79 . 
MODEL FORMAFFl =SEXl AGEl RXNUMX REVIEWX DEGl PRACTYPX LICYEARX: 
TITLE ' FINAL THESIS MODEL': 
.TITLE2 'THE DEPENDENT VARIABLE IS FORM AFFECTS DECISION '; 
TITLE3 ' FOR THOSE IN PRACTICE AFTER 1979': 
PROC LOGIST DATA =AFTER79: 
MODEL THERPREl =SEXl AGEl SPECLTYX DEGl PRACTYPX 
RXNUMX LICYEARX REVIEWX : 
TITLE ' FINAL THESI S MODEL': 
TITLE2 THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE': 
TITLE3 ' FOR THOSE IN PRACTICE AFTER :979 ' : 
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APPENDIX C 
Frequencies of Data 
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DEGREE 
DDS I DMD 
DO 
DPM 
DVM 
MD 
SPECLTY 
YES 
NO 
f'RE~UE:TCIES fOrt 2ACH \"AR:AELE 
FOR ENTIRE DATA SET 
PRIMARY PROFESSIONAL DEGREE 
Cumula~ive Cumu~ative 
Frequency Percent Frequency Percent 
64 9.7 64 9.7 
40 6. 1 104 15 . 8 
10 1.5 114 17.3 
13 2.0 127 19.3 
532 80.7 659 100.0 
Frequency Missing 2 
519 
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SPECIALTY PRACTICE 
Cumulative Cumulative 
Percent Frequency Percent 
82.6 
17.4 
519 
628 
82.6 
lOC1 • 0 
Frequency Missing 33 
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SPECIALTY PRACTICE Pl 
C>1~·1 ~ G: .. ·.·E- C'.2:n ·_ 
- c.. : :. v·e 
SPECTYPl F'~·e ~ 'Je ncy Pe r·cent f i eq uency Per-c:e nt 
- . 
- - - - - - -· - -
ALLERGY 5 0 9 5 0 9 
ANESTHESIOLOGY 1 l 2 0 16 2 9 
C.l\RDIO:..OGY 13 2 4 29 5 3 
DERMATOLOGY 13 2 4 42 7 6 
EM2RGENCY MEDIC I 19 3 4 6 1 1 1 
ENDOCRINOLOGY 3 0 5 6 4 1 l 6 
ENDODONTICS 3 0 5 67 12 
FAY.I;_·!· MEDICINE 43 7 8 ' 10 : 9 9 
GASTR02NTEROLOGY 8 1 4 l 15 2~ 4 
GEN:t:RA:... PRACTICE 3 0 5 12 l 2 9 
GER:.l\TR I CS 3 0 5 124 22 5 
HEX!-. TO LOGY 4 G 7 125 - -, '--~ ~ 
:::HEC?IOUS [1ISEA 4 c 7 132 23 9 
INT~RNt-.~ MEDIC IN 1 1 3 2C = 24: 
-· - -
i:::: ?ERO:...OG:.· 3 0 5 2.0::. 44 9 
NE'JROi,OGY 6 l 2 54 4 6 0 
NUCLEAR MEDICINE i c 2 2 :::: 46 2 
03S':°E:'!i.ICS GYl'EC 3:. 6 3 29C. 5 2 
ORTHODONTICS 0 2 29: 5 2 
o ?::T::!-.:.,110:...oc.- lQ 
-
3"" :'.4 
OllCC•:..oc,· RAI:lATI .- ~ - :.t 
-
-
\,...; _,,;:_ 
ORTHO?EDICS 9 6 32 SC :::.  
OTO?E:NO:...ARYNGOL 7 .) 326 59 
PATP.O:.OGY 9 6 337 6 : 
PE: .'IT:ucs 46 6 3 383 6 9 4 
PERIODONTICS 4 0 7 387 70 
PROSTHODONTICS 1 0 2 385 7C 3 
PS!'CE I ATRY 42 7 6 4 3 0 7 7 9 
?G:..MONARY 6 436 79 
:<.A::IOLOGY 7 3 44 3 a: c · 
RE=:: !.~Y..A.TOLOGY 3 c 
-
4.;6 ~-
sw:.:G~::: ·~· -G~?-;ERAL 
-
' 
::; c 4-,.,.._ 
- ' 
Ee .., 
s·:r:G~?, ':.' - DEl;'!'AL 
-
-. 4 5 5 _: 
-SURGE·:· - F:...ASTIC 5 c 9 4 "1 ES' ~ 
-
S'Jr'GE?. : - OTEEr. 2l 3 E :::. 9: 
·.:r:c·. :...c,:·.:.· 2 = g: -
- - -
--· 
er:·::::::: 12 
-
:2 5~ g--
NOT S?=-::C~:· :::::; 9 c s~ 9 S· 
s:.1r::c r:~·::· - PCJ!)l:ATRI 3 c ~ 5~ ~ G= 
F~~~~ en~~ Miss~ng • 1 J9 
112 
BOARD CERTIFIED 
Cum~lative Cumulative 
BORDCERT Frequency Percent Frequency Percent 
YES 
NO 
PRACTYPE 
SOLO 
SMALL GROUP ( 2-4 
LARGE GROUP ( ' 5 ) 
HOSPITAL 
GOVT · INDUSTRY 
OTHER 
450 
109 
80.5 
19.5 
450 
559 
80.5 
100.0 
Frequency Missing 102 
PRACTICE TYPE 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
271 42.3 271 42.3 
129 20.l 40C1 62.4 
82 12.8 482 75.2 
109 17.0 591 92.2 
14 2.2 605 94 . 4 
36 5.6 541 ~.i. 100.0 
Frequency Missir.g 20 
# YEARS IN PRACTICE 
Cumulative Cumulative 
LICYEARS Frequency Percent Frequency Percent 
UNDER 5 103 l ::':.7 10~ 15. ,... ( 
6-10 165 25 . l 26E 4C .7 
11 - 20 10 i ..., ~ 29. ,J 45 9 69.8 
21-30 102 15.5 561 85.3 
31-4[. 56 8. 5 617 93.8 
OVEF: 4.:· 41 6. 2 ESE 100 . 0 
FrecruencY Missing 3 
113 
RIPRACTl 
YES 
NO 
RI?RACT2 
YES 
NO 
YRSRIPRA 
0 
1-10 
11 - 20 
21-30 
3l - 40 
OVER 40 
PRESENTLY PRACTICING IN RI 
Frequency 
591 
63 
Curoula:1ve Cumulative 
Percent Frequency Percent 
90.4 
9.6 
591 
654 
90.4 
100.0 
Frequency Missing 7 
EVER PRACTICED IN RI 
Frequency 
43 
l ..... 
.. ( 
Cumulative Cumulative 
Percent trequency Percent 
71 . 7 
28 . 3 
43 
60 
71. 7 
100 .0 
Frequency Missing 601 
~ YEARS PRACTICE IN RI 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
19 2 . 9 19 2.9 
346 52.7 365 55.6 
155 23.6 520 79.3 
75 11 . 4 595 90.7 
4C 6.1 635 96.8 
21 3.2 656 100.0 
FTequency Missing 5 
SEX 
Cumulative Cumulative 
SEX Frequency Pe:::-cent Frequency PeTcent 
M 
F 
545 
108 
83.5 
16.5 
545 
653 
Frequency Missing = 8 
114 
83.5 
100.0 
AGECAT 
UNDER 30 
30-39 
40-49 
50-59 
60-69 
OVER 70 
RXISSUE 
YES 
NO 
RXNUM 
0 
1 - 85 
26 - 5C 
51-75 
76-100 
OVER 1 O'.::"· 
AGE CATEGORY 
Currulative Cumulative 
Frequency Percent Frequency Percent 
19 2 . 9 19 2.9 
240 36 . 4 259 39.3 
182 27.6 441 66.9 
107 16 . 2 548 83 . 2 
73 11. 1 621 94.2 
38 5.8 659 100.0 
Frequency Missing 2 
ISSUANCE OF C-II RX 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
585 
62 
90.4 
9 . 6 
585 
647 
Frequency Missing 14 
APPROX # C- II RXS WRITTEN / MONTH 
9C.4 
100 . 0 
·Cumulative Cumulative 
FTequency Percent Frequency Percent 
143 22 4 143 22. 4 
466 73. c 6 n ~ ~';;j Qt:; ....,~. 5 
20 0. 1 629 98.6 
4 0.6 633 99.2 
l 0.2 67-4 99.4 
4 0.6 633 lOC . 0 
Freque!lcy MiSS2..ng 23 
115 
f:: : l 97 9 
YES 
NO 
YES 
!J(i 
PRACTICED IN RI PRIOR TO 1979 
c~ ~~ : a::vs CLr L! a t :ve 
Frequencv Pe rcen t Fre que ncy Percent 
295 
355 
45.4 
54 6 
295 
65C 
Frequency Missing 11 
HAS CHANGED PRESCRIBING PATTERNS 
45 4 
100 0 
Cumulative Cumulative 
Freque:-icy Percent Frequencv Fercent 
59 29 l 59 29. 
144 70 . 9 2'"" ~v 100 0 
F'req·-iency Mi ss ing 453 
THERAPEUTIC A~TE~NATIVES 
Cu muiative Cumulative 
TE ERACT Frequenc y ?er cent Frequency Pe rcent 
STRONGLY AGREE 
AGREE 
NOEFFEC 
J: SAG?.E 
S!~ONGL S:SAGRE 
N .:-. 
13 
13 
6 
7 
<; 
53: 
F :·ec;u.e ricv 
116 
2 3 
2 3 
o. 
2 
c 7 
92 ~ 
Mi ss ::. 2~ 
1 3 2 3 
26 4 5 
32 5 6 
39 6 8 
43 7 
" 5:; 4 l OC c 
37 
PRESCRIBES 1 ED NARCOTICS 
C~rn~lative Cumulative 
CA TN ARC Frequency Percent Frequency Percent 
- - - - - --- --- ---- -- - ---- --- --- -- - - - --- -- - - ----------------- - ----
NARCOTIC ANALGES 506 100.0 506 100.0 
Frequency Missing = 155 
PRESCRIBES 1ED SEDATIVE / HYPNOTICS 
Cumulative Cumulative 
CATSED Frequency Percent Frequency Percent 
SEDATI\'E HYPNOTI 146 100.0 146 100.0 
Frequency Missin~ = 515 
PRESCRIBES ' E~ CNS STIMU~ANTS 
Cumulative Cumulative 
CATCNS Frequency · Percent Frequency ?ercent 
CNS STIMULANT 118 100.0 118 100.0 
Frequency Missing 543 
?RESCRIBES t ED OTHER C-I : 
Cumulative Cumul ative 
CATOTHER Frequency Percent Frequency Percent 
OTEEF 39 lDO.C 3 9 lQC.C 
Frequehcy Mi s sing 622 
117 
RISK3Elic 
STRONGLY AGREE 
AGREE 
NOEFFECT 
DISAGREE 
STRONGLY DISAGRE 
N A 
.~G?E~ 
:; o ::??EC'.:-
2: S.'IGr.EE 
:O':"R')!lC.:: :::::;: S.,:,,G?::: 
i; !-. 
S'!' O'.iGL·:· .'\GRE:O 
i-.G 
NG 'C":-
,;G 
s: ON :_.y T'"'> "'" .- • ,,.....-, -1...: ..:...-::>.,v:-. .:.. 
RISK BENEFIT RAT i O 
r_: ~ : ~ : -~ ~ c ~~~l a:: v e 
r y·e ·=! ·J 2 n C _\~ ~er- :=: e n : ~ :eque n 8v Fe r cent 
-- - - - - -
9 1 5 9 5 
17 2 9 26 4 _ 5 
6 1 0 3 2 c 5 _, 
6 1 0 38 6 5 
3 0 5 41 7 1 
54 0 92 9 581 100 0 
Fre~~enc y Mi 5sing 8 0 
CumLla:ive Cumula:ive 
Frequenc:.,.~ Fer-cent 
9 
22 
3 
5 
546 
Frequen8::,-
6 
3 
118 
9 5 
3 c 3: 5 3 
., 5 3~ 5 8 ·~ 
'.) 9 39 6. ~ I 
93 3 585 100 0 
MiSSl.:l g 76 
C~rnulative Cumulative 
Fer8en: ~requen8~ Fercen: 
l ._· 
4 
.J 2 
93 . 7 
3 
3 
53 
C· 
-· 
9 
-
~ 
6 2 
f 3 
lO C:: 0 
NOTAPPL l 
- - - - -
STRONGLY AGREE 
!JOEFFECT 
STRONGL: DISAGRE 
1; /'. 
STf'O'<G :... ': AG; EE 
.">Gi<::: 
!iCE??E.:C-:-
s :::S.l\Grt::::: 
·AG - -
nAKJ:: 
- -
STATEMENT DOE S NOT APPLY 
?:e:;c;enc y :oe ,·c ert 
3 0 :: 
5 0 E 
7 1 
596 97 :: 
C~s~ : a :: ~~ C 2~~:at~ve 
Freq ue ncy ?ercent 
3 
8 
15 
611 
0. 5 
1 .3 
2. 5 
100. 0 
Frequency Missing 50 
C-:: FORM DI?F =C ULT TO USE 
C~mulative Cumulative 
":-equency Percent 
6 ' 7 c 8 7 8 
' -
:: ·, ' i 13 2e 9 
E .i. ..., E 21 46 7 
' 
' : 24 4 32 71 1 
-
~· 2E 9 45 100 0 
? : e ·~ue~c: ... ~ E!. SS !.ng = el6 
c - - T FORM NOT HAND:Y ·TO u SE 
Cumulative Cumulat i ve 
fr·eq'...len::::: y ?ercent ~requency Percent 
l5 33 1 
"' '-''--' 
3 
13 2 3 25 6 2 2 
E: 13 :34 7~ 6 
6 13 4 0 oE 9 
-· l 
-
45 lOC C 
119 
?Rt::.3CO!iF 
S'.RONGLY AGt<EE 
;GR:::: 
!JOEF>ECT 
:::i=s i".G r<E:E 
S':'RONGLY DISAGRE 
NOEF':CECT 
:;= S.t-.GR.EE 
?HA~~1 ?R3 
s-, O!<G:_,:· 
AG ::E 
'.') •) 
. - c 
_!;( !:. 
;:, r ·.1.· ~ - · 
CONFIDENTIALITY TO PRESCRIBE 
F:·8quency ?ercer:t ?e~·cen"C.. 
6 13 . 3 6 13. 3 
2 2 7 15 . 6 
17 37 8 24 53 . 3 
13 2 8 . 9 37 82. 2 
8 17 8 45 100 . 0 
frequency Missing = 616 
?ATIEN'. CONF ~DENTI AL!TY 
Cumulative Cum~ lative 
?er~ert Frequen~y ?ercen: 
6 13 6 6 
6 13 6 l2 
13 29 . 5 25 
l i 25 0 36 
6 .!..~ 2 4'1 
:C;· s~:.:en cy ~'. i ssing 
-
6l7 
Pt<03~EMS WITH PHARMACY 
?requency 
6 
4 
... 2"; 
1 r 
........... 
lC 
Percer.t 
14 
9 
30 
23 
2: 
Cumula: ive 
Fr-equenc y 
Fre~u~ncv M~ ssing 61 6 
120 
i3 6 
27 3 
56. 8 
61 . 8 
:.oo 0 
C1 mulative 
Percen-c 
i4 0 
23 3 
53 
-
76 7 
~OG [' 
NOTAPPL2 
STRONGLY AGREE 
AGREE 
N02FFECT 
L" ISAGREE 
STRONGLY DISAGRE 
STRO!'G:..:.· AGREE 
E<.GREE 
FOEFFECT 
r=:SAGRE~ 
ST!-<ONG:.. : DIS."IGRE 
i; f. 
':'HERALT 
STRONG:... ·:· AGj;EE 
.t,G?E::O 
NOEFFE~':' 
::C:'.:SAGRSE 
S':~ONG:.;.:.· r::s.~GRE 
r _t .. _ 
STATEMENT DOES NOT A?PL"! 
r requenc y Percent f:equency Percent 
4 28.6 4 28 .6 
2 14 3 6 42 . 9 
5 35 . 7 11 78 .6 
1 7. l 12 85 . 7 
2 14.3 14 100 .o 
Frequency Missing ~ 647 
PR2FER TO PRESCRIBE ~ON-C-II 
Cu~ulative Cumulative 
Pe::-cer.: Percent 
'"' 
'r, 
.!.'-'. 9 72 lC. 9 
145 21 9 217 32 8 
54 8. ;: 271 41 0 
2 1C 32 . 7 487 ~.., (,_. 7 
l3C 20. E 623 94 3 
3c 5 .7 661 lOC 0 
AVAILABLE ALT TO C-II FACTOR 
Cunu lative Cumulative 
Frequency Percen: F~equency Percent 
1 32 20 l 38 2C 
33 
-
SD 469 I " 
60 9 529 8'J 
59 8 588 89 
3~ ::: 622 94 
39 ~ 66 
" 
lOC 
121 
C- II FORM AFFECTS PRESCRIBING 
C".-JJ";·..: ~a :_ ·v E Ci..:m:..:~::. :: :..-~-~ 
FORM A FF Frequency Pe:cent Frequency Fercen: 
---- - - - -- - --- - ---- - ------ -- -
- ·- -- - -· -· - - - - -- - - - - - . -· -· - - - -- -
STRONGLY AGREE 56 8 5 56 8 5 
AGR EE 170 25 7 226 3 4 2 
JJOEFF'ECT 1 53 23 379 57 . 3 
DISAGREE ll C 16 6 489 74 0 
STRONGLY DISAGRE 133 20 622 94 1 
N A 39 5 9 661 100 0 
MALFRAC~ICE RESULTING FROM ALT DRUG 
S':"RONG:.,-~- -"GRE2 
AGRE 
NOEP!-'ECT 
D:SAGREE 
S~?ONGLY DISAGR E 
ADVCONS: 
S':' t\O~<G:..,:.· AGt\ 22 
. .:,G:;2::: 
HOE??EC':" 
:;: S.-"GF.22 
,. :-. 
Cuffiula::ve Cumulat:ve 
?e:c8rt ~:e~~e ncy Percent 
2. i ., '--' "-· 2~ 3 2 
9S' 15 c 12C 18. 2 
' ""' .;......, •.. : 2C' 2S3 38 3 
24c 37 2 499 75 5 
l ' - 7 ,;. ' ,- 6:6 93 2 
4: 6 E: 66~ 1 oc 0 
ADVERSE CONSEQUENCES W C- II! - V 
Cumu:a:1ve Cumulat : ve 
Prequency F r·eJue ncv Perce nt 
"· 
= 5:: 3 
2R S 337 5 0 
~~ .;3 
-
6 2 
l - 5':"E 5 4 
-
3 ·; 6 
-
~ 9 G 
..;E:. 66 10 
-
122 
ADVERSE CONSEQUENCES W NON SCHEDULE 
P.DVCONS2 
- . - - - - ----- --- - - -
STRONGLY AGREE 
AGRE E 
NOEF'!"ECT 
DI S.'IGREE 
STRONGLY DISAGRE 
N _A, 
::...E S SF:I.3!: 
D::: S.~GRE~ 
S-:'RJNGL. CI S.!\GR::: 
6 
" ' l" t . 
Ct:.:.t. la.: i ·y·e C,urr:L.::.c.t::.. -..:e 
F1equencv ?c .L ce nt Fr ec;ue nc:; Fer-cent 
- - - - -· - - - - -· -- -- - - - - - -- - ---- ---
63 9. 5 63 9 . 5 
29~ 4 4 5 357 54 0 
96 14 5 453 65 5 
l l 
-
16 8 564 85 3 
3 1 4 7 595 90. 0 
66 10. 0 661 100 0 
LESS RIS~ CSI NC NON - c - r : DRCG 
Cu mu lative Curnulat!ve 
~~rcent F requenc~ Percent 
' : - . 3 15 2 3 
113 ; ::--., . ' 128 19 . 4 
l)f le 0 234 35 . 4 
31 : 47 0 54 5 82. 5 
62 9 · 5 603 92 0 
c 6 0 9 92 . ' 
-
52 j 9 661 100 . 0 
3ETTER COM?LIANCE W NON - C ~I DRUG 
Cumulative Cumulative 
Pe:·c e:r?t Frequen~y Percent 
-;-
AG - - < '> 
'-' .. J 3 
10 ~ 20 3 
34 2 S'i 8 
5- 5.:; 9 
5 :? 66 10 
123 
DECABUSE 
STRONGLY AGREE 
AGREE 
NCJEFF"ECT 
I:·ISAGREE 
STRONGLY DISAGRE 
N A 
DOCS HO? 
STRO!-JG:..Y AGREE 
AGREE 
NOEF!"EC':' 
rISAGREE 
ETRONG:..:.· DISAGRE 
1; !-. 
REDUCTION OF DRUG ABUSE 
Frequency Per·cent Fr·equency 
120 18. 2 12C 
307 46 4 427 
88 13 3 515 
56 8 5 571 
37 5 . 6 60E 
53 8 0 661 
THWARTS DOCTO~ SHOFPERS 
Pe:lcent 
12C :a. 2 
264 39 9 
113 l r;-
76 5 
3;, 4 . c 
56 8 
= 
Cum ·c: lat.iYE 
F:-ec:uE:r.cy 
l2C 
3c<: 
40 ... 
-- ' 
57~ 
6C: 
6C 
Percent 
18 . 2 
64 . 6 
77 9 
86 4 
92.0 
100.0 
Curnu2.c.ti··/€ 
?e! cen-;: 
is 2 
55 1 
75 2 
86 . 7 
g: .5 
1 OC· . ~ '-' 
DECREASES AVAILABILITY OF C- 11 
Cumulative Cumulative 
DECAVAIL Freq'.iency Percent Frequeccy ?ercent 
S':' ONG: .. .":' AGREE 7 9 ... ~ 9 '.:: 
1-.G EE 23 3C.;; 4 0 
1~ c: ~"== 6 3 
AG :.2 ~· 56E 6 . 6 
::>1 S . ;GRE 3 7 6(-;; 9 .... 
~ E 6E: 10 L , . , . 
124 
FORGRX 
STRONGLY AGREE 
.!\GREE 
:J I S.t\GR EE 
STRONGLY DISAGRE 
AW.t;RESE 
S7RONGLY AGREE 
D:::SAGREE 
s~ ;:ONGLY DISAGRE 
1; f-. 
MAKES RX FORGERY DIFFICULT 
Cumul a::ve Cumuiati~e 
Frequency Percent Frequency Perce nt 
138 24 . 9 138 24 9 
372 67 0 5 10 9 1 .9 
31 5 . 6 541 97 . 5 
14 2 5 555 100. 0 
Frequency Missing = 106 
MORE AWARE OF DRUG S E 
Cumula: : ve Cumulative 
Frequency ?e~cen: Frequency Percent 
9 2 :3 . 9 92 13 . 9 
287 43 379 57 . 7 
-
v 
11 3 17 40 -:0 74 4 
95 14. 4 587 88 . 8 
28 4 
-
6' ~ 93 . 0 
4 6 7 C · 66: 100 . 0 
DECREASES OVERUTILIZATION OF C- II 
Cumulat :ve Cumu l ative 
DECOVRUT Fre::rue ncy ?ercen: Frequency Percent 
s: ·;.O!JG:_.y AGR:SE 88 3 6 '7. iu 3 
AG::. ~~ 35 ; 43 66 4 
!JOE?!"E i •J3 E: 5.; 32 r. v 
:; : S.4.G::. 5 0 c 59 39 6 
3:-t=:O!;G DISAGRE 23 6 93 c 
l ! 46 6 S 1 :J C, ,-. u 
125 
ID DEALERS / ABUSERS IN MED COMMUN 
c ~~ u lat:ve Cum u l ative 
:D.A.3USR ~requency Per c ent Frequency ?erc ent 
STRONGLY AGREE 70 10 . 6 70 10 6 
AGREE 271 4l 0 34 1 51 6 
NOEFF'ECT 146 22. 1 487 73 7 
DISAGREE 75 l } .3 562 85.0 
STRONGLY DISAGRE 36 5 4 598 90 5 
N A 63 9 5 66 1 100 0 
NECESSITY TO REGULATE PRESCRIBING 
REG'LP.TE 
STRONG;_,y AGREE 
AGREE 
NOEFr'EC':-
DISAGREE 
STRONGLY DISAGRE 
N A 
QLTYCARE 
Y~~ 3EN2?IC:!:.4.~ 
YE::: . NEG . :..:rv::: 
NC 
Cumulative Cumulative 
?requency Percent Frequency Perce nt 
86 .i.0 ~ 86 13 0 C.,· 
301 4'°' ~ 367 58 5 
7c. 
' 
-
-
461 69 7 
107 16. 2 566 85 9 
46 7 - 614 92. 9 
. ~· 
4-;- .., 1 6E< 100 0 
' 
RID?L AFFECTS QUALITY OF CARE 
FTequency 
149 
4 i 
293 
Cumulative Cumulative 
Percent Freque~cy Per~ent 
30 
E 
61 
-
4 
149 
l9C 
485 
3 ~ 
3 9 
10 c 
KNOW~EDGE OF RI DDC REVIEW OF C-I! 
':'ES 
NO 
33~ 
302 
Per-cenT.. 
52 C· 
47 . 7 
C~m~lat:ve Cumu:at:ve 
r~eque::cy 
33~ 
f.33 
Frequency Miss:r.g 2E _ 
1 26 
REPORTED DIFFICULTIES FILLING C- II 
FILLRX Frequency Fer cent Frequency Pe r c; ent 
YES 
NO 
121 
505 
19 .3 
80 7 
121 
626 
Frequency Mi ss ing 35 
RIDP~ PROTECTS PRESCRIBER FROM PT 
1 9 3 
lO'J 0 
Cumulat1ve c~mu:atlVE 
PROTEC':° 
STR ONG:..;! AGREE 
AGREE 
NOEFFECT 
r: s . .;GREE 
S':' r:ONG :..Y DI S.l\GRE 
l\ .l\ 
Frequency 
106 
317 
129 
42 
23 
44 
Percent ~req ·,_ien c~: 
16 0 106 
48 . r · u 4.,...,,"" - Gv 
19 5 S"' ·? 
6 4 594 
3 : 5· ':-
6 . 7 66 i 
KNOWS COLLEAGUE UNDER DDC RE VI EW 
16 0 
54 1::) 
32 5 
39 9 
93 v 
l JG c 
Cumulative Cumulative 
YES 
NC· 
'fE;O 
NO 
COLLE AG Frequency 
93 
536 
Percent 
14 7 
65 3 
Frequenc:: 
93 
63l 
Frequency Missing 30 
RESG~TING LIMIT OF P?ESCRI~!NG C - :: 
?er·cer: : 
22 26 " 
6 
-
7;:: 5 
Frequency Missing 2 •0 
1 27 
?e;·cent 
:4 7 
:JC C 
SPECTYP2 
ANESTHESIOLOGY 
CARDIOLOGY 
EMERGENCY MEDICI 
ENDOCRINOLOGY 
GASTROENTEROLOGY 
GENERAL PRACTICE 
GERIATRICS 
HEMATOLOGY 
IMMUNOLOGY 
INTERNAL MEDIC IN 
NEPHROLOGY 
ONCOLOGY RAD!ATI 
PULMONARY 
RHEU~'..<,TOLOGY 
SURGER ":'- FLASTIC 
SPECTYP3 
HEMATOLOGY 
ONCOLOGY · RADIATI 
r;: S . .;GREE 
AGR::: :S 
2ND SPECIALTY PRACTICE 
C~mLla:1ve c~~~ :a :: ve 
Frequency Pe i cent Frequency Pe i cent 
l 2.7 l 2 7 
2 5.4 3 e l 
5 13 . 5 6 21 6 
l 2 7 9 24 3 
l 2 . 7 10 27 0 
l 2 . 7 l l 29 7 
2 5 4 13 35 
3 6. 16 43 2 
1 2 7 17 45 9 
6 16 2 ~., G'-' 62 2 
1 2. 7 24 64 9 
e ~-G; 6 .., , . vG 56 : 
2 c .., , 9: 9 .J 
-
1,...''":, 
2 ~ 4 3c 97 3 
l 2 7 ... - 1 J C ,, ~ 
Frequenc y ~lSSl!1f = 6 24 
3RD EFECIAL~Y ?RAC:IC~ 
Frequency 
2C 
8 6 
128 
2 
1 
Cu~ulat 1 ve Curnu:ative 
?ercent ?~equer.cy Pe rcen t 
66 7 
33 · 3 
2 
3 
66 7 
100 c 
Perce~ : 
RISKBENl 
DISAGREE 
AGREE 
PTMIXl 
DISAGREE 
AGREE 
UTILPROl 
DISAGREE 
AGREE 
NOTAPP2.2 
D=SAGREE 
AGREE 
RISK / BENEFIT RATIO 
Frequency 
28 
70 
Cumula:ive Cumulative 
Percent Frequency Percent 
28 . 6 
71. 4 
28 
98 
28.6 
100.0 
Frequency Missing 563 
Frequency 
23 
28 
PATIENT MIX 
Cumulative Cumulative 
Percent Frequency Percent 
45. l 
549 
23 
51 
4 c:; ; -~ . .I. 
100 . 0 
Frequency Missing 610 
UNDER 1 0VER UTILIZATION PROBS 
Frequency 
31 
47 
Cumulative Cumulative 
Percent Frequency Percent 
39.7 
60.3 
31 
78 
39.7 
100.0 
Frequency Missing 583 
STATEMENT DOES NOT APPLY 
Cumulative Cum~lative 
Frequency Percent Frequency ?ercen: 
19 
31 
33 . c 
62. (i 
Frequency Mi ss ing 611 
129 
19 
50 
3c.C 
100.C 
THERPREl 
DISAGREE 
AGREE 
THERALTl 
DISAGREE 
l'>GREE 
FORMAFFl 
DISAGREE 
AGREE 
1-fA i.., ?RACl 
D:::SAGREE 
AGREE 
PREFER TO PRESCRIBE NON-C-II 
Cumu lative Cumu lat i ve 
Fr equency Pe rce n t Frequency Pe rcent 
352 
217 
61 . 9 
38 . 1 
Frequency Missing 92 
352 
569 
AVAILABLE ALT TO C- II FACTOR 
6 1. 9 
100 . 0 
Curnu~at ive Cumul a tive 
Fr e q uency Pe rcent Fre que ncy Fe r cent 
93 
469 
16 .5 
83.5 
Frequency Missing 99 
93 
562 
C-II FORM AFFECTS PRESCKIEING 
16 . 5 
100 . 0 
Cumulat ive Cumulat ive 
Frequency Percent Frequency Per cent 
243 
226 
5 1 . 8 
48. 2 
Frequency Missing , 0 ? .._ v~ 
243 
469 
MALPRACTICE RESULTING FROM ALT DRUG 
5 1. 8 
100 . 0 
Cum~:a~ive Cumulative 
F reque:ccy 
7 ro '7, 
<->0<--
120 
Percen"l: 
75. 2 
246 
F req:uency 
363 
46 Z 
Freque n cy Missing 178 
130 
Per cer:t 
7~.2 
100.0 
AD\7CON11 
DISAGREE 
AGREE 
ADVCON21 
I:ISAGREE 
AGREE 
ADV CON S 
LESSRIS l 
AGREE 
ADVERSE CONSEQUENCES W/ C- III - V 
Curnula~ive Cumulative 
Frequency Percent Frequency Percent 
184 
337 
35.3 
64 . 7 
Frequency Missing 140 
184 
521 
ADVERSE CONSEQUENCES W NON - SCHEDULE 
35 . 3 
100 . 0 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
142 
357 
28.5 
71.5 
Frequency Missing 16 2 
142 
499 
28 . 5 
100.0 
Cumulative Cumulative 
Frequency Pe rcent Frequency Percent 
Frequency Missing = 661 
LESS RISK USING NON-C-I I DRUG 
Cumulative Cumulative 
Frequency 
374 
12 8 
Percent 
7 4 . 5 
25 . 5 
Frequency 
37~ 
502 
Frequency Mis s ing 15 9 
131 
Percen"t 
74 .5 
l OC; . 0 
COMPLNCl 
DISAGREE 
AGREE 
DECABUSl 
DISAGREE 
AGREE 
DOCSHOPl 
DISAGREE 
AGREE 
DECAVAi l 
DISAGREE 
AGREE 
BETTER COMPLIANCE W/ NON-CII DRUG 
Cumulative Cumula t ive 
Frequency Percent Frequency Percent 
409 
39 
91.3 
8.7 
Frequency Missing 213 
REDUCTION OF DRUG ABUSE 
409 
448 
91.3 
100.0 
Cumulative Cumulative 
Frequency 
93 
427 
Percent 
17 . 9 
82. 1 
Frequency 
93 
520 
Frequency Missing 141 
THWAR~S DOCTOR SHOPPERS 
Frequency 
108 
384 
Percent 
22.0 
78.0 
Cumulative· 
Frequency 
108 
492 
Frequency Missing 169 
DECREASES AVAILABILITY OF C- II 
Percent 
17 . 9 
100.0 
Cumulative 
Percent 
22 . 0 
100.0 
Cum~lative Cumu lative 
Frequency 
159 
304 
Percen"t 
34. ::: 
Frequenc y 
i 59 
463 
Frequency Missing 195 
132 
?e:- c en t 
34.3 
100.0 
FORGRXl 
DISAGREE 
AGREE 
AWARESEl 
DISAGREE 
AGRZ:t: 
DECOVRUl 
DISAGREE 
AGREE 
IDA?:_TSR l 
AGR:2E 
MAKES RX FORGERY DIFFICULT 
Frequency 
45 
510 
Percent 
8. l 
91.9 
CumuJ..ative 
Frequency 
45 
555 
Frequency Missing 106 
MORE AWARE OF DRUG S/ E 
Cumulative 
Percent 
8.1 
100.0 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
123 
379 
24.5 
75.5 
Frequency Missing 159 
123 
502 
DECREASES OVERUTILIZATION OF C- II 
24.5 
100.0 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
73 
.439 
14". :3 
85.7 
Frequency Mis s ing 149 
73 
512 
ID DEALERS ABUSERS IN MED COMMUN 
14.3 
100.0 
Cumulative Cumulat ive 
Frequ ency 
11 ~ 
34l 
Percenc; 
24.6 
75.4 
f requency 
l l l 
452 
Frequency Missin g 209 
133 
Percen "t: 
24 .6 
100.0 
NECESSITY TO REGULATE PRESCRIBING 
REGULATl 
DISAGREE 
AGREE 
Frequency 
153 
387 
Curnula:ive Cumulative 
Percent Frequency Percent 
28.3 
71. 7 
153 
540 
28.3 
100.0 
Frequency Missing 121 
RIDPL PROTECTS PRESCRIBER FROM PT 
PROTECTl 
DISAGREE 
AGREE 
DEGl 
NON-MD DEGREES 
MD 
Frequency 
65 
423 
Cumulative Cumulative 
Percent Frequency ?er cent 
13.3 
86.7 
65 
488 
13.3 
100.0 
Frequency Missing 173 
PRIMARY PROFESSIONAL DEGREE 
Cumulative Cumulative 
Frequency Percent Frequency 
127 
532 
19.3 
80.7 
Frequency Missing 2 
CURRENTLY PRACTICING IN RI 
127 
659 
Percent 
19.3 
100.0 
CumulaTive Clirn~laT1ve 
F.IPRACX Frequency Percent: Frequency Percent 
NO 
'-'PC: 
- .6....11...,..-
63 
591 
S.6 
90.4 
Frequency Missing 7 
134 
63 
6 -.:. J_ 
RXISSUX 
NO 
YES 
Ril979X 
NO 
YES 
RE"-/IEWX 
NO 
YES 
NO 
YES 
EVER ISSUED C-II RX 
Frequency 
62 
585 
Cumulative Cumulative 
Percent Frequency Percent 
9.6 
90 . 4 
62 
647 
9.6 
100.0 
Frequency Missing 14 
PRACTICED IN RI PRIOR TO 1979 
Frequency 
355 
295 
Cumulative Cumulative 
Percent Frequency Percent 
54.6 
45. 4 
355 
650 
54.6 
100.0 
Frequency Missing 11 
AWARE OF DDC REVIEW 
Frequency 
302 
331 
Cumulative Cumulative 
Percent Frequency Percent 
47 . 7 
52.3 
302 
633 
47.7 
100.0 
Frequency Missing 28 
HAS SPECIALTY PRACTICE 
Frequency 
109 
"', G v ~ ....... -
Cumu~a~ive Cumulative 
Percent Frequency Percent 
17.4 
82.6 
109 
626 
11.4 
100. 0 
Frequency Missing 33 
135 
BOARD CERTIFIED 
Cumulat i ve Cumulative 
BORDCERX Frequency Percent Frequency Percent 
NO 
YES 
109 
450 
19.5 
80.5 
Frequency Missing 102 
SEX CATEGORY 
109 
559 
19.5 
100.0 
Cumulative Cumulative 
SEXl Frequency Percent Frequency Percent 
MALE 
FEMALE 
AGEl 
UP TO 40 
40 AND OVER 
PRACTY?:t= 
SOLO 
NO:N - SOLO PR.A.CT IC 
545 
108 
83.5 
16.5 
Frequency Missing 8 
AGE CATEGORY 
545 
653 
83 . 5 
100.0 
Cumulative Cumulative 
Frequency Percent Frequency Percent 
259 
400 
39.3 
60. 7 . 
Fr~quency Missing 2 
PRACTICE TYPE 
259 
659 
39.3 
100.0 
Curnula~~ve Curnula~ive 
Freque~cy Percent Frequency Percent 
,...., :--- -
GI_ 
37 0 
42 . 3 
57.7 
Frequency Missing 20 
136 
2 '7 •. 
' .. 42.3 
64~ 100.0 
LICYEARX 
10 YEARS & UNDER 
OVER 10 YEARS 
NUMBER YEARS LICENSED 
CumLlat:ve Cumulative 
Frequency Percent Frequencv ?ercent 
268 
390 
40 7 
59 3 
Frequency Mi ssi ng 3 
268 
653 
40.7 
100 0 
NUMBER OF C- II RX ISSUED?E? MONTH 
RXNUMX 
NO RX ?ER MONTH 
ON E OR MOR E RX P 
137 
l43 
495 
Cumulative Cumulat i ve 
Percent Frequencv ?ercent 
2::0 4 
77 . 6 
143 
636 
22 4 
lOC C 
APPENDIX D 
Multicollinearity Results 
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The SAS System 
Model: MODELl 
Dependent Variable: FORMAFFl C-II FORM AFFECTS PRESCRIBING 
Source 
Model 
Error 
C Total 
Root MSE 
Dep Mean 
C . V 
Variable DF 
INTERCEP 1 
RIPRACX 1 
RXISSUX 1 
RI1979X 1 
SEXl 1 
AGEl 1 
SPECLTYX 1 
REVIEWX 1 
RXNUMX 1 
DEGl 1 
PRACTYPX 1 
LICYEARX 1 
SEX.'IGE 1 
iJEGAGE 1 
PRAC79 1 
DEG79 1 
SEXDEG 1 
Variable DF 
INT;::RCEP 1 
RIPRACX 1 
RXISSUX 1 
RI1979X 1 
SEXl 1 
AGEl . 1 
SPECLTYX 1 
REVIEWX 1 
RXNUMX 1 
DEGl 1 
PRACTYPX 1 
LICYEARX 1 
SEXAGE 1 
DEGP.GE 1 
PRAC79 1 
DEG79 1 
Analysis of Variance 
Sum of Mean 
DF Squares Square F Value Prob>F 
16 7.56545 0.47284 
398 95.86588 0.24087 
414 103.43133 
0.49078 R- square 0.0731 
0.47229 Adj R-sq 0.0359 
103.91602 
Parameter Estimates 
Parameter 
Estimate 
Standard 
Error 
T for HO: 
Parameter=O 
0. 105550 
0.208933 
0. 165671 
-0.228913 
-0.132718 
0.209511 
0. 110903 
-0.041174 
- 0. 192394 
0.158378 
-0.008209 
0.085262 
-0.102879 
-0.287722 
0.000666 
0.202674 
- 0.022639 
Variable 
Label 
Intercept 
0. 16292041 
0. 10915777 
0.11432768 
0.21594740 
0. 18361069 
0. 18631449 
0 . 07808857 
0.04937178 
0.07268749 
0.10215335 
0.07287930 
0.08600025 
0.15873i26 
0. 19828573 
0.10461084 
0.21102728 
0. 19647697 
CURRENTLY PRACTICING IN RI 
EVER ISSUED C-II RX 
PRACTICED IN RI PRIOR TO 1979 
SEX CATEGORY 
AGE CATEGORY 
HAS SPECIALTY PRACTICE 
AWARE OF DDC REVIEW 
NUMBER OF C-II RX ISSUEDPER MONTH 
PRIMARY PROFESSIONAL DEGREE 
PRACTICE TYPE . 
NUMBER YEARS 4ICENSED 
139 
0.648 
1.914 
1. 449 
-1.060 
-0.723 
1. 124 
1.420 
-0.834 
-2.647 
1.550 
- 0 . 113 
0.991 
- 0.648 
- 14.51 
0 006 
0.960 
-0.115 
1.963 0.0144 
Prob > IT I 
0.5174 
0.0563 
0.1481 
0.2898 
0.4702 
0.2615 
0. 1563 
0.4048 
0.0084 
0.1218 
0.9104 
0.3221 
0.5173 
0. 1476 
0.9949 
0.3374 
0.9083 
Number 
1 
2 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
The SAS System 
Variable 
Variable DF Label 
SEX DEG 1 
Collinearity Diagnostics 
Eigenvalue 
10.34643 
2 . 33880 
1.33425 
0.73705 
0.59157 
0.48986 
0 . 27475 
0.24560 
0.15563 
0. 11932 
0 . 10620 
0.08276 
0.07162 
0.04262 
0.03800 
0.01636 
0 . 00919 
Condition 
Number 
1 . 00000 
2. 10329 
2.78468 
3.74668 
4. 18209 
4 . 59578 
6. 13662 
6 . 49048 
8.15369 
9 . 31209 
9 . 87013 
11 . 18121 
12 . 01945 
15 . 58040 
16 . 50124 
25 . 15072 
33.55447 
Var Prop 
INTERCEP 
0.0002 
0 . 0001 
0.0006 
0 . 0001 
0 . 0001 
0 . 0000 
0.0012 
0 . 0017 
0.0038 
0 . 0055 
0 . 0031 
0.0055 
0.0000 
0 . 0021 
0.0018 
0 . 9740 
0.0003 
Var Prop 
RIPRACX 
0 . 0004 
0 . 0001 
0 . 0017 
0.0001 
0.0006 
0 . 0000 
0 . 0076 
0 . 0065 
0 . 0135 
0 . 0255 
0.0251 
0. 1059 
0 . 0103 
0.3753 
0.0130 
0 . 4127 
0.0016 
Var Prop 
RXISSUX 
0.0004 
0.0001 
0 .0018 
0.0001 
0 . 0001 
0.0003 
0 . 0095 
0.0032 
0 . 0024 
0.0001 
G.0008 
0.0105 
0.0166 
0.5804 
o. 1815 
0 . 1907 
0 . 0015 
Var Prop 
RI1979X 
0 . 0002 
0.0009 
0. 0014 
0.0000 
0 . 0025 
0.0025 
0.0081 
0.0071 
0 . 0016 -
0 . 0073 
0 . 0008 
0.0369 
0.0328 
0 . 0023 
0.0641 
0.0092 
0.8222 
Var Prop 
SEXl 
0.0001 
0.0145 
0 .0040 
0.0000 
0.0168 
0.0018 
0.0017 
0.0054 
0.0002 
0 . 0719 
0.0815 
0 . 0002 
0.4846 
0.0617 
0.0846 
0. 1075 
0 .0637 
Number 
Var Prop 
AG El 
Var Prop 
SPECLTYX 
Var Prop 
REVIEWX 
Var Prop 
RXNUMX 
Var Prop 
DEGl 
Var Prop 
PRACTYPX 
Var Prop 
LICYEARX 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
0 . 0002 
0.0004 
0 . 0006 
0 . 0017 
0 . 0005 
0.0009 
0 . 0007 
0.0222 
0.0005 
0.0019 
0.0385 
0.0185 
0 . 0248 
0.0028 
0 . 0580 
0 . 0102 
0 . 8176 
0.0009 
0 . 0001 
0 . 0036 
0.0001 
0.0000 
0.0034 
0 . 0243 
0.0248 
0. 1303 
0. 1336 
0 . 0298 
0 . 4035 
0 . 0755 
0.0249 
0 . 1121 
0 . 0325 
0 . 0005 
Var Prop Var Prop 
Number SEXAGE DEGAGE 
1 0.0004 0.0002 
8 0.0229 0 . 0005 
3 0.1314 0 . 0007 
4 0.0403 0.0020 
0.0023 
0 . 0003 
0 . 0072 
0.0025 
0 . 0246 
0.6834 
0. 1587 
0 . 0562 
o. 0148 
0.0063 
0.0018 
0.0005 
0 . 0097 
0.0001 
0 . 0092 
0.0198 
0.0026 
Var ~_Prop 
PRAC79 
0.0009 
0.0029 
0.0200 
0 . 2225 
0. 0010 
0.0002 
0.0051 
o.ooo: 
0.0001 
0 . 0003 
0.0786 
0.0000 
0.3847 
0. 1314 
0 . 0047 
0.0505 
0 . 0673 
0. 1939 
0.0730 
0.0085 
0.0006 
Var Prop 
DEG79 
0.0002 
0 . 0011 
0 . 0023 
0.0000 
140 
0 .0005 
0 . 0001 
0.0009 
0.0006 
0.0010 
0 . 0066 
0.0495 
0.0084 
0 . 9000 
0.0166 
0.0333 
0.0847 
0 .0022 
0.0361 
0.6819 
0.0765 
0.0009 
Var Prop 
SEXDEG 
0 . 0001 
0 0143 
0.0040 
0.0000 
0.0010 
0 . 0028 
0 .0038 
0.0604 
0 0212 
0 . 0155 
0 0123 
0.0374 
0 0025 
0 . 3355 
C.2370 
0 . 1982 
0 0120 
0 . 0075 
0 . 0029 
0.0267 
0.0234 
0 . 0010 
0 . 0019 
0 . 0022 
0 . 0029 
0.0016 
0.0001 
0 . 0417 
0 . 0820 
0 . 1290 
0 . 0331 
0 . 4062 
0 . 0605 
0. 1803 
0.0018 
0.0378 
0.0004 
0 0174. 
The SAS System 
Var Prop Var Prop Var Prop Var Prop Var Prop 
Number SEXAGE DEGAGE PRAC79 DEG79 SEXDEG 
5 0.4628 0.0000 0.0020 0.0049 0.0355 
6 0.00 19 0.0043 0.0017 0.0002 0.0000 
7 0.0032 0.0151 0.0003 0.0059 0.0006 
8 0.1851 0 .0129 0 . 0000 0.0249 0.0070 
9 0 . 0001 0.0136 0.0014 0 . 0157 0.0000 
10 0.0432 0.0002 0.2594 0.0244 0.0610 
11 0.0794 0.0122 0.2099 0.0098 0 . 0173 
12 0 . 0012 0.0055 0 .2109 0.0003 0.0002 
13 0.0002 0 . 0008 0.0107 0.0128 0 . 4911 
14 0.0001 0.0030 0.0125 0 . 0059 0.0728 
15 0 .0000 0.0719 0.0021 0.0678 0. 1328 
16 0 . 0002 0.0124 0 . 0212 0 . 0020 0.0880 
17 0.0278 0.8447 0.02 15 0.8220 0 . 0753 
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Model: MODELl 
Dependent Variable: THERPREl PREFER TO PRESCRIBE NON - C- II 
Sou r ce 
Model 
Error 
C Total 
Root MSE 
Dep Mean 
c.v. 
Variable 
INTERCEP 
RIPRACX 
RXISSUX 
RI1979X 
SEXl 
AG El 
SPECLTYX 
REVIEWX 
RXNUMX 
DEGl 
PRACTYPX 
LICYEARX 
SEXAGE 
DEG AGE 
?RAC79 
DEG79 
SEX DEG 
DF 
l 
l 
l 
l 
l 
l 
1 
l 
l 
l 
l 
l 
l 
1 
l 
1 
1 
Variable DF 
INTERCE P l 
RIPRACX l 
RXISSUX l 
RI1979X l 
SEXl l 
AG El l 
SPECLTYX 1 
REVIEWX l 
RXNUMX l 
DEGl l 
PRACTYPX 1 
LICYEARX 1 
SEXAGE 1 
DEGP.GE l 
PRAC79 l 
DEG79 l 
Analysis of Variance 
Sum of Mean 
DF Squares Square F Value Prob >F 
16 4.06783 0 . 25424 
478 112.53015 0.23542 
494 116.59798 
0 . 48520 R-square 0.0349 
0.37980 Adj R-sq 0.0026 
127 . 75204 
Parameter Estimates 
Parameter 
Estimate 
Standard 
Error 
T for HO: 
Parameter=O 
0.552834 
0.051689 
-0 . 090838 
- 0. 131222 
0. 110330 
0. 167924 
0 . 017043 
0.020344 
- 0.099561 
-0.082303 
- 0.051729 
-0.049020 
- 0.036213 
-0.071505 
- 0 . 072242 
0.130436 
- 0 . 098237 
Variable 
Label 
0 . 14407701 
0.09143191 
0.10173271 
o. 17479017 
0.14630034 - · 
o. 15517959 
0.06679454 
0.04446442 
0 . 06300870 
0.09026043 
0.06602601 
0. 07714833 
0.13580973 
0.16757733 
0.09576892 
0. 17740783 
0. 16167370 
Intercept 
CURRENTLY PRACTICING IN RI 
EVER ISSUED C-II RX 
PRACTICED IN RI PRIOR TO 1979 
SEX CATEGORY 
AGE CATEGORY 
HAS SPECIALTY PRACTICE 
AWARE OF DDC REVIEW 
NUMBER OF C-II RX ISSUEDPER MONTH 
PRIMARY PROFESSIONAL DEGREE 
PRACTICE TYPE 
NUMBER YEARS LICENSED 
142 
3.837 
0.565 
-0.893 
- 0.751 
0 . 754 
1.082 
0.255 
0.458 
- 1 . 580 
-0 . 912 
- 0 . 783 
-0 . 635 
-0 . 267 
- 0 427 
- 0.754 
0.735 
- 0 . 608 
1 . 080 0.3714 
Prob , IT I 
0.0001 
0.5721 
0.3724 
0.4532 
0 . 4511 
0.2797 
0.7987 
0.6475 
0. 1147 
0 . 3623 
0 . 4337 
0.5255 
0.7899 
0.6698 
0.4510 
0.4626 
0.5437 
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Variable 
Variable DF Label 
SEXDEG 1 
Number 
1 
2 
3 
4 
5 
6 
7 
8 
9 
~o 
11 
12 
13 
14 
15 
16 
17 
Number 
l 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Number 
l 
2 
3 
4 
Eigenvalue 
10 . 24544 
2.28714 
1. 41754 
0.77509 
0.53514 
0.47688 
0 . 31746 
0.23992 
0.17055 
0.13473 
0. 10945 
0.09211 
0.08203 
0. 04674 
0.04073 
0.01750 
0.01154 
Var Prop 
AG El 
0.0003 
0 . 0006 
0 . 0007 
0.0013 
0 -0006 
0.0020 
0.0023 
0 . 0258 
0 . 0007 
0 . 0001 
0 . 0395 
0 . 0002 
0.0614 
0 . 0048 
0 . 0492 
0. 0011 
0 .8096 
Var Prop 
SEXAGE 
0 . 0005 
0 . 0226 
0 . 11 83 
0.0188 
Collinearity Diagnostics 
Condition 
Number 
1.00000 
2. 11650 
2.68843 
3 .63571 
4 .37554 
4 .63513 
5 . 68097 
6.53476 
7 . 75058 
8.72038 
9 . 67530 
10.54630 
11. 17573 
14.80518 
15 . 86033 
24 . 19353 
2 9 .80064 
Var Prop 
INTERCEP 
0.0002 
0 . 0001 
0.0006 
0. 0001 
0 . 0001 
0.0000 
0.0012 
0 . 0014 
0 . 0024 
0.0051 
0 . 0010 
0.0053 
0 . 0001 
0 . 0062 
0.0021 
0 . 9576 
0 . 0167 
Var Prop 
RIPRACX 
0.0005 
0 . 0001 
0 0021 
0 . 0002 
0.0005 
0.0001 
0.0084 
0 . 0054 
0 .0097 
0.0342 
0.0116 
0. 1532 
0.0059 
0.4210 
0.0085 
0 . 3305 
0 . 0080 
Var Prop 
RXISSUX 
0.0004 
0.0001 
0 . 0017 
0.0002 
0.0001 
0.0002 
0.0067 
0 . 0050 
0 . 0018 
0.0000 
0.0000 
0.0176 
0.0019 
0.5187 
0. 1988 
0.2457 
0.0012 
Var Prop 
RI1979X 
0.0002 
0.0012 
0 . 0017 
0.0000 
0 . 0024 
0 . 0046 
0 . 0088 
0 . 0112 
0. 0025 -. 
0.0043 
0. 0014 
0 . 0094 
0.0784 
0.0002 
0.0711 
0 . 0438 
0 . 7588 
Var Prop 
SEXl 
0.0002 
0.0174 
0.0044 
0.0000 
0.0194 
0 . 0055 
0.0033 
0 . 0115 
0 . 0004 
0.1197 
0 . 1239 
0 . 0767 
0.2752 
0. 0714 
0 . 1434 
0 . 1091 
. 0 . 0183 ' 
Var Prop 
SPECLTYX 
Var Prop 
REVIEWX 
Var Prop 
RXNUMX 
Var Prop 
DEGl 
Var Prop 
PRACTYPX 
Var Prop 
LICYEARX 
0.0010 
0 . 0001 
0 .0036 
0 . 0001 
0 . 0007 
0.0051 
0.0208 
0.0273 
0. 1947 
0 . 1079 
0.0767 
0.37 15 
0 . 0002 
0 . 0440 
0 . 1201 
0.0252 
0. 0011 
Var Prop 
DEG AGE 
0 . 0 002 
0.0006 
0.0009 
0.0015 
0 . 0023 
0 . 0002 
0.0066 
0 .0064 
0.0909 
0 . 6128 
0. 1403 
0 . 0910 
0 . 0011 
0 . 0159 
0 .0000 
0 . 0010 
0.0041 
0 .0002 
0 . 0012 
0 . 0256 
0.0003 
Var Pr·op 
PRAC79 
0 . 0010 
0 . 0037 
0.0132 
0.2483 
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0. 0011 
0.0002 
0.0047 
0.0007 
- 0. 000 1 
0 . 0001 
0.0500 
0. 0.062 
0.4006 
0 . 1496 
0 .0021 
0.1152 
0 0293 
0. 1536 
0 . 0781 
0 . 0043 
0.0041 
Var Prop 
DEG79 
0.0002 
0 . 0013 
0.0028 
0.0000 
0.0006 
0 . 0001 
0 .0007 
0 .0006 
0.0026 
0 . 0074 
0.0512 
0.0053 
0 .0001 
0 . 0134 
0.0437 
0 . 0618 
0 . 009 1 
0.0442 
0. 6721 
0.0632 
0 . 0039 
Var Prop 
SEXDEG 
0.0002 
0 . 0167 
.o . 0055 
0.0000 
0. 0010 
0 . 0029 
0 . 0068 
0 .0572 
0.0139 
0.0170 
0 . 0073 
0.0357 
0 . 0090 
0 . 2199 
0 . 2 194 
0 . 1871 
0 . 1623 
0.0187 
0.0034 
0 . 0342 
0.0042 
0.0010 
0.0022 
0 . 0022 
0.002 3 
0.0017 
0.0000 
0.0454 
0 . 0870 
0.0713 
0.0222 
0 . 4169 
0.0060 
0.2976 
0.0029 
0.0324 
0.0004 
0.0085 
The SAS System 
Var Prop Var Prop Var Prop Var Prop Var Prop 
Numbe r SEXAGE DEG AGE PRAC79 DEG79 SEXDEG 
5 0.5040 0.0000 0 .0023 o. 0055 0.0404 
6 0.0315 0.0060 0.0032 0. 0014 0 . 0011 
7 0.0006 0. 0143 0 . 0006 o. 0101 0.0005 
8 0. 1906 0.0171 0.0002 0 . 0267 0.0066 
9 0.0026 0.0140 0 . 0013 o. 0140 0.0005 
10 0.0166 0. 0011 0. 1867 0. 0325 0.1 113 
11 0.0642 0.0177 o. 1635 0 . 0072 0.0320 
12 0.0044 0 . 0025 0. 1836 0.0057 0.0776 
13 0.0054 0.0028 0 1360 0.0060 0 . 3036 
14 0.0003 0.0034 0.0213 0.0050 0.0801 
15 0.0000 0.0716 0.0037 0.0706 0.2041 
16 0.0047 0.0009 0.0278 0 .0203 0 .0954 
17 0.0149 0.8452 0.0036 0 7907 0.0242 
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FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS FORM AFFECTS DECISION 
FOR THE ENTIRE DATA SET 
The LOGISTIC Procedure 
Data Set: WORK.NEW_DAT 
Response Variable: FORMAFFl C-II FORM AFFECTS PRESCRIBING 
Response Levels: 2 
Number of Observations: 419 
Link Function: Logit 
Response Profile 
Ordered 
Value FORMAFFl 
1 AGREE 
2 DISAGREE 
Count 
199 
220 
WARNING: 242 observation(s) were deleted due to missing values for the !esponse 
or explanatory variables. 
Variable 
RXNUMX 
RI1979X 
SEXl 
AGEl 
SPECLTYX 
REVIEWX 
DEGl 
PRACTYPX 
LICYEARX 
Criterion 
AIC 
SC 
-2 LOG L 
Score 
Simple Statistics for Explanatory Variables 
Standard 
Mean Deviation Minimum Maximum 
0.809069 0.393504 0 1.00000 
0.427208 0.495264 0 1.00000 
0.152745 0.360171 0 1.00000 
0.572792 0.495264 0 1.00000 
0.847255 0.360171 0 1.00000 
0 . 529833 0.499706 0 1.00000 
0.816229 0.387760 0 1.00000 
0.594272 0.491619 0 1.00000 
0.565632 0.496266 0 1.00000 
Criteria for Assessing Model Fit 
Intercept 
Only 
581.804 
585.842 
579.804 
Intercept 
and 
Covariates 
576.269 
616.648 
556.269 
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Chi -Square for Covariates 
23.535 with 9 DF (p=0.0051) 
22.648 with 9 DF ( p=0.0070) 
Variable 
INTERCPT 
RXNUMX 
RI1979X 
SEXl 
AG El 
SPECLTYX 
REVIEWX 
DEG l 
PRACTYPX 
LICYEARX 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS FORM AFFECTS DECISION 
FOR THE ENTIRE DATA SET 
The LOGISTIC Procedure 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr > 
Estimate Error Chi - Square Chi - Square 
- 0.2399 0.3961 0.3668 0 . 5448 
- 0 . 5169 0.2639 3.8384 0.0501 
-0. 1262 0.3193 0. 1562 0.6927 
-0.8337 0 . 3144 7.029 1 0 . 0080 
-0.2003 0.3372 0.3527 0.5526 
0.5206 0.3351 2.4 135 0 . 1203 
-0.2560 0 . 2035 1.5828 0.2084 
0.4459 0.3087 2.0855 0. 1487 
- 0.00840 0.2175 0 00 15 0.9692 
0.3127 0.3567 0.7688 0.3806 
Standardized 
Estimate 
- 0.112150 
-0.034460 
- 0 . 165541 
-0. 054681 
0. 103372 
- 0.070521 
0 . 095321 
-0 . 002278 
0.085568 
Association of Predicted Probabilities and Observed Responses 
Concordant = 60.7% 
Discordant = 36 . 2% 
Tied 3.1% 
(43780 pairs) 
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Somers · D 
Gamma 
Tau-a 
c 
0.245 
0.252 
0 122 
0.622 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE 
FOR THE ENTIRE DATA SET 
The LOGISTIC Procedure 
Data Set: WORK.NEW_DAT 
Response Variable: THERPREl PREFER TO PRESCRIBE NON - C-II 
Response Levels: 2 
Number of Observations: 499 
Link Function : Logit 
Response Profile 
Ordered 
Value THERPREl 
1 AGREE 
2 DISAGREE 
Count 
191 
308 
WARNING: 162 observation(s) were deleted due to missing values for the ;esponse 
or explanatory variables. 
Variable 
RI1979X 
SEXl 
AG El 
SPECLTYX 
RXNUMX 
!:lEGl 
PRACTYPX 
LICYEARX 
REVIEWX 
Criterion 
AIC 
SC 
-2 LOG L 
Score 
Simple Statistics for Explanatory Variables 
Standard 
Mean Deviation Minimum Maximum 
0.420842 0.494190 0 1.00000 
0. 164329 0.370945 0 1.00000 
0.563126 0.496497 0 1.00000 
0.825651 0.379790 0 l.oopoo 
0.805611 0.396127 0 1.00000 
0.789579 0 408017 0 1.00000 
0.589178 0.492477 0 1.00000 
0.557114 0.497226 0 1.00000 
0.533066 0.499406 0 1.00000 
Criteria for Assessing Model Fit 
:!nter·cept 
Only 
666.071 
670.284 
664.071 
Intercept 
and 
Covariates 
668.987 
711.113 
648.987 
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Chi - Square for Covariates 
15.084 with 9 DF (p=0.0887) 
15.095 with 9 DF (p=0.0884) 
Variable 
INTERCPT 
RI1979X 
SEXl 
AG El 
SPECLTYX 
RXNUMX 
DEGl 
PRACTYPX 
LICYEARX 
REVIEWX 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE 
FOR THE ENTIRE DATA SET 
The LOGISTIC Procedure 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr > 
Estimate Error Chi -Square Chi - Square 
0.3103 0.3450 0 8090 0 3684 
-0.2570 0.3030 0.7198 0 3962 
0. 1461 0.2683 0.2965 0.5861 
0 . 4860 0 . 3175 ,2. 3440 0. 1258 
0.0586 0.2816 0 .0433 0.8352 
- 0.5353 0.2334 5.2626 0.0218 
-0.3343 0.2644 1.5981 0.2062 
-0 .4172 0.2041 4. 1794 0.0409 
-0.2656 0 . 3303 0.6467 0.4213 
0.0946 0. 1894 0.2495 0.6175 
Standardized 
Estimate 
-0.070033 
0. 029884 
0. 133045 
0.012269 
-0.116916 
-0.075192 
-0. 113282 
-0.072813 
0 . 026043 
Association of Predicted Probabilities and Observed Responses 
Concordant = 59.3% 
Discordant = 38 . 1% 
Tied 2.6% 
(58828 pairs) 
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Somers ' D 
Gamma 
Tau-a 
c 
0.212 
0.217 
0. 100 
0.606 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS FORM AFFECTS DECISION 
FOR THOSE IN PRACTICE BEFORE 1979 
The LOGISTIC Procedure 
Data Set: WORK.BEFORE79 
Response Variable: FORMAFFl C-II FORM AFFECTS PRESCRIBING 
Response Levels: 2 
Number of Observations: 194 
Link Function: Logit 
Response Profile 
Ordered 
Value FORMAFFl 
1 AGREE 
2 DISAGREE 
Count 
97 
97 
WARNING: 101 observation(s) vere deleted due to missing values for the Eesponse 
or explanatory variables. · 
Variable 
RXNUMX 
REVIEWX 
PRACTYPX 
RXISSUX 
Criterion 
AIC 
SC 
- 2 LOG L 
Score 
Variable 
INTERCPT 
RXNUMX 
REVIEWX 
PRACTYPX 
RXISSUX 
Simple Statistics for Explan~tory Variables 
Standard 
Mean Deviation Minimum Maximum 
0.829897 0.376695 0 1 .00000 
0:5 92784 0.492587 0 1 . 00000 
0 . 438144 0.497443 0 1.00000 
0.943299 0 .231869 0 1 . 00000 
Criteria for Assessing Mode~ Fit 
Intercept 
Only 
Intercept 
and· 
Covariates Chi-Sq uare for Covariates 
270.941 
274 .209 
268.941 
273.495 
289.835 
263.495 5'.446 with 4 DF ( p=0 . 2445 ) 
5.319 with 4 DF (p= 0 .256 1 ) 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr ' Standardized 
Estimate Error Chi-Square Chi-Square Estimate 
-0.6887 0 . 7246 0.9033 0.3419 
-0.3699 0.4657 0 . 6309 0.4270 -0.076829 
-0.4487 0.2969 2.2838 0. 1307 -0.121854 
0.0543 0.2946 0.0339 0.8539 0.014882 
1.3089 0.8095 2 . 6142 0 . 1059 0. 167328 
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FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS FORM AFFECTS DECISION 
FOR THOSE IN PRACTICE BEFORE 1979 
The LOGISTIC Procedure 
Association of Predicted Probabilities and Observed Responses 
Concordant = 49.2% 
Discordant = 33. 1% 
Tied 17.7% 
(9409 pairs) 
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Somers ' D 
Gamma 
Tau-a 
c 
0. 162 
0. 197 
0.081 
0.581 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE 
FOR THOSE IN PRACTICE BEFORE 1979 
The LOGISTIC Procedure 
Data Set : WORK.BEFORE79 
Response Variable : THERPREl PREFER TO PRESCRIBE NON - C-II 
Response Levels: 2 
Number of Observations: 216 
Link Function : Logit 
Response Prof i le 
Ordered 
Value THERPREl 
1 AGREE 
2 DISAGREE 
Count 
81 
135 
WARNING : 79 observation(s) were deleted due to missing values for the r!sponse 
or explanatory variables. 
Variable 
SPECLTYX 
DEGl 
PRACTYPX 
REVIEWX 
RXISSUX 
Criter i on 
AIC 
SC 
-2 LOG L 
Sc ore 
Variable 
INTERCPT 
S::>ECLTYX 
DEGl 
PRACTYPX 
REVIEWX 
RXISSUX 
Simple Statistics for Explanatory Variables 
Standard 
Mean Deviation Minimum Maximum 
0.851852 o . 356072 0 1.00000 
0.833333 o. 373544 0 1 . 00000 
0.402778 0.491596 0 1.00000 
0 . 592593 0.492493 0 1 . 00000 
0 . 935185 0 . 246771 0 1 . 00000 
Criteria for Assessing Model Fit 
Intercept 
Only 
Intercept 
and 
Covariates Chi-Square for Covariates 
287.795 
291 . 171 
285.795 
288.174 
308.426 
276. 174 9 .621 with 5 DF (p=0.0867) 
9 . 5 1 ~ with 5 DF ( p=0.0902 ) 
Analysis of Maximum Likelihood Estirr.ates 
Parameter Standard Wald Pr ; Standardized 
Estimate Error Chi-Square Chi - Square Estimate 
0 . 9578 0 . 7320 1 . 7120 0 . 1907 
-0 . 0685 0.4288 0 . 0255 0 . 8731 -0.013440 
0.000708 0. 4103 0 . 0000 0 . 9986 0.000146 
-0.6066 0.3052 3 . 9508 0.0468 -0 . 164411 
-0 . 5184 0.2910 3. 1732 0.0749 - 0.140757 
-0 . 9430 0.5706 2 . 7307 0.0984 - 0 . 128292 
152 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE 
FOR THOSE IN PRACTICE BEFORE 1979 
The LOGISTIC Procedure 
Association of Predicted Probabilities and Observed Responses 
Concordant = 54.7% 
Discordant = 29.4% 
Tied = 15.9% 
(10935 pairs) 
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Somers' D 
Gamma 
Tau - a 
c 
0.253 
0.300 
0. 119 
0.626 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS FORM AFFECTS DECISION 
FOR THOSE IN PRACTICE AFTER 1979 
The LOGISTIC Procedure 
Data Set : WORK . AFTER79 
Response Variable : FORMAFFl C-II FORM AFFECTS PRESCRIBING 
Response Levels : 2 
Number of Observations: 244 
Link Function: Logit 
Response Profile 
Ordered 
Value FORMAFFl 
1 AGREE 
2 DISAGREE 
Count 
112 
132 
WARNING : 111 observation(s) were deleted due to missing values for the response 
or explanatory variables . 
Variable 
SEXl 
AG El 
RXNUMX 
REVIEWX 
DEGl 
PRACTYPX 
LICYEP.RX 
Criterion 
AIC 
SC 
-2 LOG L 
Score 
Simple Statistics for Explanatory Variables 
Standard 
Mean Deviation Minimum Maximum 
0 . 237705 0 . 426552 0 1 . 00000 
0.282787 0 . 451279 0 1.00000 
0.790984 0 . 407442 0 1 . 00000 
0 . 483607 0.500758 0 1 . 00000 
0.782787 0.413196 0 1 . 00000 
0 . 704918 0.457017 0 - 1 . 00000 
0.254098 0 -436248 0 1.00000 
Criteria for Assess i ng Mode l Fit 
Intercept 
Only 
338.615 
342 . 112 
336 . 615 
Intercept 
and 
Covariates 
334.113 
362.091 
318 . 113 
154 
Chi-Square for Covariates 
18 . 501 with 7 DF ( p=0 . 0099) 
17.892 with 7 DF ( p =0 . 0125) 
Vari a ble 
INTERCPT 
SEXl 
AGEl 
RXNUMX 
REVIEWX 
DEGl 
PRACTYPX 
LICYEARX 
FINAL THESIS MODEL 
7HE DEPENDENT VARIABLE IS FORM AFFECTS DECISION 
FOR THOSE IN PRACTICE AFTER 1979 
The LOGISTIC Procedure 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr ) 
Estimate Error Chi - Square Chi - Square 
0.0207 0 . 4218 0.0024 0 9608 
-0.8632 0 . 3323 6.7491 0. 0094 
-0.0114 0.3537 0 . 0010 0 . 9742 
-0.8234 0.3438 5.7377 0.0166 
- 0.1321 0.2683 0 . 2424 0 . 6225 
0.6814 0.3429 3.9487 0 . 0469 
0 . 146 8 0. 3031 0.2347 0.6281 
0 . 3469 0 . 3637 0.9100 0.3401 
Standardized 
Estimate 
- 0.203008 
- 0.002847 
- 0 . 184967 
- 0 . 036461 
0. 155217 
0 . 036994 
0 . 083438 
Association of Predicted Probabilities and Observed Responses 
Concordant = 62.5% 
Discordant = 33.5% 
Tied 4.0% 
( 14784 pairs) 
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Somers ' D 
Gamma 
Tau-a 
c 
0.290 
0.302 
0. 145 
0.645 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE 
FOR THOSE IN PRACTICE AFTER 1979 
The LOGISTIC Procedure 
Data Set : WORK . AFTER79 
Response Variable: THERPREl PREFER TO PRESCRIBE NON - C- II 
Response Levels : 2 
Number of Observations: 289 
Link Fun c tion: Logit 
Response Profile 
Ordered 
Value THERPREl 
1 AGREE 
2 DISAGREE 
Count 
112 
177 
WARNING: 66 observation(s) were deleted due to missing values for the response 
or explanatory variables . 
Variable 
SEXl 
AG El 
SPECLTYX 
DEGl 
PRACTYPX 
RXNUMX 
LICYEARX 
REVIEWX 
Criterion 
AIC 
SC 
-2 LOG L 
Score 
Simple Statistics for Explanatory Variables 
Standard 
Mean Deviation Minimum MaximUJll 
0 . 238754 0.427062 0 1.00000 
. 0 . 266436 0 . 442862 0 1.00000 
0 . 802768 0 . 398599 0 1 . 00000 
0 . 761246 0 . 427062 0 1.00000 
0.723183 0.448201 0 1 . 00000 
0.778547 0 . 415945 0 l . 00000 
0.245675 0.431233 0 1.00000 
0 . 487889 0.500720 0 1.00000 
Criteria for Assessing Model Fit 
Intercept 
Only 
387 . 894 
391 . 560 
385 . 894 
Intercept 
and 
Covariates 
387. 797 . 
420.795 
_369 . 797 
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Chi-Square for Covariates 
16 . 097 with 8 DF (p=0.0410) 
15 . 950 with 8 DF l p=0.0431 ) 
Variable 
INTERCPT 
SEXl 
AGEl 
SPECLTYX 
DEGl 
PRACTYPX 
RXNUMX 
LICYEARX 
REVIEWX 
FINAL THESIS MODEL 
THE DEPENDENT VARIABLE IS THERAPEUTIC PREFERENCE 
FOR THOSE IN PRACTICE AFTER 1979 
The LOGISTIC Procedure 
Analysis of Maximum Likelihood Estimates 
Parameter Standard Wald Pr > 
Estimate Error Chi - Square Chi-Square 
0.2394 0.4210 0 . 3235 0.5695 
0 . 0408 0 . 3049 0.0179 0 . 8936 
0.5253 0.3389 2.4018 0. 1212 
0 . 1037 0 . 3779 0 . 0753 0.7838 
- 0.5013 0.3559 1.9842 0.1589 
- 0.2068 0 . 2821 0.5375 0.4635 
- 0.7879 0 .2992 6.9361 0 . 0084 
-0. 1636 0.3433 0.2271 0.6337 
0.4793 0.2515 3.6337 0 . 0566 
Standardized 
Estimate 
0 . 009603 
0. 128255 
0.022788 
- 0.118025 
- 0. 051109 
-0. 180686 
-0.038901 
0. 132324 
Association of Predicted Probabilities and Observed Responses-
Concordant = 62 . 4% 
Discordant = 34.7% 
Tied 2.8% 
(19824 pairs) 
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Somers' D 
Gamma 
Tau-a 
c 
0.277 
0.285 
0. 132 
0.639 
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